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I 
 
Summary 
Schizophrenia is a debilitating psychiatric disorder with high heritability. Genome wide 
association studies (GWASs) have identified association between schizophrenia and an intronic 
single nucleotide polymorphism (SNP) in zinc finger domain containing 804A (ZNF804A). The 
biological functions of ZNF804A are largely unknown. Thus, the aim of this thesis was to 
determine the function of ZNF804A.  
 
Yeast two-hybrid (Y2H) screens were used to determine the protein binding partners of 
ZNF804A in the brain. This identified ZNF804A interacted with transcription factors (zinc 
finger protein 40 (ZNF40); trans-acting transcription factor 1 (Sp1) and basic helix-loop-helix 
family, member e40 (Bhlhe40)) and regulators of pre-mRNA splicing, including RNA binding 
protein, fox-1 and -2 (Rbfox1 and RBFOX2) and neuro-oncological ventral antigen 2 (NOVA2). 
Therefore, we hypothesised that, via interactions with its protein binding partners, ZNF804A 
may have a role in regulating transcription and pre-mRNA splicing.  
 
Exon arrays were used to determine the effects of ZNF804A knockdown on gene expression in 
SH-SY5Y neuroblastoma cells. Enrichment analysis on the differentially expressed or spliced 
genes indicated a significant effect of ZNF804A knockdown on genes involved in nervous 
system development, particularly synaptic contact and axon guidance. Among the most 
significantly differentially expressed genes were the known schizophrenia susceptibility genes 
reelin (RELN) and neuropeptide Y (NPY). Several alternative splicing events were confirmed 
empirically, including increased exclusion of exon 11a of enabled homolog (ENAH). Consistent 
with our hypothesis, splicing of exon 11a of ENAH is known to be regulated by RBFOX2.  
 
In complementary experiments, exon arrays were used to identify differentially expressed genes 
in a stable cell line expressing myc-ZNF804A. Enrichment analysis on the differentially 
expressed genes indicated an over-representation of genes involved in the regulation of epithelial 
to mesenchymal transition and receptor-mediated axon growth repulsion. Among the genes with 
the largest fold changes in expression was a gene implicated in synapse development: secreted 
protein acidic and rich in cysteine (SPARC). Enrichment analysis of the alternatively spliced 
genes indicated a significant effect of myc-ZNF804A over-expression on genes involved in cell-
matrix interactions.  
 
These data suggest that ZNF804A regulates the expression of genes implicated in processes 
underlying schizophrenia pathology, and provide the first evidence that ZNF804A may be 
involved in the regulation of alternative splicing.   
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Chapter 1: Introduction 
 
1.1. Introduction 
Schizophrenia is a major psychiatric disorder that alters an individual’s perception, thoughts, 
behaviour and mood. Schizophrenia affects as many as 1% of the world’s population, making 
it the most common form of psychotic disorder.  
 
The first symptoms of schizophrenia present in early adulthood and persist throughout the 
life-time. On average, males experience the onset of disease 1.07 years earlier than females 
(Eranti et al., 2012). Schizophrenia is associated with reduced fertility and may result in a 
reduced life expectancy, due to an increased risk of suicide, health problems, and risky 
behaviour (Bundy et al., 2011; Chang et al., 2011). The difficulties experienced by people 
with schizophrenia are compounded by social adversity and isolation, poverty, homelessness 
and the stigma associated with mental illness (NICE, 2010; Overton and Medina, 2008). As 
such, schizophrenia is considered among the top ten leading causes of disability worldwide 
(WHO, 2001). Additionally, a diagnosis of schizophrenia places strain on the family and 
friends of the patient (Baronet, 1999) whilst, in economic terms, schizophrenia places large 
demands on the healthcare system. For example, in 2004/2005 the societal cost of 
schizophrenia in England alone was £6.7 billion (Mangalore and Knapp, 2007).  
 
The incidence rate of schizophrenia in England from 1950-2009 was 15 people per 100 000 
per year (Kirkbride et al., 2012). The lifetime prevalence of schizophrenia is estimated to be 
0.4% (Saha et al., 2005).   
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Although medication remains paramount in the treatment of schizophrenia, the drugs which 
are currently available are ineffective for as many as one third of patients and have 
undesirable side effects, which can often lead to poor compliance (Conley and Buchanan, 
1997; Kahn et al., 2008; Lewis et al., 2006; Lieberman et al., 2005). The lack of effective 
treatments is generally attributed to our poor understanding of the biological aetiology of 
schizophrenia. Therefore, it is hoped that an improved understanding of the underlying 
molecular pathophysiology of schizophrenia may enable more effective treatments to be 
developed (Insel and Scolnick, 2006).  
 
1.2. What is schizophrenia?  
The modern concept of schizophrenia was first recognised by Emil Kraepelin (1855-1926). 
Kraepelin defined two courses of mental illness: a progressive deterioration of symptoms, 
with increasing impairment; and a fluctuating pattern, with frequent relapses and full 
recovery between episodes (Kraepelin, 1896). Kraepelin termed these mental illnesses 
dementia praecox (later known as schizophrenia) and manic-depressive insanity (later known 
as bipolar disorder). Kraepelin defined the primary symptoms of dementia praecox as 
delusions, hallucinations, formal thought disorder, and negativism. Although Kraepelin was 
pessimistic about the prognosis of dementia praecox, other psychiatrists believed the long-
term outcome of the disease was more positive. Indeed, the term ‘schizophrenia’ was coined 
by Eugen Bleuler in 1911 to describe a group of related mental disorders in a way which did 
not suggest a deteriorating course (Bleuler, 1950). In contrast to Kraepelin, Bleuler believed 
that the essence of schizophrenia was negative symptoms, rather than delusions and 
hallucinations. Later, Kurt Schneider proposed that the primary deficits in schizophrenia were 
positive symptoms (Schneider, 1959). The modern-day international diagnostic criteria for 
schizophrenia (including the World Health Organisation’s (WHO) International 
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Classification of Disease’s (ICD) and the American Psychiatric Association Diagnostic and 
Statistical Manual (DSM)-IV)) incorporate Kraepelin chronicity, Bleulerian negative 
symptoms and Schneiderian positive symptoms (Table 1.1) (Tandon et al., 2009).  
 
Despite the use of common diagnostic criteria, many psychiatrists continue to argue that the 
clinical definition of schizophrenia is arbitrary because there are no known biomarkers for 
schizophrenia and no disorder-specific brain abnormality (Carroll and Owen, 2009). The 
findings of genetic studies support this argument and suggest that, rather than being a single 
disease entity, schizophrenia may represent a group of disorders with similar pathology. For 
example, copy number variations (CNVs) in neurexin 1 (NRXN1) have been associated with 
both schizophrenia and other neurodevelopmental disorders, such as autism (Kim et al., 2008; 
Kirov et al., 2009b). The issue of defining schizophrenia is important, not only because a 
diagnosis of schizophrenia has a huge impact on a patient’s life; but also to facilitate research 
into its aetiology, pathogenesis and treatment.  
 
1.3. Clinical symptoms of schizophrenia 
The clinical presentation of schizophrenia falls into three collections of symptoms: positive, 
negative and cognitive. Positive symptoms of schizophrenia are those that are in excess of 
normal functions, such as delusions and hallucinations (Lindermayer and Khan, 2006). The 
most common hallucinations in schizophrenia are auditory, with as many as 75% of patients 
perceiving sounds without the presence of an auditory source (Shinn et al., 2012). The 
negative symptoms of schizophrenia involve an absence or reduction in affective and 
conative functions. These include, abulia (loss of motivation), alogia (poverty of speech), 
anhedonia (inability to experience pleasure), avolition (lack of initiative), apathy (lack of 
interest) and reduced social drive (Bleuler, 1950). These symptoms occur frequently and  
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DSM-IV diagnostic criteria for schizophrenia 
A. characteristic symptoms: at least two of the 
following each present for a significant amount of 
time during a one month period.  
i) delusions 
ii) hallucinations 
iii) disorganised speech 
iv) grossly disorganised or catatonic behaviour 
v) negative symptoms  
 
B. social or occupational dysfunction 
 
C. duration: continuous signs of disturbance persist 
for at least 6 months 
 
D. exclusion of mood disorders 
 
E. exclusion of known organic causes (e.g.: 
substance abuse or a known brain disorder) 
 
 
Table 1.1. DSM-IV diagnostic criteria for schizophrenia  
(Adapted from the American Psychiatric Association, 2000.) 
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persistently in schizophrenia and are considered to be associated with poor long-term 
prognosis (Kirkpatrick et al., 2001; Strauss et al., 2010). The current medications have only 
modest effects on the negative symptoms of schizophrenia. Therefore, these symptoms 
remain a debilitating component of schizophrenia pathology (Erhart et al., 2006; Leucht et 
al., 1999). The cognitive impairments associated with schizophrenia include general 
intelligence (IQ), verbal memory, attention and executive function (Fioravanti et al., 2005; 
Keefe et al., 2006; Reichenberg, 2010). However, data suggests that deficits in IQ may not be 
universally characteristic in schizophrenia (Weickert et al., 2000). For example, some 
patients experience intellectual decline from childhood (David et al., 1997; Reichenberg et 
al., 2005), while others have an IQ within the normal range directly before the onset of the 
illness and do not show impairments in intellectual performance after the first episode 
(Reichenberg et al., 2005; Weickert et al., 2000). The cognitive profile of schizophrenia is 
highly heterogeneous; for example, as many as 27% of patients may have no 
neuropsychological deficits (Palmer et al., 1997). Despite this, the importance of cognitive 
symptoms, and their broad presence at the onset of disease, has led to the suggestion that they 
should be incorporated into the major diagnostic criteria for schizophrenia (Keefe, 2007).  
 
1.4. The neurobiology of schizophrenia  
The underlying molecular basis of schizophrenia remains elusive, yet there are several 
neuroimaging, neuropathological and neurochemical findings which have been reproducibly 
associated with the disease.  
 
There are two reproducible neuroanatomical findings that distinguish schizophrenia patients 
from controls: enlarged ventricles and a reduction in whole brain volume at both the outset of 
illness and in the longer-term (Shepherd et al., 2012). Although the clinical relevance of these  
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changes is unclear, their presence at the outset of disease provides evidence for the 
neurodevelopmental hypothesis of schizophrenia (see section 1.5) (MacDonald and Schulz, 
2009).  
 
Post-mortem studies of brains from patients with schizophrenia have identified several 
changes associated with the disease. These include an increased density of pyramidal cells in 
the prefrontal cortex, without changes in total neuron number and without neuronal loss 
(Selemon and Goldman-Rakic, 1999). The absence of neuronal loss precludes 
neurodegeneration and supports the neurodevelopment hypothesis of schizophrenia (see 
section 1.5) (Harrison, 1997). The increase in neuronal density may be due to decreased soma 
size or decreased interneuronal space, known as neuropil (Figure 1.1) (Akbarian et al., 1995; 
Harrison, 1999; Selemon and Goldman-Rakic, 1999). Additionally, dendrites were found to 
be shorter and less branched in schizophrenia patients (Black et al., 2004; Guidotti, 2000). 
Furthermore, there was a reduction in the density of glutamate dendritic spines in the 
forebrains of schizophrenia patients (Glantz and Lewis, 2000; Kalus et al., 2000; Lewis et al., 
2003).  
 
Neuropathological studies have also identified changes in the interneurons of the cortex. 
Specifically, several studies have shown a decrease in the mRNA and protein abundance of 
glutamic acid decarboxylase (GAD) 67, one of the key enzymes for synthesis of the 
inhibitory neurotransmitter γ-aminobutyric acid (GABA) (Fatemi, 2000; Guidotti, 2000; 
Impagnatiello, 1998). Impaired synthesis and uptake of GABA was found to be associated 
with schizophrenia (Akbarian et al., 1995; Volk et al., 2000). The reduction in GAD67 in 
schizophrenia was associated with a decrease in the mRNA and protein abundance of reelin, 
a large extracellular matrix protein that is encoded by the gene reelin (RELN) and is critical  
Chapter One: Introduction 
7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Schematic diagram of the cytoarchitectural features of schizophrenia  
In schizophrenia, the number of neurons is unchanged but the somal size of the pyramidal neurons 
(yellow) is reduced, and the neurons are more densely packed. This reflects a reduction in the neuropil 
volume. The glial cells (blue) are unaffected. For clarity, potential changes in the distribution or 
organisation of the interneuron populations (purple and green) are omitted. I-VI represents the cortical 
layers; wm = white matter. (Adapted from Harrison, 1999.) 
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for the correct migration of neurons during development (Impagnatiello et al., 1998; Fatemi 
et al., 2000; Guidotti et al., 2000; Fatemi, 2005). Studies using heterozygous reln mice 
revealed that deficits in reln were associated with deficits in GABAergic systems and deficits 
in the molecular composition of synapses in the adult brain (Nullmeier et al., 2011; Ventruti 
et al., 2011). These data suggest that decreased reln expression may contribute to disease via 
impaired GABA neurotransmission and consequently, a reduction in neuronal connectivity 
(Costa et al., 2001; Costa et al., 2002).  
 
The myelin hypothesis of schizophrenia was first presented by Hakak and colleagues (2001) 
following transcriptomic analysis of post-mortem brain tissue which identified differential 
expression of several genes involved in myelination in patients compared to controls. 
Subsequently, several studies have shown a reduction in oligodendrocyte number in various 
brain regions in schizophrenia (Byne et al., 2006; Vostrikov et al., 2007). It is postulated that 
these changes may contribute to aberrant neuronal connectivity in disease (Schmitt et al., 
2011).  
 
The neurochemical hypotheses of schizophrenia have been largely driven by observations 
that antipsychotic drugs modulate neurochemical pathways. For instance, the glutamate 
hypothesis developed after it was shown that psychomimetic drugs, such as phencyclidine 
and ketamine, elicited psychosis-like symptoms reminiscent of schizophrenia by blocking 
neurotransmission at N-methyl-D-aspartic acid- (NMDA) type glutamate receptors and 
inducing a NMDA receptor hypofunction state (Javitt and Zukin, 1991; Olney et al., 1999). 
The resulting increase in glutamate release is thought to be linked to the behavioural deficits 
observed (Moghaddam et al., 1997). Data from post-mortem analyses of brain tissue obtained 
from patients with schizophrenia support a role for dysregulation of glutamatergic systems in 
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disease pathology. For example, Oni-Orisan (2008) reported a reduced abundance of the 
presynaptic protein vesicular glutamate transporter 1 (VGLUT1) in the anterior cingulate 
cortex (ACC) but not dorsolateral prefrontal cortex of patients with schizophrenia. However, 
the transcript expression of VGLUT1 was unaltered in the ACC in schizophrenia (Oni-Orisan 
et al., 2008; Eastwood and Harrison, 2010). Additionally, alterations in glutamate receptor 
expression in schizophrenia have been found (Beneyto et al., 2007). Recent genetic studies of 
copy number variations in schizophrenia are consistent with a role for glutamate synapse 
disruption in disease (Walsh, 2008; Kirov, 2012); these data are discussed in more detail in 
section 1.6.3.2.  
 
The dopamine hypothesis proposes that the symptoms of schizophrenia arise due to 
dopaminergic overactivity (Howes and Kapur, 2009). This hypothesis emerged after it was 
observed that anti-psychotic drugs were dopamine receptor D2 antagonists (Carlsson et al., 
1957). Molecular imaging studies confirm that all antipsychotics block striatal D2 receptors 
(reviewed by Frankle and Laruelle, 2002). There is considerable evidence to suggest that the 
neurochemical pathways underlying schizophrenia pathology may converge and interact to 
contribute to disease (Tost and Meyer-Lindenberg, 2011). For example, using imaging 
techniques Stone and colleagues (2010) showed the relationship between hippocampal 
glutamate and striatal dopamine was altered in patients at high risk of psychosis.  
 
1.5. The neurodevelopmental hypothesis of schizophrenia  
The neurodevelopmental hypothesis of schizophrenia suggests that the disorder arises as a 
result of a pathogenic process which occurs earlier in life than the onset of features of the 
illness (Weinberger, 1987). Considerable evidence from a wide range of studies supports this 
model of schizophrenia (Fatemi and Folsom, 2009). For example, Brown and colleagues 
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showed poor maternal nutrition and maternal infection in the prenatal period was associated 
with increased risk for schizophrenia in offspring (Brown and Patterson, 2011; Brown et al., 
1996). Other studies revealed children who later went on to develop schizophrenia had subtle 
cognitive impairments; memory and language difficulties; and motor abnormalities (Chua 
and Murray, 1996; Erlenmeyer-Kimling et al., 2000; Walker et al., 1996). Additionally, the 
offspring of schizophrenics had a higher incidence of minor physical abnormalities, which 
may be indicative of a disruption in early neurodevelopment (Lawrie et al., 2001). It has been 
argued that an abnormality in late neurodevelopment, such as aberrant synaptic pruning in 
adolescence, may increase risk for schizophrenia (Feinberg, 1982; Lewis and Levitt, 2002). 
Consistent with this, Keshavan (1999) proposed a ‘two-hit’ neurodevelopmental hypothesis 
which posited that abnormalities at critical time points in both early and late 
neurodevelopment may act in concert to increase risk for schizophrenia. 
  
Often schizophrenia is co-morbid with child-onset neurodevelopmental disorders such as 
intellectual disability, autism and attention deficit hyperactivity disorder (ADHD) (Stahlberg 
et al., 2004). This co-morbidity, and recent findings which point to genetic overlap between 
neurodevelopmental disorders, have led some psychiatrists to suggest that these disorders 
may represent a continuum of genetic and environmentally induced neurodevelopmental 
impairment (Owen et al., 2011).  
 
1.6. Genetics of schizophrenia  
1.6.1. Genetic epidemiology 
The meta-analysis of modern (post-1980) family studies of schizophrenia indicated that first 
degree relatives were nearly 10 times more likely to be affected with schizophrenia than 
comparison subjects (Kendler and Diehl, 1993). This finding was consistent with a large 
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population-based study which showed that offspring whose parents both had schizophrenia 
had a risk of developing the disease of greater than 25% (Gottesman et al., 2010). Research 
using twin studies showed that the proportion of liability for schizophrenia that may be 
attributed to genetic differences between individuals was approximately 80% (Cardno and 
Gottesman, 2000; Sullivan et al., 2003). Furthermore, the results of adoption studies for 
schizophrenia demonstrated that the genetic contribution was relatively more important to the 
aetiology of schizophrenia than the environmental contribution (Kety, 1987). However, data 
suggests environmental factors specifically associated with a disadvantaged socioeconomic 
position, such as unemployment and a single-parent household, may increase risk for 
psychosis more in children with genetic susceptibility to disease (Wicks et al., 2010).  
 
In summary, the results of genetic epidemiological studies strongly support the notion of a 
major genetic component to schizophrenia. Such data are important as they provide a strong 
case for the search for genes that underlie susceptibility to schizophrenia.       
 
1.6.2. Genetic models of schizophrenia 
The genetic architecture of complex disorders such as schizophrenia is determined by the 
number, frequency and penetrance of risk alleles that contribute to disease in the population. 
In this context, there are two primary models used to explain the genetic architecture of 
schizophrenia: 1) the common disease-rare variant (CDRV) hypothesis, which states that 
multiple rare variants contribute to risk for common disease; and 2) the common disease-
common variant (CDCV) hypothesis, which states that variants of modest effect, with a 
relatively high frequency in the population, explain risk for common diseases (Lander, 1996). 
Data presented in section 1.6.3 suggest that risk for schizophrenia is influenced by the 
combined effect of both rare and common variants (Figure 1.2) (Mowry and Gratten, 2013). 
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However, the proportion of genetic susceptibility that can be explained by either rare or 
common variants remains a point of controversy (McClellan and King, 2010; Rodriguez-
Murillo et al., 2012).  
 
1.6.3. Candidate gene discovery in schizophrenia 
1.6.3.1. Early genetic studies of schizophrenia 
The early genetic studies of schizophrenia focused on linkage studies. Linkage analysis uses 
genetic markers to map co-segregation of chromosome regions with disease in related 
individuals. Linkage studies were based on the assumption that a relatively small number of 
genes of major effect could be identified. The early linkage studies for schizophrenia 
identified many regions of the genome which showed linkage with disease. For example, 
there was reproducible linkage between chromosome 8p and disease (Kendler et al., 1996; 
Pulver et al., 1995). Fine-mapping of chromosome 8p identified a haplotype in neuregulin 
(NRG1) that was associated with disease (Stefansson et al., 2002). NRG1 was considered to 
be a likely schizophrenia candidate gene because its expression was highest in the brain and 
the protein had known key roles in neurodevelopmental processes (Corfas et al., 1995; 
Yarden and Sliwkowski, 2001). However, it remains unclear how genetic variation in NRG1 
mediates susceptibility for schizophrenia. Additionally, on chromosome 6p22-24, linkage for 
dystrobrevin binding protein 1 (DTNBP1) in schizophrenia was reported in more than 10 
independent samples (Williams et al., 2005). The disease-associated DTNBP1 haplotypes 
appeared to associate with low DTNBP1 expression (Bray et al., 2005). Reductions in the 
amount of DTNBP1 at the presynapse led to alterations in glutamate output, this may suggest 
that genetic alteration in DTNBP1 may increase risk for schizophrenia via modulation of 
glutamate output (Jentsch et al., 2009; Numakawa et al., 2004; Talbot et al., 2004).  
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Figure 1.2. Schematic representation of the current genetic findings in schizophrenia, in relation 
to the proposed genetic models of the disease  
Genome wide association studies (GWAS) have identified common single nucleotide polymorphisms 
(SNPs) with small effect size associated with schizophrenia. These data are consistent with the 
common disease common variant (CDCV) hypothesis. Rare disease-causing variants that have large 
effect, such as copy number variations (CNVs), have been identified by array-comparative genomic 
hybridisation (aCGH) and next generation sequencing (NGS). These data are consistent with the 
common disease rare variant (CDRV) hypothesis. (Adapted from Owen, 2009; Mowry and Gratten, 
2013).  
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Notwithstanding these examples, many of the published linkage studies show inconsistent 
findings and a lack of replication (Owen, 2009). This was likely to arise because these studies 
were underpowered to detect rare alleles of large effect (section 1.6.3.2) or common alleles of 
small effect (section 1.6.3.3).  
 
1.6.3.2. Studies of structural variation: common disease-rare variant  
Rare variation can manifest as either rare single nucleotide variants (SNVs), copy number 
variations (CNVs) or large chromosomal abnormalities such as excisions, insertions and 
translocations of genetic material (Beckmann et al., 2007). The first chromosomal aberration 
associated with schizophrenia was a reciprocal translocation between 1q42 and 11q14.3, 
which co-segregated with schizophrenia, major depression and bipolar disorder in a large 
Scottish family (St Clair et al., 1990). The translocation disrupted disrupted in schizophrenia 
1 and 2 (DISC1 and DISC2). The molecular characterisation of the DISC1 protein implied it 
may be involved in neural development; therefore, disruption of DISC1 may contribute to 
schizophrenia by affecting neuronal development (Brandon and Sawa, 2011).  
 
CNVs are submicroscopic duplications and deletions of the genome (Hastings et al., 2009). 
The consequences of CNVs may be loss of gene function, disruption of a regulatory element 
or the creation of a novel gene fusion. The first CNV found associated with schizophrenia 
was a microdeletion of velo-cardio-facial syndrome (VCFS) on chromosome 22q11.2 
(Lindsay et al., 1995). Subsequently, several studies showed schizophrenia patients had an 
increased mutational burden of rare CNVs (Kirov et al., 2008; Magri, 2010; Walsh et al., 
2008). The CNVs observed in schizophrenia arise both from rare de novo mutations and 
inherited CNVs (Kirov et al., 2009a; Kirov et al., 2012; Liao et al., 2012).  
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Locus CNV type References 
Genes of particular 
interest within this region 
1q21.1 deletion 
(Glessner et al., 2010; Grozeva 
et al., 2012; Levinson et al., 
2011; Stefansson et al., 2008; 
Vacic et al., 2011; Walsh et al., 
2008) 
ERBB4, GJA8 
7q36.3 duplication (Vacic et al., 2011) VIPR2 
2p16.3 deletion 
(Walsh et al., 2008;(Kirov et al., 
2009b; Magri et al., 2010; 
Vrijenhoek et al., 2008)   
NRXN1 
3q29 deletion 
Grozeva, 2012; Magri, 2010; 
Mulle, 2010; Levinson, 2011 
DLG1 
3q29 duplication (Vacic et al., 2011) CR597873, SDHALP2 
15q11.2 deletion 
(Grozeva et al., 2012; Kirov et al., 
2009b; Magri, 2010; Stefansson 
et al., 2008) 
CYFIP1 
15q11.2 duplication (Liao et al., 2012) UBE3A 
15q13.3 deletion 
(Grozeva et al., 2012; Levinson 
et al., 2012; Stefansson et al., 
2008) 
CHRNA7 
15q13.3 duplication (Ingason et al., 2011) UBE3A, ATP10A 
16p11.2 duplication 
(Grozeva et al., 2012; McCarthy 
et al., 2009) 
DOC2A 
16p13.1 deletion (Ingason et al., 2011) NTAN1, NDE1 
16p13.1 duplication 
(Ingason et al., 2011; Magri, 
2010) 
NDE1  
17p12 deletion 
(Kirov et al., 2009b; Magri, 2010; 
Vacic et al., 2011) 
PMP22 
17q12 deletion 
(Magri, 2010; Moreno-De-Luca et 
al., 2010; Vacic et al., 2011) 
CCL genes 
22q11.2 deletion 
(Grozeva et al., 2012; Kirov et al., 
2009a; Vacic et al., 2011) 
VCFS, BCR 
 
Table 1.2. Summary of the CNVs identified in schizophrenia 
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The studies of CNVs in schizophrenia have identified genomic loci which harbour multiple 
structural variants associated with disease; these loci are outlined in Table 1.2. Two large, 
genome-wide scans of rare CNVs reported a significant over-representation of copy number 
changes which affected single genes, namely a duplication of vasoactive intestinal peptide 
receptor gene (VIPR2) and a deletion of neurexin 1 (NRXN1) (Kirov et al., 2009b; Vacic et 
al., 2011).   
 
Enrichment analysis of genes containing CNVs showed the genes were enriched for 
involvement in signalling networks controlling neurodevelopment (Walsh, McClellan et al. 
2008). For example, there were deletions of the v-erb-a erythroblastic leukemia viral 
oncogene homolog 4 (avian) (ERBB4) gene, which encodes a type 1 transmembrane tyrosine 
kinase receptor for neuregulin; and deletions of the glutamate receptor, metabotropic 7 
(GRM7) gene, which encodes a G protein-coupled metabotropic glutamate receptor (Walsh et 
al., 2008). Furthermore, de novo CNVs were significantly enriched for genes which function 
in synaptic plasticity such as syntaxin 1A (brain) (STX1A), discs, large homolog 1 
(Drosophila) (DLG1) and rabphilin 3a homolog (mouse) (RPH3A) (Glessner et al., 2010; 
Kirov et al., 2012). These findings support the glutamate hypothesis of schizophrenia (see 
section 1.4) and suggest that CNVs may lead to pathogenesis via influences on neural 
development and cognition (Kirov et al., 2012; Walsh et al., 2008).  
 
Genetic studies have shown that some rare structural variants confer risk for other 
neuropsychiatric diseases in addition to schizophrenia. For example, CNVs in NRXN1 were 
associated with schizophrenia and other neurodevelopmental disorders, such as autism (Kim 
et al., 2008; Kirov et al., 2009b). Additionally, the 22q11.2 deletion was implicated in 
schizophrenia, ADHD and autism spectrum disorder (ASD) (Sahoo et al., 2011). 
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Furthermore, CNVs at 16p13.1 were found in both schizophrenia patients and patients with 
autism and mental retardation (Behjati et al., 2008; Ingason et al., 2011). These data provide 
further evidence for an overlap in the underlying biology of schizophrenia and other mental 
illnesses.   
 
Studies using small-exome sequencing have reported that schizophrenia cases had a higher 
rate of putatively functional SNVs than would be expected by chance (Girard et al., 2011; Xu 
et al., 2011). Specifically, using targeted exome sequencing of 14 parent-case trios Girard and 
colleagues found 15 de novo mutations in eight of the probands, of which four were nonsense 
mutations in the genes low density lipoprotein receptor-related protein 1 (LRP1); 
karyopherin alpha 1 (KPNA1); zinc finger protein 480 (ZNF480); and ALS2 C-terminal like 
(ALS2CL) (Girard et al., 2011). Xu and colleagues sequenced the exomes of 53 affected and 
22 unaffected trios and identified 34 de novo point mutations, of which 19 affected 
evolutionarily conserved residues and were predicted by PolyPhen to be damaging (Xu et al., 
2011). Both studies showed that the ratio of nonsense to missense de novo changes was 
significantly higher than expected, suggesting that the mutations were likely to cause 
schizophrenia (Girard et al., 2011; Xu et al., 2011). Additionally, Girard and colleagues 
calculated that the de novo mutation rate in the probands was significantly higher than the 
normal de novo mutation rate (1000 Genomes Project Consortium, 2010;(Girard et al., 2011). 
In a recent, larger exome sequencing study, Need and colleagues considered 166 affected 
individuals and selected more than 5000 SNVs. These were then evaluated in an independent 
cohort of 2617 cases and 1800 controls, which found that no single variant met the cut-off for 
genome-wide significant association with disease (Need et al., 2012). However, even larger 
exome sequencing studies are forthcoming and these should help pinpoint definitive 
associations (Sullivan et al., 2012).  
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1.6.3.3. Genome-wide association studies: common disease-common variant 
Genetic association studies compare the allele or genotype frequencies between two groups 
of individuals, usually cases and unaffected controls. For schizophrenia, the cases are defined 
by the discrete DSM-IV and ICD-10 diagnostic categories. The increasing size of association 
studies means that large birth cohort control datasets are often used. The association of an 
allele with disease denotes either that the allele is directly associated with disease, and has 
potential functional relevance to disease pathology; or that the allele is indirectly associated 
with disease through its non-random association with another genomic variant (Corvin et al., 
2010; Wang et al., 2005). The non-random association between alleles at two or more loci is 
known as linkage disequilibrium (LD) (Slatkin, 2008). The basis of LD is the phenomenon of 
recombination, which is the exchange of DNA segments between chromosomes during 
meiosis. Recombination is less likely to occur between genetic loci which are physically 
close together (<50kb) therefore, these loci have a higher probability of being inherited 
alongside one another. Most polymorphic SNPs tend to be in strong LD with one another, 
therefore a significant proportion of common variation can be determined using LD mapping 
of a subset of the SNPs that capture most of the allelic variation in a region. Thus, the 
phenomenon of LD can be used in association studies to reduce costs and increase the 
feasibility of a study.  
 
The association signal may be better localised using high-density LD mapping of the region, 
known as fine-mapping (Corvin et al., 2010). Yet, to date, fine-mapping studies have not 
identified new common alleles with larger effect sizes than their tagging SNPs (Park et al., 
2010). The power of an association study to detect a susceptibility variant is influenced by the 
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frequency of the disease causing allele, the effect size and the sample size (Hirschhorn and 
Daly, 2005; Zondervan and Cardon, 2004). 
 
Traditionally, association studies searched for common variants associated with disease in 
known candidate genes. Instead of a candidate gene approach, it was proposed that 
susceptibility variants could be identified using indirect genotyping of thousands of common 
SNPs (Collins et al., 1997; Risch and Merikangas, 1996). Subsequently, a genome-wide 
haplotype map (HapMap) that catalogued the common genetic variation throughout the 
human genome was created (Gibbs et al., 2003). The most recent HapMap lists the genotypes 
of over three million SNPs in 270 individuals from four populations (West European, West 
African, Han Chinese and Japanese) (Frazer et al., 2007). The freely available HapMap 
(available at http://hapmap.ncbi.nlm.nih.gov/) enabled the generation of SNP assays for 
genome-wide association studies (GWASs). The term GWAS refers to association using a 
dense array of genetic markers that capture a large proportion of genetic variation. GWAS 
data are analysed using logistic regression, with the dependent variable case-control status 
and a SNP genotype as an independent variable. The output of a logistic regression is the 
identity of the reference allele and an odds ratio with its standard error along with a statistic 
and a P value that tests whether the odds ratio differs from one (Corvin et al., 2010). In 
GWAS, statistical tests are done for every SNP (approximately 1 x 10
-6
 logistic regression 
models). To correct for multiple testing, a SNP is considered associated with disease if its P 
value surpasses the ‘genome-wide significance’ threshold of P < 7.2 x 10-8. This is equivalent 
to a Bonferroni correction of the traditional 0.05 Type I error level for 1 x 10
-6
 statistical tests 
(Dudbridge and Gusnanto, 2008). In traditional candidate gene studies, the genes were 
selected based on knowledge of pathophysiology or gene location; as such, these studies were 
‘hypothesis-driven’. By contrast, GWASs are hypothesis-free as they evaluate variation 
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throughout the genome. This is an important consideration for a disorder such as 
schizophrenia, where pathogenesis is highly complex and largely unknown (Corvin et al., 
2010). 
 
To date, there have been 15 published GWASs of schizophrenia (summarised in Table 1.3) 
and four meta-analyses of GWAS data. The early GWASs for schizophrenia used DNA 
pooling (Kirov et al., 2009c; Mah et al., 2006; Shifman et al., 2008). DNA pooling entails 
estimating the allele frequency from aggregated cases and aggregated controls rather than 
individual DNA samples (Sham et al., 2002). These studies identified common variants 
associated with schizophrenia in genes including RELN (Shifman et al., 2008) and retinol 
binding protein 1 (RBP1) (Kirov et al., 2009c). RELN was only identified as associated with 
schizophrenia in women, suggesting that it may be a female-specific risk factor for the 
disorder (Shifman et al., 2008). These results were particularly promising as both RELN and 
RBP1 had been previously implicated in the aetiology of schizophrenia (see section 1.4) 
(Fatemi, 2005; Kalkman, 2006). However, the practice of pooling DNA for GWAS was 
criticised as it reduced the ability to accurately predict allele frequencies of the samples that 
comprised the pools, compared to if each subject was genotyped individually (Corvin et al., 
2010; Schosser et al., 2010). Although individual genotyping was initially less economically 
viable, advances in technology led to decreasing costs and it became feasible to perform a 
GWAS using individual genotyping.  
 
Several of the early GWASs using individual genotyping failed to identify associations that 
reached genome-wide significance, potentially due to small sample sizes (Lencz et al., 2007; 
Need et al., 2009) (Table 1.3). Consequently, the study performed by O’Donovan and 
colleagues, which was the first to identify a polymorphism associated with disease with 
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Table 1.3. Summary of the results of GWASs of schizophrenia  
        Sample size cases/controls  
Reference Population Discovery  Replication Genes identified with genome-wide significance 
Mah, 2006 European 320/325 n/a none 
Lencz, 2007 European 178/144 200/300 CSF2RA 
Sullivan, 2007 European 738/733 n/a none 
O’Donovan, 2008 European 479/2937 6829/9897 ZNF804A 
Shifman, 2008 Ashkenazi Jewish 2274/4401 n/a RELN (only in women) 
Shi, 2009  
European/African-
American 
2681/2653 European; 
1286/973 African-
American 
8008/19077 MHC 
Need, 2009 European 871/863 1460/12995 none 
Kirov, 2009c European 574/605 (trios) n/a RBP1 
Athanasiou, 2011 European 201/305 2663/13780 none 
Djurovic, 2010 European 230/336 435/10258 none 
Ikeda, 2011 Asian 575/564 n/a none 
Yamada, 2011 Asian 120 (trios)  none 
Yue, 2011 Han Chinese 746/1599 4027/5603 ZKSCAN4, NKAPL, PGBD1, TSPAN18 
Levinson, 2012  European 
2461 individuals (631 
pedigrees) 
n/a none 
Bergen, 2012 European 1507/2093  
none, but combining these samples with others that had 
been previously reported (2111/2535) gave GWA in MHC 
region. 
Stefansson, 2009 European 2663/13 498  
none, but considering top markers in combined samples 
gave MHC region, NRGN, TCF4 
Purcell, 2009  European 3322/3587 8008/19 077 MHC region 
Ripke, 2011  European 9394/12 462 8442/21 397 
MIR137, PCGEM1, TRIM26, CSMD1, MMP16, CNNM2, 
NT5C2, STT3A, CCDC68, TCF4 
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genome-wide significance, is considered to be a landmark paper in schizophrenia genetics 
(O'Donovan et al., 2008). In their study O’Donovan and colleagues used a discovery sample 
of 479 cases and 2937 controls and a replication sample of 6829 cases and 9897 controls. 
They identified a variant (rs1344706, risk allele T) in intron two of zinc finger binding 
protein 804A (ZNF804A) that was significantly associated with schizophrenia (P = 1.61 x 10
-
7
;
 
Odds ratio (OR) 1.12) (O’Donovan, 2008). Initially, the significance of the association did 
not reach the genome-wide threshold; however, the significance exceeded this cut-off when 
the affected group was extended to include bipolar disorder cases (P = 9.96 x 10
-9
) 
(O’Donovan et al., 2008).   
 
Subsequent GWASs have combined the case and control subjects from different consortia to 
increase sample sizes. In 2009, three GWASs that used combined samples were published 
(Purcell et al., 2009; Shi et al., 2009; Stefansson et al., 2009). Purcell and colleagues (2009) 
genotyped the International Schizophrenia Consortium (ISC) case-control sample (3322 cases 
and 3587 controls) and identified significant association with disease at the major 
histocompatibility complex (MHC) locus. When the genotyped SNPs from the Molecular 
Genetics of Schizophrenia (MGS) (Shi et al., 2009) and the SGENE (Stefansson et al., 2009) 
consortia were included in the analysis, to give a sample size of 8008 cases and 19 077 
controls, the MHC region had a combined significance value which exceeded genome-wide 
significance.  
 
Using only the SGENE genotyped SNPs (2663 cases and 13 498 controls), Stefansson and 
colleagues did not find any SNPs that exceeded the genome-wide significance for association 
(Stefansson et al., 2009). However, when the top markers were evaluated in a combined 
sample from the ISC (Purcell, 2009) and the MGS (Shi et al., 2009), several markers in the 
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MHC region, a marker located upstream of the neurogranin (NRGN) gene and a marker in 
intron four of transcription factor 4 (TCF4) were significantly associated with disease 
(Stefansson et al., 2009).  
 
Additionally, the Irish Schizophrenia Genomics Consortium found significant association 
signals in the MHC region, TCF4 and ZNF804A using the combined samples from the 
Psychiatric GWAS Consortium (PGC) schizophrenia sample, the SGENE+ consortium 
sample (Stefansson et al., 2009) and the Welcome Trust Case Control Consortium  2 
(WTCCC2) replication dataset (Strange, 2012)in press).  
 
The largest published meta-analysis of GWASs to date was performed by Ripke and 
colleagues in 2011. Ripke and colleagues combined data from 17 studies to give 51 695 
independent subjects. This analysis identified markers within five novel candidate genes as 
associated with schizophrenia, in addition to replicating the association of markers within the 
MHC region and TCF4 (Ripke et al., 2011). The strongest association was at a SNP within an 
intron of microRNA 137 (MIR137) (P = 1.6 x 10
-11
), a gene which has been implicated in 
neurodevelopment (Ripke et al., 2011). Consistent with previous findings, the statistical 
significance of the associations increased when the case group was extended to include 
patients with bipolar disorder (O'Donovan et al., 2008; Ripke et al., 2011; Williams et al., 
2011).  
 
To summarise, GWASs have identified a number of highly likely susceptibility genes for 
schizophrenia including ZNF804A, TCF4, the MHC region and MIR137. However, the 
percentage of the genetic basis of schizophrenia which is unaccounted for remains large. 
Recent data suggests that as the size of GWAS samples increases, so does the confidence 
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with which a GWAS can identify genes associated with disease. However, it is conceivable 
that it will never be possible to identify all of the common variants which contribute to 
schizophrenia susceptibility using the methods currently available (Bergen and Petryshen, 
2012; Ripke et al., 2011). 
 
1.6.3.4. Risk-conferring molecular pathways 
The large number of alleles which confer risk for schizophrenia are expected to cluster in 
molecular pathways which are relevant to disease pathology (Mowry and Gratten, 2013). The 
current evidence suggests genes which function at the synapse may be relevant to disease 
pathology (Figure 1.3). For example, pathway analysis of SNP data from the ISC and Genetic 
Association Information Network studies showed the cell adhesion molecule pathway was 
significantly associated with both schizophrenia and bipolar disorder (O’Dushlaine et al., 
2011). This pathway is involved in synaptic formation. Additionally, enrichment analyses of 
CNV data implicate synaptic genes in the pathogenesis of schizophrenia (Glessner et al., 
2010; Kirov et al., 2012) (see section 1.6.3.2).  
 
1.7. ZNF804A   
ZNF804A (NM_194250; OMIM: 612282) is located on the cytogenetic band 2q32.1 of 
chromosome two. ZNF804A encodes a mRNA transcript of 4.7 kb comprising of four coding 
exons extending from 595 bp to 4224 bp (Figure 1.4). Recently, a novel transcriptional 
variant of ZNF804A was identified in human lymphoblastoid cell lines and post mortem brain 
samples (Okada et al., 2012). This variant contained an additional exon in intron two and was 
predicted to generate an immature 88 amino acid protein (Okada et al., 2012). There are two 
known paralogs of ZNF804A: G patch domain containing 8 (GPATCH8) and zinc finger 
domain containing 804B (ZNF804B). At the time of the GWAS discovery, ZNF804A was a  
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Figure 1.3. Genes implicated in schizophrenia converging at the synapse 
The schematic shows the relationship between schizophrenia susceptibility genes which are involved 
in glutamate synapse function. Linkage studies implicate a role for neuregulin 1 (NRG1) in 
schizophrenia while deletions of the NRG1 receptor, v-erb-a erythroblastic leukemia viral oncogene 
homolog 4 (avian) (ERBB4) have been found in schizophrenia. NRG1-ERBB4 signalling regulates 
synapse morphology and function. Linkage studies also implicate a role for dystrobrevin binding 
protein 1 (DTNBP1) in disease. Data shows DTNBP1 regulates glutamate release. Genetic studies of 
schizophrenia have identified de novo CNVs in genes encoding components of the postsynaptic 
density, including discs, large homolog 1 and 2 (Drosophila) (DLG1 and DLG2), discs, large 
(Drosophila) homolog-associated protein 1 (DLGAP1) and syntaxin 1A (brain) (STX1A). DLG1, 
DLG2 and DLGAP1 associate the N-methyl-D-aspartate receptor (NMDAR) with downstream 
pathways which modulate calcium (Ca
2+
) release. CNVs have also been identified in glutamate 
receptor, metabotropic 7 (GRM7), rabphilin 3a homolog (mouse) (RPH3A) and neurexin 1 (NRXN1). 
NRXN1 is a synaptic cell adhesion molecule that, with neuroligin-1 (NLGN1), connects pre- and 
postsynaptic terminals. For references, see text. (Adapted from Harrison, 2005; Kirov, 2012.)   
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Figure 1.4. ZNF804A gene structure  
This schematic depicts the gene structure of the known ZNF804A transcript variants (not to scale). 
The location of the disease-associated SNP (rs1344706) in intron two is also indicated. (A) The 
ZNF804A NCBI RefSeq (NM_194250) suggests that the mRNA transcript comprises of four coding 
exons. The four exons are represented by grey boxes, while the intronic sequences and the 
untranslated regions are represented by black lines and black rectangles respectively. This mRNA 
transcript encodes a predicted protein of 1209 amino acids. (B) Recently, Okada and colleagues 
(2012) identified a novel ZNF804A transcript variant which included an additional exon termed 2.2. 
Exon 2.2 is represented by a blue box. This mRNA transcript encodes a predicted immature protein of 
88 amino acids. (C) Two alternative ZNF804A mRNAs are described in NCBI’s AceView: bAug10-
unspliced and cAug10. These mRNA transcripts encode predicted proteins of 602 amino acids and 54 
amino acids respectively.  
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gene of unknown function. As such, subsequent studies have endeavoured to establish how 
ZNF804A may contribute to susceptibility for disease using genetics, functional molecular 
biology, brain imaging, neuropsychology testing and pharmacology. The findings of these 
studies are discussed here. 
 
1.7.1. Genetic studies of ZNF804A   
The genetic association between ZNF804A and schizophrenia has been independently 
replicated (Purcell et al., 2009; Riley et al., 2009; Steinberg et al., 2011; Strange, 2012). 
Consistent with these data, meta-analysis in 60 000 subjects supported an association 
between rs1344706 and schizophrenia (P = 2.5 x 10
-11
), and a combined schizophrenia and 
bipolar disorder affected group (P = 4.1 x 910
-13
) (Williams et al., 2011). Using fine mapping, 
Williams and colleagues showed that rs1344706 was most likely to be the disease causing 
allele (Williams et al., 2011).  
 
It is possible that rare variation in ZNF804A may also increase susceptibility for 
schizophrenia. While Dwyer and colleagues (2010) showed that no rare, non-synonymous 
SNVs in ZNF804A were associated with schizophrenia, Steinberg and colleagues (2011) 
identified two CNVs spanning at least part of ZNF804A in psychosis patients. Specifically, 
Steinberg and colleagues identified a deletion of ZNF804A in an individual with 
schizophrenia and an individual with anxiety disorder, and a duplication of ZNF804A in an 
individual with bipolar disorder. These data were contrary to evidence from other CNV 
studies that did not find CNVs in ZNF804A associated with schizophrenia (Kirov et al., 
2009a; Walsh et al., 2008; Xu et al., 2008). Interestingly, the current evidence suggests that 
rare variation in ZNF804A may also contribute to risk for other neuropsychiatric diseases. 
Notably, inspection of autism CNV datasets showed that complete or partial duplications of 
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ZNF804A were associated with autism (Griswold et al., 2012; Steinberg et al., 2011). 
Furthermore, Talkowski and colleagues (2012) identified a pathogenic chromosomal 
rearrangement of ZNF804A in a neurodevelopment disorder case that was inherited from a 
similarly affected parent. Taken together, these data highlight the importance of ZNF804A in 
healthy neurodevelopment, and are consistent with the hypothesis that ZNF804A’s 
contribution to disease extends beyond schizophrenia (O'Donovan et al., 2008).  
 
1.7.2. Functional studies of ZNF804A  
The ZNF804A transcript was predicted to generate a protein of 1209 amino acids. 
Bioinformatics sequence analysis predicted ZNF804A has a C2H2 type zinc finger (ZnF) 
domain at the N-terminus of the protein (O'Donovan et al., 2008). The C2H2 type of ZnF 
domains can bind to DNA, RNA and proteins, and are prevalent in transcription factors 
(Matthews and Sunde, 2002). Therefore, it was speculated that ZNF804A may be a regulator 
of gene expression (O'Donovan et al., 2008). Further bioinformatics analysis of the ZNF804A 
amino acid sequence revealed two putative nuclear localisation signals (D. Blake, personal 
communication). The nuclear localisation of transiently expressed and endogenous ZNF804A 
has been confirmed experimentally (Girgenti et al., 2012).  
 
There have been very few published functional studies of ZNF804A. Notably, using 
microarrays, Hill and colleagues (2012) showed that, after knockdown of ZNF804A to 60% 
of wild type levels in human neural progenitor cells, there was differential expression of 
genes enriched for the gene ontology (GO) process cell adhesion. The authors proposed these 
findings may suggest a role for ZNF804A in processes such as neural migration, neurite 
outgrowth and synapse formation (Hill et al., 2012a). Girgenti and colleagues (2012) 
investigated the effects of over-expressing ZNF804A on a subset of genes which had been 
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previously implicated in schizophrenia. The results showed that transient over-expression of 
myc-ZNF804A altered the expression of dopamine receptor D2 (DRD2), phosphodiesterase 
4B, cAMP-specific (PDE4B), catechol-O-methyltransferase (COMT) and protease, serine, 16 
(thymus) (PRSS16) between three- and five-fold (Girgenti et al., 2012). Subsequent chromatin 
immunoprecipitation (ChIP) showed ZNF804A bound directly to the promoter/enhancer 
regions of PRSS16 and COMT and up-regulated their transcription (Girgenti et al., 2012). 
Recently, Umeda-Yano and colleagues (2013) showed that over-expression of ZNF804A in 
human embryonic kidney (HEK) cells led to differential expression of genes associated with 
TGFβ signalling. In summary, the current literature is consistent with initial speculation that 
ZNF804A may be a regulator of gene expression.  
 
1.7.3. The effects of the SNP rs1344706 on ZNF804A  
The disease-associated SNP rs1344706 is located in intron two of ZNF804A (O'Donovan et 
al., 2008). The literature suggests that intronic regions of DNA are important for the 
regulation of gene expression; for example, trans-acting regulatory proteins may bind to 
intronic regions (Maston et al., 2006). Using electromobility shift assays, Hill and colleagues 
demonstrated that the risk allele of rs1344706 resulted in reduced binding of unidentified 
nuclear protein in neural cells (Hill and Bray, 2011). This result may suggest that the SNP 
rs1344706 may disrupt binding of trans-acting regulatory proteins and consequently 
influence ZNF804A expression (Hill and Bray, 2011). Subsequently, Hill and Bray (2012) 
investigated the effects of SNP rs1344706 on the cis regulation of ZNF804A. The results 
showed that the disease-associated allele was associated with a relative decrease in ZNF804A 
expression during the second trimester of foetal brain development with no effect on the 
regulation of ZNF804A in the three adult brain regions examined (Hill and Bray, 2012). 
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Consequently, the authors proposed that the disease-associated SNP rs1344706 may 
contribute to disease risk in early brain development.    
 
1.7.4. The effects of the SNP rs1344706 on brain structure and function   
Initial reports suggested that the disease-associated SNP rs1344706 was associated with 
differences in brain structure in healthy controls (Lencz et al., 2010; Voineskos et al., 2011), 
and that rs1344706 affected brain volumes in schizophrenia patients, but not controls 
(Donohoe et al., 2011). However, these studies used small sample sizes (<110) and therefore, 
they were superseded by a recent study which used 892 healthy controls to examine the 
effects of the risk allele on brain structure (Cousijn et al., 2012). These data showed there was 
no effect of the disease-associated SNP on total brain volume, grey or white matter volume, 
or the volume of specific brain structures (Cousijn et al., 2012). While these data suggest that 
the genetic variation in ZNF804A is more likely to increase risk for disease through changes 
in brain function than structure, this conclusion would be more definitive if a case-control 
sample had been used.  
 
Functional magnetic resonance imaging (fMRI) studies showed that the rs1344706 risk allele 
was associated with altered connectivity in the brains of healthy controls (Esslinger et al., 
2011; Esslinger, 2009; Rasetti et al., 2011; Walter et al., 2011). To investigate the hypothesis 
that ZNF804A may contribute to disease through alterations in connectivity, researchers used 
tasks that probe the core neuropsychological deficits of schizophrenia, such as cognition. The 
results showed that the rs1344706 risk allele was associated with less impaired cognitive 
performance in patients but not healthy controls (Chen et al., 2012; Esslinger et al., 2009; 
Walters et al., 2010). This suggests that the risk allele may be associated with a subtype of 
patients for which deficits in cognition are a less significant feature of the disease (Walters et 
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al., 2010). Walters (2010) argued that, because deficits in cognition are less severe in patients 
with bipolar disorder than those with schizophrenia, these findings may be indicative of 
ZNF804A’s overlapping role in schizophrenia and bipolar disorder. Further 
neuropsychological studies showed association between SNP rs1344706 and impairments in 
the theory of mind network, suggesting that ZNF804A may contribute to disease through 
impairment of social cognition (Walter et al., 2011). However, this result was not replicated 
in a subsequent study (Hargreaves et al., 2012).  
 
1.7.5. The effects of the SNP rs1344706 on neuropharmacology  
The influence of the risk allele of ZNF804A on neuropharmacology was assessed by 
genotyping schizophrenia patients for the SNP rs1344706, treating the patients with atypical 
anti-psychotics and measuring the response of their positive and negative symptoms 
(Mossner et al., 2012). The data showed that the risk allele was associated with less 
improvement in the positive symptoms than the protective allele. This finding was consistent 
with the association between the risk allele and psychotic symptoms (O'Donovan et al., 2008; 
Williams et al., 2011). These data suggest either that ZNF804A may directly perturb the 
action of anti-psychotics, or that the rs1344706 risk allele may denote a distinct subtype of 
schizophrenia that is more resistant to treatment with atypical anti-psychotics (Mossner et al., 
2012; Xiao et al., 2011).  
 
1.8. The aims of this thesis 
At the outset of this study, the biological function of ZNF804A had not been experimentally 
demonstrated. Therefore, nothing was known about the cellular processes ZNF804A might be 
involved in, and how this may contribute to susceptibility for schizophrenia. As such, the 
association of ZNF804A with disease represented a unique opportunity to understand more 
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about the biological aetiology of schizophrenia. The primary aim of this study was to gain a 
greater understanding of the biological function of ZNF804A. Firstly, the putative protein 
binding partners of ZNF804A were identified using yeast two-hybrid (Y2H) screening 
(Chapter Three). These data suggest a potential role for ZNF804A in transcriptional 
regulation and pre-mRNA splicing. Consequently, in Chapters Four and Five, human exon 
arrays were used to investigate the effects of knocking down and over-expressing ZNF804A 
on genome-wide gene expression and pre-mRNA splicing. The novel findings presented in 
this thesis are summarised and discussed in Chapter Six.  
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Chapter 2: Materials and Methods 
 
2.1. Reagents and kits 
All chemicals used for experiments were of analytical grade and were purchased from Fisher, 
Sigma or Invitrogen unless otherwise stated. All molecular biology reagents were purchased 
from New England Biolabs or Promega. All kits were used as per manufacturer’s 
instructions.  
 
2.2. Maintenance of cell lines and media 
2.2.1. Bacterial cell culture 
Propagation of DNA expression plasmids was performed using Escherichia coli (E. coli) 
XL1-Blue cells (Stratagene), genotype: recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 
lac[F’ proAB lac1qZΔM15 Tn10(Tetr)]c. Bacterial cells were grown in Luria-Bertani (LB) 
media (liquid culture) and on LB-agar media (plate culture) (Tryptone (pancreatic digest of 
casein) 10 g/l, yeast extract 5 g/l, NaCl 5 g/l and agar 15 g/l). Media was autoclaved and 
cooled to below 50°C prior to addition of the appropriate antibiotic. For bacterial cell culture, 
the final concentrations of antibiotics used were: ampicillin 100 µg/ml (LB-amp), kanamycin 
30 µg/ml (LB-kan), zeocin 50 µg/ml (LB-zeo) and tetracycline 100 µg/ml (LB-tet). In liquid 
culture, E. coli strains were grown for 16-20h at 37°C in LB with shaking at 200 rpm for all 
recombinant DNA methods. In solid culture, E. coli strains were grown on LB plates for 16-
20h and stored at 4°C for up to one month. Before picking colonies, the LB plates were 
removed from storage one hour before use, inverted and allowed to dry. For long term 
storage of E. coli strains, fresh cultures in mid-log phase (optical density measured at 600 nm 
(OD600) = 0.6-0.8) were frozen in 15% (v/v) glycerol and stored at -80°C.  
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2.2.2.  Yeast cell culture  
The L40 strain of Saccharomyces cerevisiae (S. cerevisiae) (Invitrogen) was used for all 
yeast work. The known genotype of L40 is: MATa his3-Δ200 trp1-901 leu2-3,112 ade2 lys2-
801am LYS2::(lexAop)4-HIS3 URA3::(lexAop)8-lacZ GAL4. L40 were grown in yeast-
peptone-adenine-glucose (YPAD) media. To prepare YPAD for liquid culture, 1% (w/v) 
yeast extract, 2% (w/v) Bacto-Peptone and 0.01% (w/v) adenine media was autoclaved. To 
prepare YPAD for plate culture, Bacto-agar (Invitrogen) was added to YPAD media to a final 
concentration of 2% (w/v). Media was autoclaved and cooled to below 50°C prior to addition 
of 20% (w/v) glucose to a final concentration of 2% (v/v). For maintenance of bait strains, 
zeocin was added to YPAD at a final concentration of 300 µg/ml following autoclaving 
(YPADZ300).  
 
For Y2H screening, yeast complete (YC) media (minimal defined media for yeast) was 
prepared: 0.67% (w/v) yeast nitrogen base (Qbiogene), 0.0652% (w/v) complete 
supplemental mixture (CSM) minus listed amino acids (Qbiogene) as indicated; 2% (v/v) 
glucose was added after autoclaving. YC-agar plates were made by adding 2% (w/v) Bacto-
agar (Invitrogen) to YC media prior to autoclaving. For selection of the bait plasmid, zeocin 
was added to autoclaved YC media at a final concentration of 300 µg/ml (YCZ300). L40 
were grown at 30°C with shaking at 200rpm or incubated for 2-4 days at 30°C on solid 
growth media. Plates were stored at 4°C for up to one month. For long term storage of 
strains, fresh cultures in stationary phase were supplemented with 15% (v/v) glycerol and 
stored at -80°C.  
 
2.2.3.  Mammalian cell culture   
COS-7 (African green monkey kidney), HEK293T (human embryonic kidney 293T) and SH-
SY5Y (neuroblastoma) cell lines were purchased from the European Collection of Cell 
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Cultures (ECACC) and the American Type Culture Collection (ATCC). The 9E10 (anti-myc) 
hybridoma cell line was obtained from the Developmental Studies Hybridoma Bank (DSHB) 
at the University of Iowa. The Flp-In TREx -293 cell line was purchased from Invitrogen. 
The Flp-In TREx -293 cell line is a derivative of HEK293 fibroblasts (obtained from ATCC) 
which has been genetically modified to contain a Flp recognition target (FRT) site.  
 
Cells were cultured in complete media: Dulbecco’s modified eagle media (DMEM, 
Invitrogen) supplemented with 10% (v/v) foetal calf serum (FCS; PAA laboratories), 1% 
(v/v) penicillin/streptomycin at 37°C, 5% CO2 in a humidified incubator. For the Flp-In 
TREx -293 cells, the cell culture media was supplemented with zeocin (100 µg/ml) and 
blasticidin (15 µg/ml) according to the manufacturer’s instructions. Cells were cultured in 
T175 cm
2 
flasks and passaged twice weekly by first washing with 10 ml Ca
2+
 and Mg
2+
 free 
Hank’s balanced salt solution (Sigma Aldrich) and then trypsinising with 5 ml of 1 X trypsin-
ethylenediaminetetraacetic acid (TE). When required, cells were counted using a 
haemocytometer and seeded at the appropriate density. For long term storage, the cells were 
resuspended in freezing medium: 90% complete medium and 10% dimethyl sulfoxide 
(DMSO), and frozen in automated controlled-rate freezing apparatus before being transferred 
to liquid nitrogen or kept at -80°C for long term storage.  
 
2.2.4. Growth and maintenance of hybridomas 
Hybridomas were grown in DMEM supplemented with 10% (v/v) FCS and 1% (v/v) 
penicillin/streptomycin. Frozen cells were established in a 75 cm
2
 tissue culture flask with 
20% (v/v) FCS, and then transferred to a 175 cm
2
 flask containing 10% (v/v) FCS after 
recovery. Cells were passaged as described above. When the cells were confluent, the 
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supernatant was removed and centrifuged for 5 min at 4000 rpm. The supernatant was stored 
at -20°C until the antibody was purified.  
 
2.3. Molecular biology 
2.3.1.  Polymerase chain reaction   
For polymerase chain reaction (PCR), oligonucleotide primers were designed complementary 
to 18-24 base pairs of the target sequence with an estimated melting temperature of 60°C. 
PCR primers are listed in Appendix 1. When required, restriction endonuclease sites were 
added to the 5’ end of the primer sequence. To increase the efficiency of restriction enzyme 
cleavage, three base pairs were included at the 5’ end of the restriction enzyme recognition 
sequence. PCR was routinely performed using Red Taq (Sigma). When proof-reading was 
required, enzymes such as PfuUltra or Easy A (Stratagene) were used. PCRs were performed 
in a PTC-220 DNA Engine DyadTM Peltier Thermal Cycler (MJ Research Inc.) as outlined 
in Table 2.1. PCR products were separated by gel electrophoresis using 0.8-2% agarose gels 
as described in section 2.3.3.  
 
Name  Volume (µl) Final concentration Program 
10X PCR buffer  5   1 x 1. 95°C  for 5 min         
Forward primer (10 µM)  1 0.2 µM 2. 95°C  for 30 sec         
Reverse primer (10 µM) 1 0.2 µM 3. 56-60°C  for 30 sec         
Deoxynucleotide mix (10 mM) 1 200 µM 4. 72°C  for 1 min/kb         
cDNA (10 ng/µl) 5 50 ng 5. Go to step 2; 20-40 
times 
DNA polymerase (5 U/µl) 0.5 0.05 U/µl 6. 72°C for 7 min 
Sterile distilled water up to 50   7. 4°C for ∞ 
 
Table 2.1 Typical PCR conditions 
 
2.3.2. Screening colonies by PCR  
To confirm the presence of an insert by PCR, bacterial or yeast colonies were individually 
inoculated into 50 µl of the appropriate media using sterile needles (Fisher). An aliquot of 5 
Chapter Two: Materials and Methods 
37 
 
µl of this mixture was used as a template for PCR using oligonucleotide primers designed 
complementary to the insert and Red Taq DNA polymerase. The PCR programme used 30 
cycles. The resulting PCR products were electrophoresed on an agarose gel to confirm the 
presence of a band of the expected size. For colonies which contained the insert, the 
remaining 45 µl was used to inoculate 5 ml LB containing the appropriate antibiotic and this 
was grown overnight (37°C, 200 rpm). Plasmid DNA was prepared from this culture as 
described in section 2.4.1.  
 
2.3.3.  Agarose gel electrophoresis    
Agarose gels were typically made as 1% (w/v) agarose (Invitrogen) in 1 X TAE buffer (40 
mM tris-acetic acid, 10 mM EDTA pH 8.0). However, 0.5-2% (w/v) agarose gels were used 
depending on the size of the expected fragments. The agarose was dissolved in TAE buffer 
by heating in a microwave and the solution was cooled to 50°C before addition of ethidium 
bromide (EtBr) solution to a final concentration of 0.5 µg/ml. Where appropriate, DNA 
samples were prepared for electrophoresis using 6 X gel loading buffer (30% (v/v) glycerol, 
20 mM EDTA pH8.0, 0.25% (w/v) bromophenol blue, 0.25% (w/v) xylene cyanol in sterile 
distilled water) before loading into wells. A 1 kb Plus DNA Ladder (Invitrogen) was used as 
a size standard. The gel was submerged in 1 X TAE and run at 100V for 30 min or until an 
appropriate resolution was achieved. EtBr stained nucleic acid was visualised using a UV 
transilluminator system (Bio-Rad Gel Doc 2000).  
 
2.3.4.  Preparation of RNA 
Total RNA was prepared from mammalian cells using the RNeasy RNA extraction kit 
(Qiagen). Cells were lysed directly using RLT buffer and homogenised using a syringe and 
needle (23 gauge). For routine use, the quality of RNA was determined by measuring 
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absorbance at 260 and 280 nm. For exon array, the quality of the RNA was determined by 
Central Biotechnology Services (CBS) at Cardiff University, using the Agilent 2100 
bioanalyser. For PCR and quantitative-PCR (Q-PCR), the samples received DNase treatment 
to remove residual DNA: 2.5-5 µg of RNA was treated with DNase using the Ambicon Turbo 
DNase free kit according to manufacturer’s instructions. The RNA was stored at -80°C.  
 
2.3.5.  First strand cDNA synthesis   
To generate 1
st
 strand cDNA, 2.5-5 µg RNA was reverse transcribed using Protoscript M-
MuLV First strand cDNA Synthesis Kit (NEB) according to the manufacturer’s instructions. 
Oligo-dT priming [d(T)23VN] was used as it ensures that all cDNA copies terminate at the 3’ 
end of the mRNA and produces the longest contiguous cDNA. A control reaction without 
reverse transcriptase (–RT) was prepared to examine the levels of residual genomic DNA 
(gDNA). Typically, the –RT sample was prepared using pooled RNA. A non-template RT 
control (5 µl of sterile distilled water instead of RNA in the RT reaction) was performed to 
examine the potential contamination of the reagents in the kit. The cDNA products were 
diluted with sterile distilled water (1:5 when the cDNA was destined for PCR and 1:20 when 
the cDNA was destined for Q-PCR) and were stored at -20°C.  
 
2.3.6.  Quantitative-PCR  
Gene expression was quantitated by Q-PCR using either Sensimix no rox SYBR-Green 
(Bioline) or Solaris primer/probes (Thermo Scientific) and a Qiagen Rotor-gene 3000 real 
time PCR machine (Qiagen) following the conditions outlined in Table 2.2. When SYBR-
Green was used, the melt curve analysis was performed from 55°C to 95°C. The threshold 
cycle (Ct) values, the fractional cycle number at which fluorescence passes the threshold, 
were calculated by the Qiagen Rotor-Gene 3000 software. The Q-PCR mastermix was  
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Sensimix  
Name Volume (µl) Program 
SYBR-Green PCR master mix 12.5   1. 95°C  for 10 min         
Forward primer (100 µM) 0.75  2. 95°C  for 15 sec         
Reverse primer (100 µM)  0.75 3. 55-60°C  for 15 sec         
Sterile distilled water 6 4. 72°C  for 15 sec         
cDNA (1.5 ng/µl) 5 5. Go to step 2; 40 times 
Solaris  
Name Volume (µl) Program 
Solaris master mix (2X) 12.5   1. 95°C  for 15 min         
Solaris primer/probe set (20X) 1.25  2. 95°C  for 15 sec         
Sterile distilled water 10.25 3. 60°C  for 1 min 
cDNA (1.5 ng/µl) 1 4. Go to step 2; 40 times 
 
Table 2.2 Typical Q-PCR conditions 
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prepared using a PCR setup pipetting robot (CAS-1200, Corbett Life Science, Qiagen). The 
samples were run in triplicate. A –RT control, a non-template RT control (5 µl of sterile 
distilled water instead of RNA in the RT reaction) and a non-template Q-PCR control (5 µl of 
sterile distilled water instead of cDNA) were included in each Q-PCR run.  
 
The details of the Q-PCR primer sequences used in this thesis are given in Appendices 1.6 
and 1.7. Both the transcript- and exon-level target validations used intron-flanking primers 
wherever possible to eliminate gDNA amplification. For accurate and reproducible Q-PCR 
measurements, it was important that the primer sets used had high amplification efficiency; a 
PCR assay has 100% efficiency if the PCR amplicon doubles in quantity during the 
geometric phase of the PCR amplification. To assess the efficiency of the primer sets, Q-PCR 
assays were performed in duplicate using, wherever possible, a four log span of input cDNA. 
Where the transcript abundance was too low to use a four log span, the dilutions were 
adjusted accordingly. The amplification efficiency was calculated from a standard curve of 
the Ct value against log input of cDNA where efficiency = (10
-1/slope 
-1) x 100. Only primers 
with amplification efficiency between 90% and 110% were used in experiments.  
 
For data analysis, a relative quantification method known as the comparative Ct method was 
applied because the aim was to compare transcript-level and exon-level abundance among 
different groups. When using the comparative Ct method, it is important to apply a 
normalisation strategy. Housekeeping genes are commonly used as an internal control in 
order to normalise the Q-PCR data for the amount of RNA that is added to a reaction. In this 
thesis, beta actin (ACTB) was selected as the reference gene (also known as the ‘control’), 
because the exon array analyses showed that the mRNA level of ACTB was not altered after 
ZNF804A knockdown or over-expression (data not shown). For transcript-level targets, the 
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target mRNA was quantified relative to ACTB. For the exon-level targets, the transcript 
variant of interest was quantified relative to an mRNA common to all transcript variants. The 
comparative Ct method was as follows: for each condition the three technical replicate Ct 
values were averaged using the mean. This average Ct value was subtracted from the average 
Ct value of the control to produce the ∆Ct value. The next step was to calculate the ∆∆Ct 
value by subtracting the ∆Ct values of the experimental group from the ∆Ct values of the un-
treated/control group. The negative ∆∆Ct value was then used as the exponent of two (based 
on the assumption that the reaction doubles the amount of product per cycle – see below). 
Finally, the 2
-∆∆Ct 
values were multiplied by 100 to give the abundance as a percentage 
relative to the control sample and represented as a graph. The error bars represent the limits 
of the standard deviation (sd) of the triplicate Ct values prior to normalisation. The upper limit 
was calculated as (2
-(∆∆Ct – sd)
 - 2
-∆∆Ct
)
 
and lower limit was calculated as (2
-∆∆Ct
 - (2
-(∆∆Ct + sd)
).   
 
It was important that the PCR amplification efficiencies of both the target and the control 
primer set were relatively equivalent. To assess this, Q-PCR assays were performed and the 
∆Ct values were calculated and plotted against log input cDNA. An R
2
 less than 0.1 signified 
that the two primer sets had relatively equivalent amplification efficiencies. The primer 
amplification efficiencies are given in Appendices 1.6 and 1.7.  
 
2.3.7.  Mammalian cell transfection and drug treatment    
Cells were seeded in 6-well plates at a density of 1 x 10
5
 (COS-7) or 5 x 10
5
 (HEK293T) 
cells per well. Transfections were carried out using Fugene-6 (Roche) as per manufacturer’s 
instructions. For proteasome inhibition, 24h after transfection the cells were treated with 
lactacystin (10 µM) (Sigma) for 17h.  
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2.3.8.  Gene silencing using small interfering RNA  
SH-SY5Y cells were transfected with small interfering RNA (siRNA) duplexes using 
Lipofectamine RNAi MAX (Life Technologies) according to manufacturer’s instructions. 
Briefly, SH-SY5Y cells were seeded in 12-well plates (5 x 10
4
 cells per well) in DMEM 
supplemented with 5% (v/v) FCS. Three wells were used per condition. The following day, 
cells were transfected with ZNF804A-specific siRNA (Dharmacon) or GAPDH-specific 
siRNA at a final concentration of 50 nM (Table 2.3). The growth media was changed 24h 
post-transfection and the following day the transfection protocol was repeated. Forty-eight 
hours later, the cells from the three wells were pooled. RNA was extracted as described in 
section 2.3.4 and frozen at -80°C.  
 
Duplex Sense strand 5’ - 
siZNFA GGAAAAUACCAUAGCAAAAUU 
siZNFB CCAGGAAAGAUGAAAGAAAUU 
siGAPDH GUCAACGGAUUUGGUCGUAUU 
             
Table 2.3 The siRNA duplexes used in this study  
 
2.4. Cloning 
2.4.1.  Purification of plasmid DNA 
DNA was isolated from small scale cultures (5 ml) or large scale cultures (>100 mls) of E. 
coli. Plasmid DNA was purified using the Qiaprep Spin Miniprep or plasmid Maxiprep kit 
(Qiagen) according to the manufacturer’s instructions. DNA was quantified using a 
spectrophotometer (BioPhotometer, Eppendorf) at 260/280 nm (A260).  
 
2.4.2.  Restriction digest of DNA   
All restriction enzymes were purchased from New England Biolabs. For preparation of 
vectors for cloning, 1 µg of purified vector was cut with the appropriate restriction enzymes 
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(approximately 20 units (U), where 1 U of restriction enzyme will completely digest 1 µg of 
substrate DNA in a 50 µl in 1h) in a total volume of 50 µl for 2h at 37°C followed by 
addition of 10 U calf intestinal alkaline phosphatase (CIP) for 1h at 37°C. The restriction 
digest products were separated by agarose gel electrophoresis as described in section 2.3.3 
and the fragment was excised and purified using the Qiagen Gel extraction kit. For digestion 
of purified PCR products, the entire purified product was mixed with the appropriate 10X 
buffer and restriction enzyme (approximately 20 U) for 1-2h at 37°C. The digest was purified 
using the Qiagen PCR purification kit. For digestion of purified DNA, for example to confirm 
the presence of an insert, 1 µl of DNA was digested with the appropriate restriction enzyme 
(approximately 10 U) and 10X buffer in a total volume of 20 µl for 1h at 37°C. The 
restriction digest products were separated by agarose gel electrophoresis. 
 
2.4.3.  Ligation of DNA fragments into vectors  
Ligation of digested DNA into vectors was performed using T4 DNA ligase (Promega). A 
typical reaction used a 3:1 molar ratio of insert to vector. In a 10 µl reaction 1 µl T4 DNA 
ligase was used. Reactions were centrifuged briefly before incubation overnight at 4°C. 
Control reactions containing insert only or vector only were prepared to confirm complete 
digestion of the insert and dephosphorylation of the vector. Typically, 5 µl of the ligation 
reaction was used to transform E. coli (section 2.4.6).  
 
2.4.4.  Preparation of chemically competent E. coli XL1-Blue cells 
Competent cells were prepared from E. coli XL1-Blue. An E. coli XL1-Blue glycerol stock 
was streaked onto LB-tet plates and grown overnight at 37°C. A single colony was inoculated 
into 10 ml LB-tet media and grown overnight (37°C, 200 rpm). 5 ml of the overnight culture 
was used to inoculate 500 ml LB-tet, which was grown at 37°C with agitation (200 rpm) until 
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the cells reached mid-log phase (OD600 approximately 0.5). The culture was cooled on ice for 
2h and the bacteria were pelleted by centrifugation at 4000 rpm for 20 min at 4°C. The pellet 
was gently resuspended in 250 ml fresh, ice-cold, filter sterilised salt buffer (100 mM calcium 
chloride (CaCl2), 70 mM manganese chloride (MnCl2), 40 mM sodium acetate (NaOAc) pH 
5.5) and incubated on ice for 45 min. After incubation, the bacteria were pelleted by 
centrifugation at 4000 rpm for 10 min at 4°C. The pellet was resuspended in a total of 50 ml 
salt buffer and 11.5 ml ice-cold filter sterilised 80% (v/v) glycerol was added drop-wise with 
gentle agitation, to give a final concentration of 15% (v/v). Single aliquots of 500 µl were 
stored at -80°C.  
 
2.4.5.  Preparation of electrocompetent E. coli XL1-Blue cells 
An E. coli XL1-Blue glycerol stock was streaked onto LB-tet plates and grown overnight at 
37°C. A single colony was picked, inoculated into 5 ml LB-tet broth and grown overnight 
(37°C, 200 rpm). The 5 ml of overnight culture was used to inoculate 500 ml LB-tet and this 
was grown at 37°C with agitation (200 rpm) until the cells reached mid-log phase (OD600 
approximately 0.5). The culture was cooled on ice for 30 min, transferred to ten pre-cooled 
50 ml Falcon tubes and centrifuged (2000g, 4°C, 15 min). The pellets were resuspended in a 
total of 500 ml cold sterile distilled water and re-centrifuged. This was repeated in a total of 
250 ml cold sterile distilled water. The pellets were washed and pooled in a total of 10 ml 
sterile, cold, 10% glycerol, re-centrifuged and resuspended in a total of 1 ml sterile, cold 10% 
glycerol. Single aliquots were stored at -80°C.  
 
2.4.6.  Transformation of E. coli XL1-Blue using heat-shock method  
Cells were removed from the -80°C freezer and thawed on ice. 50 µl of cells were added to 
pre-chilled 2059 polypropylene tubes. 5 µl of ligation reaction (section 2.4.3) or 10 ng diluted 
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plasmid was added to the cells and incubated on ice for 30 min. Cells were heat-shocked at 
42°C for 1 min using a water bath and chilled on ice for 2 min. 1 ml LB media was added and 
the cells were incubated at 37°C for 1h to enable the expression of antibiotic resistance genes. 
Cells were transferred to a microcentrifuge tubes and centrifuged in a desktop microfuge (13 
000 rpm, 1 min). The pellet was resuspended in 100 µl fresh LB, plated onto LB plates 
containing the appropriate selective antibiotic and incubated overnight at 37°C.  
 
2.4.7.  Transformation of E. coli XL1-Blue using electroporation  
Cells were removed from the -80°C freezer and thawed on ice. 5 µl of ligation reaction 
(section 2.4.3) or Y2H ‘prey’ plasmids extracted from yeast (section 2.5.4), were added to 
cells and the sample was incubated on ice for 1 min. The sample was added to a pre-chilled 
2mm electroporation cuvette and electroporated with a 5 ms pulse of 2.5 kV, 600 Ω, 10 µF 
using the MicroPulser electroporation apparatus (Bio-Rad). Cells were recovered in 1 ml LB 
and incubated at 37°C for 1h to enable the expression of antibiotic resistance genes. Cells 
were transferred to a microcentrifuge tube and centrifuged in a desktop microfuge (13 000 
rpm, 1 min). The pellet was resuspended in 100 µl fresh LB, plated onto LB plates containing 
the appropriate selective antibiotic and incubated overnight at 37°C.  
 
2.4.8.  DNA sequencing   
Purified templates were sequenced by SourceBioscience Life Sciences Oxford DNA 
sequencing services. All sequencing was performed using ABI BigDye Terminators V3.1 
(Applied Biosystems). The sequencing chromatogram traces were checked using Chromas 
Lite, version 2.01 (Technelysium Pty Ltd).  
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2.5. Yeast two-hybrid screening 
The version of the yeast two-hybrid (Y2H) system used in this study is based on the Hybrid 
Hunter interaction trap (Invitrogen).  
 
2.5.1.  Generating the Y2H bait strain  
The bait plasmids (N-term-ZNF804A-pHybLex/ZeoA and C-term-ZNF804A-
pHybLex/ZeoA) and the bait strains used in this study were obtained from C.L. Tinsley. The 
bait strains were generated by transforming the bait plasmids into L40 using the lithium 
acetate (LiAc) method as follows: to generate a starter culture 10 ml of YPAD was inoculated 
with a colony of L40 and shaken overnight at 30°C. The starter culture was diluted to an 
OD600 of 0.4 in 50 ml of YPAD and grown for an additional 2h. The cells were centrifuged at 
2500 rpm and the pellet was resuspended in 40 ml sterile distilled water. The cells were 
centrifuged at 2500 rpm, resuspended in 2 ml of 1X LiAc/0.5X TE and incubated at rt for 10 
min. For each transformation, 1 µg plasmid DNA and 100 µg denatured salmon sperm DNA 
was mixed with 100 µl of the yeast suspension. Subsequently, 700 µl of 1X LiAc/40% 
polyethylene glycol (PEG) -3350/1X TE was added and the sample was mixed well. The 
solution was incubated at 30°C for 30 min and then 88 µl DMSO was added. To heat shock, 
the sample was incubated at 42°C for 7 min. To allow expression of antibiotic resistance by 
the plasmid, the sample was then incubated at 30°C for 1h. The mixture was centrifuged in a 
table top microcentrifuge (13 000 rpm, 10s) and the supernatant was removed. The cell pellet 
was resuspended in sterile distilled water and re-centrifuged. The transformation mix was 
resuspended in 100 µl sterile distilled water and plated on YPADZ300 plates. The plates were 
incubated at 30°C for 3-4 days.  
 
 
Chapter Two: Materials and Methods 
47 
 
2.5.2.  Testing for self-activation of the bait plasmid  
To confirm that the bait plasmid did not self-activate, transformants were selected from the 
YPADZ300 plates and transferred to 50 µl sterile distilled water in microcentrifuge tubes. 
These colonies were then streaked onto the YPADZ300 plates containing 3-aminotriazole (3-
AT) at the following concentrations: 0; 5; 10; 15 and 20 mM. Bait strains that grew on plates 
containing 20 mM 3-AT were deemed unsuitable for use in the Y2H experiments. In 
subsequent Y2H screens for baits that could be used, YPADZ300 plates were supplemented 
with the lowest 3-AT concentration at which no growth was observed after five days.  
 
2.5.3.  Small scale transformation of yeast using the lithium acetate method  
The bait strain was co-transformed with the prey mouse brain cDNA library (Invitrogen) in 
the pPC86 vector or the human foetal brain cDNA library (Invitrogen) in the pDEST
™
22 
vector according to the transformation of yeast (TRAFO) protocol (Agatep et al., 1998; Gietz 
and Woods, 2002). A 5 X TRAFO scale screen was used. A starter culture was generated by 
inoculating a yeast bait strain colony into two aliquots of 5 ml YPAD media and incubating at 
30°C with 200 rpm overnight. The OD600 was measured using a spectrophotometer and the 
cell titre was determined using the formula OD600 of 1 = 1 x10
7
 cells. A volume of cells that 
yielded 1.25 x 10
8
 cells was used. The culture was centrifuged at 3000 x g for 5 min and 
resuspended in 25 ml YPADZ300. This was incubated at 30°C with shaking at 200 rpm until 
the cells had reached mid-log phase (OD600 of 2). The cells were harvested at 3000 x g for 5 
min and the pellet washed with 12.5 ml sterile distilled water and centrifuged again. The 
pellet was resuspended in 1.5 ml sterile 100 mM LiAc and incubated in a water bath at 30°C 
for 15 min. The cells were harvested as above and the components of the transformation mix 
added to the pellet in the following order: 34% (v/v) PEG3000, 100 mM LiAc, 150 µg boiled 
salmon sperm DNA, 20 µg prey plasmid in sterile distilled water. The pellet was resuspended 
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by vigorous vortexing, incubated for 30 min at 30°C and the tube mixed gently several times 
after 10 and 20 min to mix the contents thoroughly. The suspension was then heat shocked at 
42°C for 50 min and mixed by inversion for 15 sec at 5 min intervals. The cells were 
harvested as previously and the cell pellet was gently resuspended in 2 ml of sterile distilled 
water. 400 µl aliquots were plated onto five 150 mm plates containing MM-Trp-Lys-His-Ura, 
Z300 (MM-TrpZ300) and 3-AT. These were incubated at 30°C for 4-7 days. Colonies that 
grew on the histidine deficient medium were re-streaked onto fresh selective plates. The 
transformation efficiency was determined by plating dilutions of the transformed yeast onto 
MM-TrpZ300 plates and was used to estimate the number of clones screened (Table 2.4). In 
error, the transformation efficiency of the N-terminal screen using the human foetal brain 
cDNA library was not measured.   
 
cDNA library Bait Number of clones screened 
Human foetal brain C 8 x 10
5
 
Mouse brain N 3 x 10
6
 
Mouse brain C 1.5 x 10
6
 
 
Table 2.4 The transformation efficiency  
 
2.5.4. Extraction of the prey yeast DNA  
The yeast containing prey plasmids were isolated by growing in MM-TrpZ300 media. 
Plasmid DNA from interacting clones was purified using the RPM Yeast Plasmid Isolation 
Kit (Q-Biogene). The resulting DNA was amplified by PCR using pDEST™22 forward and 
reverse primers (see Appendix 1.5 for primer sequences) and the resulting products analysed 
by agarose gel electrophoresis as described in section 2.3.3. When a clear DNA band was 
obtained, the PCR product was PCR purified and sent for direct sequencing using the pPC86 
vector forward sequencing primer (section 2.4.8). When a clear DNA band was not observed 
by agarose gel electrophoresis, 5 µl of the yeast DNA was transformed into electrocompetent 
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E. coli XL1-Blue using electroporation (section 2.4.7). Three colonies were picked for each 
clone, grown overnight and the DNA isolated (section 2.4.1). The resulting DNA was 
digested with the restriction enzyme BSRG1 to determine the size of the insert. The 5’ end of 
the cDNA was sequenced using pPC86 vector forward sequencing primer and the identity of 
the insert was determined using the National Centre Biotechnology Information (NCBI) basic 
local alignment search tool (BLAST).  
 
2.6. Protein analysis  
2.6.1.  Sample preparation 
For the preparation of protein samples from transfected cell lines, 5 x 10
5 
HEK293T cells, 
myc-ZNF804A Flp-In TREx or GFP-TCF4 Flp-In TREx cells were seeded and after 24h the 
cells were transfected or induced as appropriate. The following day, protein lysates were 
prepared. Cells were washed twice with phosphate buffered saline (PBS) and lysed in 250 µl 
2X sample buffer (0.125 M Tris pH 6.8, 4% sodium dodecyl sulphate (SDS), 20% (v/v) 
glycerol, 5% (v/v) β-mercaptoethanol, 0.001 (w/v) bromophenol blue). Cells were scraped, 
placed in a microcentrifuge tube and sonicated with a Vibra-Cell ultrasonic processor 
(Sonics) using 10 sec pulses with a 15 sec rest at 50W for two cycles. Samples were stored at 
-20°C and 15 µl was used for analysis by SDS- polyacrylamide gel electrophoresis (SDS-
PAGE). Samples were boiled for 5 min at 95°C and cooled on ice before use.  
 
2.6.2.  SDS-PAGE  
Protein samples were separated on 10% (v/v) acrylamide gels by SDS-PAGE, under 
denaturing and reducing conditions using the Mini Protean III Gel System. The resolving gel 
contained 380 mM Tris-hydrogen chloride (Tris-HCl), pH 8.8, 10% (v/v) acrylamide (30% 
(w/v) acrylamide; 0.8% (w/v) bis-acrylamide (37.5:1)), 0.1% (w/v) SDS, 0.1% (w/v) 
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ammonium persulphate (APS) and 0.08% N,N,N,N-Tetramethylethylenediamine (TEMED). 
The stacking gel consisted of 125 mM Tris-HCl pH 6.8, 5% (v/v) acrylamide (30% (w/v) 
acrylamide: 0.8% (w/v) bis-acrylamide (37.5:1)), 0.1% (w/v) SDS, 0.1% (w/v) APS and 
0.1% TEMED. The resolving gel was layered with isopropanol (IPA) during the 
polymerisation process to ensure that the resolving gel was packed tightly and had an even 
interface with the stacking gel. Following polymerisation, the IPA was discarded and the top 
of the gel was gently washed with sterile distilled water. The stacking gel was then layered 
onto the resolving gel and a lane-forming comb was inserted. When the stacking gel had 
polymerised, the gels were immobilised in the clamp system, submerged in SDS-PAGE 
running buffer (25 mM Tris-base, 192 mM glycine, 1% (w/v) SDS) and samples were loaded. 
A pre-stained, broad range molecular weight marker (7-175 kDa, NEB) was loaded as a 
reference on each gel to allow confirmation of band size after migration. Gels were 
electrophoresed at 150V for 70 min.  
 
2.6.3.  Western blotting  
Following electrophoresis, proteins from the SDS-PAGE gels were transferred to 
nitrocellulose membrane using the Mini Trans-blot electrophoretic transfer cell. Gels were 
submerged in transfer buffer (25 mM Tris-base, 192 mM glycine, 1% (w/v) SDS, 20% (v/v) 
methanol) and proteins were transferred for 1h at 70V for a single gel or at 80V for two gels. 
The membrane was blocked either for 1h at room temperature or overnight at 4°C in blocking 
solution (5% (w/v) dried skimmed milk powder in Tris buffered saline-Tween (TBST) (150 
mM NaCl, 50 mM Tris-HCl pH 7.5, 1% (v/v) Tween-20)). After blocking, the membrane 
was incubated with the primary antibody diluted to the appropriate concentration in blocking 
solution at room temperature for 1h or at 4°C overnight. The primary antibodies used in this 
thesis are listed in Table 2.5. The membrane was washed twice in TBST for 5 min with 
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shaking and then washed once in blocking solution for 5 min with shaking. The membrane 
was incubated with the appropriate secondary antibody diluted in 10 ml blocking solution at 
room temperature for 1h or at 4°C overnight, in both instances the membrane was protected 
from the light. The secondary antibodies used in this thesis are listed in Table 2.5. The 
membrane was washed three times with TBST for 5 min with shaking, before visualisation 
using the Odyssey Infrared Imaging System (LI-COR Biosciences). The images were 
assembled using Adobe Photoshop CS2 and Illustrator, and were cropped and adjusted for 
brightness and contrast but otherwise not manipulated.  
 
2.6.4. Purification of monoclonal antibody from hybridomas  
To purify the antibody, a 1 ml protein-G column was packed in an Econo-Pac® disposable 
chromatography column, equilibrated with PBS and a frit was inserted. The supernatant (200 
ml) was poured over the column repeatedly for 1h. The purified antibody was eluted with 
ImmunoPure® IgG Elution buffer in 1 ml fractions and neutralised with 50 µl/ml Tris pH 
9.0. The column was washed with PBS and stored at 4°C in PBS with 0.025% (v/v) sodium 
azide. 
 
2.7. Proteomics   
2.7.1.  Crosslinking of the anti-myc antibody to protein A agarose 
Anti-myc antibody-conjugated protein A beads were prepared by coupling the anti-myc 
antibody (9E10) to protein A agarose (Invitrogen). Protein A agarose was prepared in a 15 ml 
falcon tube by washing 1 ml of 50% protein A agarose slurry with PBS by centrifugation at 
2000 rpm for 5 min. 2 mg of affinity-purified antibody was diluted 1:1 with PBS to a final 
volume of 4 ml and incubated with the protein A agarose for 2h at room temperature with 
rotation. The beads were centrifuged at 2000 rpm for 5 min and were washed twice with 5 ml  
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Antibody Specificity 
Dilution for western 
blot 
Dilution for cell culture 
immunofluorescence 
Source 
Primary antibodies         
Rabbit polyclonal         
3077 human ZNF804A 1:50 – in-house, described Appendix 3.1 
001 mouse Zfp804a 1:50 – in-house, described Appendix 3.2 
002 mouse Zfp804a 1:50 – in-house, described Appendix 3.2 
D-14 human ZNF804A 1:400 – Santa Cruz 
S-16 rat and mouse ZNF804A 1:400 – Santa Cruz 
P-13 rat and mouse ZNF804A 1:400 – Santa Cruz 
Mouse monoclonal 
   
  
9E10 c-myc 1:400 1:200 DSHB 
12G10 α-tubulin 1:10000 – DSHB 
FK2 mono- and poly- ubiquitin conjugates 1:1000 – Biomol 
GFP green fluorescent protein 1:1000 – Covance 
SC35 SC-35 (nuclear speckle marker) 
 
1:2000 Abcam 
Secondary antibodies 
  
  
  
  
Alexa Fluor 488 mouse/rabbit IgG – 1:1000 Invitrogen 
Alexa Fluor 568 mouse/rabbit IgG – 1:1000 Invitrogen 
Alexa Fluor 680 rabbit IgG 1:10000 – Invitrogen 
IRDye 800 mouse IgG 1:10000 – Rockland Immunocytochemicals 
 
Table 2.5 The antibodies used in this thesis  
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0.1 M borate buffer (0.2 M di-sodium tetraborate, 0.2 M boric acid, pH 9.0). The antibody 
was cross-linked to the protein A beads by adding 20 mM dimethyl pimelimidate (DMP) in 
9.5 ml borate buffer and incubating with rotation at room temperature for 30 min. The beads 
were centrifuged at 2000 rpm for 5 min and the reaction was stopped by washing the beads in 
5 ml 0.1 M ethanolamine, pH 8.0. Unreacted DMP was quenched by incubating the beads 
with 5 ml 0.1 M ethanolamine at room temperature for 1h. The beads were then centrifuged 
at 2000 rpm for 5 min, washed in PBS and centrifuged again. To remove any uncoupled IgG 
the beads were washed with 5 ml of ImmunoPure® IgG Elution Buffer (Pierce). The beads 
were then washed twice with PBS and resuspended as a 50% slurry in PBS with 0.05% 
sodium azide. The beads were stored at 4°C.  
 
2.7.2.  Immunoprecipitation    
For immunoprecipitation, cells were seeded in 10 cm dishes at 2 x 10
6
 cells per dish. The 
following day, the cells were either transfected with 1-6 µg DNA or induced to express the 
gene of interest with 1 µg/ml tetracycline. 24h later, the cells were washed in 5 ml PBS and 
lysed in RIPA buffer (150 mM NaCl, 50 mM Tris, pH 8.0, 1% (v/v) Triton X-100, 0.5% (v/v) 
sodium deoxycholate (DoC), 1 mM ethylene glycol tetraacetic acid (EGTA) in sterile 
distilled water) and homogenised using a polytron. The samples were incubated on ice for 30 
min and were then centrifuged at 25 000 rpm for 35 min at 4°C in a SW41Ti rotor (Beckman) 
to remove insoluble protein. To limit the non-specific binding of the sample with the protein 
A agarose beads, the supernatant was pre-cleared with 50 µl packed protein A agarose beads 
(equilibrated in RIPA buffer) at 4°C for 2h with rotation. The protein A agarose beads were 
pelleted by centrifugation at 1000 rpm for 5 min at 4°C. The supernatant was then divided 
into two samples and incubated with either 50 µl packed 9E10-conjugated protein A beads 
(IP sample) or 50 µl packed protein A agarose beads (control sample) overnight at 4°C with 
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rotation. The beads were pelleted by centrifugation at 1000 rpm for 5 min at 4°C and the 
supernatant was discarded. The beads were extensively washed with RIPA buffer and the 
protein was eluted from the beads using 100 µl 1 X NuPAGE lithium dodecyl sulphate (LDS) 
(Invitrogen) sample buffer containing 30 mM dithiothretol (DTT) at room temperature for 5 
min. The samples were boiled at 95°C to denature the immune complexes and cooled on ice 
before centrifugation at 13 000 rpm for 1 min to pellet the beads. The presence of myc-tagged 
protein in the supernatant was analysed by western blot.   
 
2.8. Cell biology 
2.8.1.  Immunocytochemistry  
COS-7 cells were seeded on sterile glass coverslips (22 mm x 22 mm) in a 6-well plate 
format at 1 x 10
5 
cells per well. 24h post-seeding the cells were transfected with a DNA 
construct expressing the gene of interest. The following day, the cells were washed twice 
with 2 ml PBS and fixed with either 1 ml 4% (w/v) paraformaldehyde (PFA) in PBS at 4°C 
for 15 min or with 1 ml ice cold methanol at -20°C for 10 min. The PFA was removed and 
the cells permeabilised with 2 ml PBS and 0.1% (v/v) Triton X-100 at 4°C for 15 min. 
Following permeabilisation, the cells were washed three times with PBS for 5 min with 
shaking. The cells were blocked with 1 ml 10% (v/v) FCS for 20 min at room temperature 
and incubated with the primary antibody in 1 ml PBS at room temperature with shaking for 
1h. The cells underwent two 5 min washes with PBS and were incubated with the secondary 
antibody in 1 ml PBS at room temperature with shaking for 1h. The antibodies used in this 
study are presented in Table 2.5. Following a further two PBS washes, the nuclei were 
stained with Hoechst (1 µg/ml) at room temperature for 15 min. Following a further two PBS 
washes, the coverslips were mounted onto glass slides with Aqua Poly/Mount (Polyscience, 
Inc.). Cells were visualised using a Leica DMRA2 epifluorescent microscope or with a Zeiss 
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LSM 510META confocal microscope. The images were captured using the confocal 
microscope with a 63x oil immersion objective lens and a pinhole setting of 1 airy unit. The 
images were assembled using ImageJ v1.421, Adobe Photoshop CS2 and Illustrator, in which 
images were cropped and adjusted for brightness and contrast but otherwise not manipulated.     
 
2.8.2. The tetracycline-inducible, stable Flp-In TREx expression system 
The tetracycline-controlled gene expression system was first described by Gossen and Bujard 
(1992) to facilitate the controlled and reversible expression of genes to a defined level. 
Subsequently, Yao and colleagues developed the tetracycline-inducible system in which 
expression of the target gene is under control of a pCMV promoter which is repressed by two 
tandem tetracycline operator sequences (TetO2) (Yao et al., 1998). This means that the 
promoter is only active when tetracycline is present in the cell culture media. Thereafter, the 
tetracycline-inducible, stable Flp-In TREx expression system was developed by Invitrogen. 
This system incorporates a yeast DNA recombination system which uses the Flp recombinase 
enzyme and site-specific recombination to facilitate integration of a desired gene at a FRT 
site at a single point in the genome (Figure 2.1). In this study, the Flp-In TREx -293 cell line 
was used as the ‘host cell line’. The Flp-In TREx -293 cell line has been genetically modified 
to contain the FRT site necessary for site-specific recombination and insertion of the gene of 
interest.  
 
The target gene was cloned into a pcDNA5/FRT/TO expression vector in frame with the 
pCMV/TetO2 promoter according to the manufacturer’s instructions (Figure 2.1A). The 
primer sequences used are given in Appendices 1.1 and 1.2. The pcDNA5/FRT/TO 
expression vector and the pOG44 vector, which encodes the Flp recombinase enzyme, were 
co-transfected into the Flp-In TREx -293 cell line at a ratio of 9:1, according to the  
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Figure 2.1 Schematic overview of the Flp-In TREx system  
Flp-In TREx expression cell line generation. (A) The gene of interest was cloned into the 
pcDNA5/FRT/TO expression vector in-frame with a pCMV/TetO2 promoter. (B) The 
pcDNA5/FRT/TO expression vector was co-transfected into the Flp-In TREx -293 host cell line with 
the pOG44 vector which expressed the Flp recombinase enzyme. (C) The Flp recombinase enzyme 
mediated a homologous recombination event between the Flp recognition target (FRT) sites on the 
pcDNA5/FRT/TO vector and in the Flp-In TREx -293 cell line. The result was incorporation of the 
gene of interest into the Flp-In TREx -293 cell genome and gene expression under the control of a 
tetracycline inducible promoter. (D) 150 µg/ml hygromycin B was used to select for cells which had 
undergone successful recombination. (E) Treatment with 1 µg/ml tetracycline induced gene 
expression.  
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manufacturer’s instructions (Figure 2.1B). To generate a control cell line which expressed the 
hygromycin B and blasticidin resistance genes, an empty pcDNA5/FRT expression vector 
and the pOG44 vector were transfected into the Flp-In TREx -293 cell line. Following co-
transfection of the appropriate expression construct and the pOG44 plasmid, the successful 
stable transformants were selected in complete media containing hygromycin B (150 µg/ml) 
and blasticidin (15 µg/ml). After 10 days, single hygromycin B-resistant, blasticidin-resistant 
foci were isolated using cloning rings and expanded to generate individual clonal cell lines. 
The individual clonal cell lines were maintained in media containing hygromycin B and 
blasticidin as recommended by the manufacturer. Where appropriate, target gene expression 
was induced using 1 µg/ml of tetracycline. For long term storage the cells (> 3 x 10
6 
per 
cyrovial) were frozen in freezing medium: 90% complete medium and 10% DMSO in an 
automated controlled-rate freezing apparatus and stored at -80°C.   
 
2.9. Exon array 
2.9.1.  Preparation of RNA for exon array 
To prepare RNA for use in the exon array experiments assessing the effect of knocking down 
ZNF804A, RNAi was performed on SH-SY5Y cells as described in section 2.3.7 and the 
RNA was extracted as described in section 2.3.4. A mock transfection sample using only the 
RNAi transfection reagents was also prepared. To prepare RNA for use in the exon array 
experiments assessing the effects of ZNF804A over-expression, myc-ZNF804A and control
 
Flp-In TREX expression cells were seeded in 6 cm dishes at 1 x 10
6 
cells per dish. The 
following day, the cells were treated with 1 µg/ml of tetracycline and 24h post induction, the 
RNA was extracted as described in section 2.3.4 and frozen at -80°C.  
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The exon arrays were performed by CBS, Cardiff University. Prior to performing the exon 
arrays, CBS assessed the quality and quantity of the RNA using the Agilent 2100 bioanalyser. 
First strand cDNA was prepared using the Ambicon WT Expression Kit (Applied 
Biosystems), fragmented and terminally labelled using the GeneChip WT Terminal Labelling 
and Hybridization Kit (Affymetrix) following methods suggested by the manufacturer. The 
cDNA samples were hybridised to the Affymetrix GeneChip human exon 1.0 ST Array plate 
at 45°C for 17h, as described in the Affymetrix User’s Manual. Following hybridisation, the 
chips were washed and stained using the GeneChip fluidics Station 450/250 according to the 
GeneChip Expression Wash, Stain and Scan User’s Manual. The chips were scanned using 
the Affymetrix GeneChip Scanner 3000.   
 
2.9.2.  Importing the exon array data into the Partek Genomics Suite 
All exon array data was analysed using tools in the Partek Genomics Suite (PGS) software 
(v6.5; Partek Inc.). The .CEL files were imported into the PGS according to the 
manufacturer’s guidelines outlined in the ‘Importing exon data into Partek Genomics Suite’ 
tutorial (available from www.partek.com). The .CEL files were labelled and grouped 
according to whether they represented a treated or control sample. Table 2.6 outlines the 
library files used for import, these library files are available from the Affymetrix website 
(www.affymetrix.com).  
Table 2.6 The library files used to analyse the exon arrays 
 
Information contained within the file Version 
Core metaprobe set list HuEx-1_0-st-v2.r2.dt1.hg18.core.mps 
Probe set annotation HuEx-1_0-st-v2.na32.hg19.probeset.csv 
Transcript annotation HuEx-1_0-st-v2.na32.hg19.transcript.csv 
Defines which probes are in each probe set HuEx-1_0-st-v2.r2.pgf 
Layout of array HuEx-1_0-st-v2.r2.cdf 
Quality control content HuEx-1_0-st-v2-r2.qcc 
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Briefly, the .CEL files were imported using the interrogating and control probes. Probe set 
reliability is ranked from more to less reliable as ‘core’, ‘extended’ or ‘full’. For the analysis 
presented in this thesis the ‘core’ metaprobe set list was used (Affymetrix, 2005). This 
represented approximately 22 000 RefSeq genes and full-length GenBank mRNAs. The 
robust multiarray averaging (RMA) algorithm was used to summarise the probe-level data to 
a single value for each probe set (Irizarry et al., 2003a). The RMA algorithm consists of 
quantile normalisation followed by fitting of the data to a model of expression and probe 
affinities using an algorithm called median polish (Okoniewski, 2008). For each probe this 
algorithm corresponded to: perfect match (PM)ij = ei + aj + Eij, where e is the chip effect and 
a represents the probe affinity for the j
th
 probe on the i
th
 array (Okoniewski, 2008). 
Adjustments were made for probe GC content on pre-background-subtracted values. The 
exon-level probe sets were summarised to the gene-level using the probe set mean. The 
output information was set to include an additional calculation of the median and mean of the 
raw data.  
 
2.9.3.  Quality assessment  
Quality assessment (QA) of the exon array data was performed using the QA metrics in the 
PGS according to Affymetrix GeneChip QA of exon and gene arrays whitepaper (v1.1) 
(2007).  
 
To determine how the samples clustered, agglomerative hierarchical clustering was 
performed in the PGS on the gene-summarised expression values of the most variably 
expressed genes. Hierarchical clustering computes a dendrogram that assembles all of the 
elements (the samples) into a tree. In agglomerative clustering, each object forms a separate 
group and each step of the computation joins the groups which are closest to one another. The 
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intensity plots presented were standardised by applying a mean set to 0.0 and a standard 
deviation of 1.0.  
 
2.9.4.  Identifying differentially expressed genes  
Exon arrays can provide estimates of gene expression by virtually assembling probe sets 
which correspond to exons into transcript clusters that correspond to genes (Kapur et al., 
2007). The exon-level signal intensities were summarised to the gene-level by calculating the 
mean log2 signal intensity of all of the probe sets across the gene. The differentially expressed 
genes were detected by a one-way ANOVA model using method of moments (Eisenhart, 
1947) with treatment group type as the ANOVA factor as follows: 
 
Where Y represents the expression of a gene, µ is the mean expression of the gene, Z is group 
type to group type effect and ε is the error term.  The output information was P value, fold 
change and mean ratio.  
 
To overcome the problem of multiple testing, a list of statistically significantly differentially 
expressed genes was generated using a maximum false discovery rate (FDR) of either 0.05 or 
0.01. The FDR is defined as the proportion of false positives among the declared 
differentially expressed genes (Benjamini and Hochberg, 1995). For example, if 100 genes 
were declared differentially expressed with a maximum FDR 0.05, a maximum number of 5 
false positive results would be expected. The FDR method is often used in microarray studies 
to correct for multiple testing and control the type I error rate (Pawitan et al., 2005). In this 
thesis, the raw ANOVA P values, rather than FDR adjusted P values (the q values), are 
presented.  
 
Y = µ + Z + ε 
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2.9.5.  Empirical validation of differentially expressed genes  
The differentially expressed genes were selected for empirical validation by Q-PCR based on: 
1) the magnitude of the fold change, where a large fold change was preferred; 2) the number 
of known transcript variants of the gene, where a single transcript variant was preferred; and 
3) the DNA sequence, where sequences with 40-60% GC content which were amenable to Q-
PCR were preferred. The Q-PCR primers were designed, optimised and validated for use 
with the ΔΔCt method as described in section 2.3.6. The sequences of the Q-PCR primers 
used in this study are given in Appendices 1.6 and 1.7. Please note, only one biological 
replicate used in the exon array was analysed using Q-PCR. 
 
2.9.6.  Identifying alternative splicing events   
When analysing alternative splicing data, an essential step is to normalise the exon-level 
signal to the corresponding gene-level signal, this ensure that any changes in transcript 
abundance between samples are not misrepresented as changes in splicing. To identify 
alternatively spliced transcripts, the alternative splicing one-way ANOVA model in the PGS 
was performed with treatment group type as the ANOVA factor. To avoid the lack of 
detection of a probe set being misconstrued as alternative splicing, only probe sets with a log2 
signal intensity of greater than three were included in the analysis. The model was as follows:  
 
 
Where Y represents the expression of a gene, µ is the mean expression of the gene, Z is group 
type to group type effect, E is the exon-exon effect (alternative splicing independent to group 
type), Z*E represents an exon expressing differently in different tissues (alternative splicing 
dependent to tissue type) and ε is the error term.  
 
Y = µ + Z + E + Z*E + ε 
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To overcome the statistical issues associated with multiple testing, the gene-level alternative 
splicing one-way ANOVA P values were corrected using the conservative Bonferroni method 
(Whistler, 2010). The Bonferroni corrected alternative splicing P values are presented. 
Transcripts were considered alternatively spliced when the corresponding Bonferroni 
corrected P value surpassed a set threshold. The threshold P values were chosen to allow a 
manageable list of statistically significant alternatively spliced transcripts to be generated. It 
is difficult to interpret splicing patterns in transcripts with few markers therefore, all genes 
represented by less than five probe sets across the transcript cluster were removed 
(Affymetrix, 2006; Whistler, 2010). To ensure the focus was on known genes, any transcript 
clusters not represented by a HUGO gene nomenclature committee (HGNC) gene symbol 
were also removed (Whistler, 2010). Additionally, to reduce the type I error rate, any gene 
with high differential expression across the transcript (defined as a fold change greater than 
five) was also removed (Affymetrix, 2006; Whistler, 2010).  
 
The literature suggests that probe-level estimation, rather than gene-level estimation, 
improves the detection of differential splicing in Affymetrix GeneChip exon array studies 
(Laajala et al., 2009). Therefore, to implement these findings in the PGS, I took advantage of 
the probe set-level results which were generated alongside the alternative splicing one-way 
ANOVA in the PGS; these methods have been previously used in the literature (Gillett et al., 
2009). The probe set-level alternative splicing one-way ANOVA P values were filtered to 
select for probe sets showing significant differential expression, determined at a FDR 0.05, 
and no differential expression at the gene-level (transcript P < 0.05). The genes were sorted 
by the fold change of the differentially expressed probe set, and the probe sets with the 
largest fold changes were considered in the downstream analysis.   
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Following identification of statistically significant alternative splicing events, the data was 
subjected to detailed manual analysis to determine if the statistical analysis had identified a 
potential true alternative splicing event (Affymetrix, 2006; Whistler et al., 2010). This was 
achieved using the PGS ‘geneviews’. A PGS geneview graphically plots the transcript’s 
probe set log2 signal intensities and the corresponding fold change in these probe set log2 
signal intensities between the groups alongside transcript variant information. The transcript 
variant information is available from the University of California Santa Cruz (UCSC) 
genome browser database. Throughout this thesis, the GRCh37/hg19 assembly was used.   
 
2.9.7. Empirical validation of alternative splicing events   
The alternative splicing events were selected for empirical validation if: 1) the event 
corresponded to a known alternative splicing event; 2) the splicing event could not be 
explained by changes in gene expression; 3) the difference in log2 signal intensity was present 
across all of the probe sets in the same exon; and 4) the alternative splicing event was not at 
the extreme 3’ or 5’ end of the sequence (Whistler, 2010). To confirm the alternative splicing 
event, RT-PCR was performed using primers designed to target constitutive exons flanking 
the exon of interest (Figure 2.2). The PCR products were resolved by agarose gel 
electrophoresis (section 2.3.3). The expected result was two bands, which represent exon 
inclusion (larger band) and exon exclusion (smaller band). Any change in the relative 
intensities of these two bands between sample groups was likely to be indicative of 
alternative splicing (Affymetrix, 2006). Please note, only one biological replicate used for the 
exon array was evaluated using RT-PCR. If two products were detected by RT-PCR, Q-PCR 
was used to quantify the amount of the spliced exon. Please note, only one biological 
replicate sample used in the exon array was evaluated using Q-PCR.  Q-PCR primers were 
designed, optimised and validated for use with the ΔΔCt method as described in section 2.3.6.  
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Figure 2.2 Using RT-PCR to assess alternative splicing  
To confirm alternative splicing events, RT-PCR primers (arrows) were designed complementary to 
the consituitive exons (white boxes) flanking the spliced exon (blue box). The PCR products were 
separated by agarose gel electrophoresis. The bands of DNA correspond to transcript variants with 
exon inclusion (higher molecular weight DNA band) and exon exclusion (lower molecular weight 
DNA band). Changes in the relative abundance of the DNA in each band between samples denotes 
alternative splicing. In the hypothetical cassette exon shown, sample A shows greater inclusion of the 
spliced exon while sample B shows greater exclusion of the spliced exon. (Adapted from Affymetrix, 
2006.) M = size marker.   
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The sequences of the Q-PCR primers used to validate the alternative splicing events are 
described in Appendix 1.7. For the exon-level targets, the transcript variant of interest was 
quantified relative to a mRNA common to all transcript variants. This was to ensure that 
quantification of alternative splicing was accurate and was not influenced by possible 
differences in transcript abundance between samples. An alternative splicing event was 
considered validated if there was a statistically significant difference in the abundance of the 
spliced exon present between the treated samples and the controls.  
 
2.10. Enrichment analysis  
The enrichment analysis was carried out using GeneGo MetaCore™ (Thomson Reuters). The 
gene lists destined for analysis were uploaded into GeneGo MetaCore™ according to the 
manufacturer’s instructions. Where appropriate, the P value and fold change for each gene 
were included in the upload and the species was specified. The analysis was performed using 
the enrichment analysis workflow in GeneGo MetaCore
™
. Briefly, the enrichment analysis
 
method maps the selected data onto GeneGo MetaCore™ ontologies in terms of their 
respective sets of genes or network objects. The significance is evaluated based on the size of 
the intersection between the selected data and the ontology using a hypergeometric 
distribution. The resulting P value represents the probability for a particular mapping of an 
experiment to a particular ontology to arise by chance, considering the numbers of genes in 
an experiment versus the number of genes in the process within the ‘full set’ of all genes in 
the ontologies. These mappings are sorted by their P values and are represented graphically in 
the form of a histogram. Where appropriate, the Affymetrix GeneChip human exon array 1.0 
ST v2 array was set as the background comparison list. Unless otherwise stated, both up- and 
down-regulated genes were used in the enrichment analysis. All reported pathways and 
biological processes are listed according to their enrichment score provided by the software 
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package as –log(P value). All reported pathways and biological processes were statistically 
significant, determined at a FDR of 0.05, according to GeneGo MetaCore™. The uncorrected 
P values are shown. The gene ontology (GO) processes represent cellular processes as 
defined by GO. GeneGo process networks represent content which is manually created by 
GeneGo MetaCore™ on the basis of GO processes and GeneGo pathway maps.   
 
2.11. Bioinformatics  
Gene sequences were obtained from the RefSeq presented by the National Centre for 
Biotechnology Information (NCBI; http://www.ncbi.nlm.nih.gov/BLAST/). DNA sequence 
data was analysed using BLAST presented by the NCBI and the BLAST-like alignment tool 
(BLAT) (Kent, 2002) presented by UCSC genome browser (http://genome.ucsc.edu/) (Fujita 
et al., 2011; Kent et al., 2002). All UCSC analysis used the February 2009 human reference 
sequence GRCh37/hg19 assembly. The putative alternative splicing events were analysed 
using UCSC genome browser using the additional tracks: Affy Exon Array (Affymetrix), 
spliced expressed sequence tags (ESTs) and Alt Events. General analysis of DNA and protein 
sequences were performed with ClustalW (Larkin et al., 2007), SMART (Simple Modular 
Architecture Research Tool; http://smart.emblheidelberg.del) (Schultz et al., 1998), Kalign 
(http://www.ebi.ac.uk/Tools/msa/kalign/) and Boxshade 3.21 (http://www.ch.embnet.org). 
DNA to protein translation and calculation of predicted molecular weights was carried out 
using the ExPASy (Expert Protein Analysis System) proteomics server from the Swiss 
Institute of Bioinformatics (Gasteiger et al., 2003).  
 
2.12. Statistical methods 
The statistical analyses related to the exon array data were performed in the PGS v6.5 and are 
described in section 2.10. All other statistical analyses were performed using SPSS 16.0 for 
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Windows (LEAD Technologies Inc.). Data was analysed by independent Student’s T test or 
one-way ANOVA. Post hoc comparisons were performed using Tukey. For these statistical 
comparisons, P values of ≤ 0.05 were regarded as significant.  
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Chapter 3: Characterising ZNF804A and identification of its protein 
binding partners 
 
3.1. Introduction  
The genome-wide significant association between the SNP rs1344706 in intron two of 
ZNF804A and schizophrenia was a landmark finding in psychiatric genetics (O'Donovan et 
al., 2008). Yet, at the time of the GWAS discovery, ZNF804A represented a gene within the 
annotation gap; that is, a gene whose function was unknown and could not be accurately 
inferred using bioinformatics techniques. Aside from a report that suggested that ZNF804A 
may be a putative binding partner for ataxin-1 (ATXN1) (Lim et al., 2006); a protein 
implicated in processes such as transcription and pre-mRNA processing (de Chiara et al., 
2009; Irwin et al., 2005; Lam et al., 2006; Lim et al., 2008; Orr, 2010; Tsai et al., 2004; Yue 
et al., 2001), there was no published information regarding ZNF804A thus, very little could 
be inferred about the protein’s function or its possible contribution to disease pathogenesis.  
 
Several strategies can be used to determine the function of a protein. Often, because most 
proteins function as part of a complex with other proteins, identifying a protein’s binding 
partners can provide useful insight into its function. If two proteins interact, it is likely that 
their functions are related. Protein-protein interactions can be identified using biochemical 
techniques, such as immunoaffinity purification; or using genetic methods, such as the yeast 
two-hybrid (Y2H) system (Fields and Song, 1989; Phizicky and Fields, 1995). The Y2H 
system is often preferred over biochemical methods because it does not require high 
quantities of purified proteins or good quality antibodies and it enables the simultaneous 
isolation of interacting proteins with their encoding genes (Van Criekinge and Beyaert,
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1999). For example, Y2H studies implicate DISC1; a protein encoded by the DISC1 gene, 
which has been associated with major mental illnesses, in processes such as neuronal 
development as a consequence of its interactions with proteins such as nuclear distribution 
element-like (NUDEL) (Camargo et al., 2007).  
 
The subcellular localisation of a protein can also provide information about its biological 
function; this is because localisation determines the environment in which the protein 
operates and which proteins it is able to interact with. For example, if a protein localises to 
the nucleus, this may suggest that it is involved in processes specific to the nucleus, such as 
gene expression. To establish a protein’s localisation in mammalian cells, the protein 
sequence is transiently expressed with an epitope tag that can be detected by 
immunocytochemistry and visualised using confocal microscopy. Alternatively, the epitope 
tag may encode a protein such as green fluorescent protein (GFP), which fluoresces when 
exposed to a specific wavelength of light.  
 
The homologs of a protein of interest can also provide insight into its function. Homologs are 
genes which share common descent either via speciation (orthologs) or gene duplication 
(paralogs) (Koonin, 2005). Theories of population genetics suggest that paralogs may be 
preserved in the genome by so-called ‘subfunctionalisation’; this implies that protein paralogs 
may share similar or co-operative functions (Force et al., 1999; Lynch and Force, 2000). 
ZNF804A has two known paralogs: GPATCH8 and ZNF804B. At the outset of this study, the 
molecular function of these paralogs was unknown; investigating the function of these 
proteins may provide insight into the biological role of ZNF804A.  
 
Chapter Three: Characterising ZNF804A and identification of its protein binding partners 
70 
 
The aim of the experiments described in this Chapter was to gain initial insights into the 
possible functions of ZNF804A. To achieve this, Y2H studies were employed to identify the 
potential protein binding partners of ZNF804A. Additionally, expression vectors were used to 
identify the localisation of transiently expressed ZNF804A and GPATCH8 in cultured cells. 
Data described in this Chapter implicate a role for ZNF804A in the regulation of gene 
expression; particularly DNA transcription and pre-mRNA processing.  
 
3.2. Yeast two-hybrid screening with ZNF804A bait strains 
For Y2H screening, the ZNF804A cDNA sequence was divided into two non-overlapping N- 
(amino acid 1 to 630) and C- (amino acid 631 to 1209) terminal baits (Figure 3.1) and cloned 
in-frame into the bait plasmid pHybLex/Zeo (section 2.4). The bait plasmids were then 
transformed into Saccharomyces cerevisiae (S. cerevisiae) L40 to generate the bait strain 
(section 2.5.1). The bait plasmids and the bait strains were kindly provided by C.L. Tinsley. 
Small scale Y2H screens were performed with a human foetal brain cDNA library (section 
2.5.3). The prey plasmid DNA was isolated from clones which putatively interacted with 
ZNF804A and the cDNA sequence was obtained by 5’ sequencing using a vector primer 
(section 2.5.4). Protein sequence alignments were made using the standard protein BLAST 
program. Only amino acid sequences which were in-frame with the prey vector were 
considered positive results. Y2H screening using the N-terminal bait identified 13 positive 
clones, while Y2H screening using the C-terminal bait identified 39 positive clones (Table 
3.1).  
 
To rationalise the assortment of ZNF804A-interacting proteins isolated from the Y2H 
screens, the available literature for each protein was obtained from the NCBI PubMed and 
web of science databases using the protein’s name and symbol as search terms, and manually  
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Figure 3.1 Schematic representation of the ZNF804A Y2H baits 
The ZNF804A cDNA sequence was divided into two non-overlapping N- (amino acid 1 to 630) and 
C- (amino acid 631 to 1209) terminal baits. NLS = putative nuclear localisation signal (D. J. Blake, 
personal communication); ZnF = zinc finger; Y2H = yeast two-hybrid.  
Chapter Three: Characterising ZNF804A and identification of its protein binding partners 
72 
 
Bait Clone RefSeq Protein name 
Protein 
symbol 
Amino acid 
alignment 
% identity E score 
N 32a NP_001989.2 Fibulin-2 isoform b precursor FBLN2 731-1011 99 0.0E+00 
N 28a NP_002105.2 Zinc finger protein 40 ZNF40 2026-2222 100 7.0E-123 
N 1a NP_001138582.1 NEL-like 2 (chicken) isoform d NELL2 373-649 99 0.0E+00 
N 7a NP_001138579.1 NEL-like 2 (chicken) isoform a NELL2 336-596 100 0.0E+00 
N 18a NP_001138579.1 NEL-like 2 (chicken) isoform a NELL2 404-681 100 0.0E+00 
N 31 NP_001138579.1 NEL-like 2 (chicken) isoform a NELL2 225-474 100 1.0E-176 
N 6 NP_006702.1 RNA binding protein S1, serine-rich domain RNPS1 140-245 100 2.0E-67 
N 11 NP_006702.1 RNA binding protein S1, serine-rich domain RNPS1 140-263 100 3.0E-67 
N 17a NP_006702.1 RNA binding protein S1, serine-rich domain RNPS1 33-245 99 2.0E-81 
N 24b NP_006702.1 RNA binding protein S1, serine-rich domain RNPS1 140-263 100 2.0E-67 
N 33a NP_006702.1 RNA binding protein S1, serine-rich domain RNPS1 33-245 99 2.0E-81 
N 34a NP_006702.1 RNA binding protein S1, serine-rich domain RNPS1 38-263 99 1.0E-78 
C 17a NP_001121.2 Amino-terminal enhancer of split  AES 1-121 100 2.0E-88 
C 73b NP_001395.1 Eukaryotic translation elongation factor 1 gamma EEF1G 7-311 99 0.0E+00 
C 11a NP_002105.2 Zinc finger protein 40 ZNF40 2196-2494 99 0.0E+00 
C 13a NP_002105.2 Zinc finger protein 40 ZNF40 2197-2496 96 0.0E+00 
C 14a NP_002105.2 Zinc finger protein 40 ZNF40 2026-2309 99 0.0E+00 
C 18a NP_002105.2 Zinc finger protein 40 ZNF40 2172-2419 100 9.0E-164 
C 24a NP_002105.2 Zinc finger protein 40 ZNF40 2026-2118 88 5.0E-48 
C 30a NP_002105.2 Zinc finger protein 40 ZNF40 2196-2478 99 0.0E+00 
C 52a NP_002105.2 Zinc finger protein 40 ZNF40 2178-2477 100 0.0E+00 
C 76a NP_002105.2 Zinc finger protein 40 ZNF40 2172-2456 99 0.0E+00 
C 56a NP_002507.1 Neuro-oncological ventral antigen 2 NOVA2 3-283 100 0.0E+00 
C 4a NP_002779.1 Proteasome (proteasome, macropain) subunit, alpha type, 3 PSMA3 1-244 99 5.0E-179 
C 10b NP_002779.1 Proteasome (proteasome, macropain) subunit, alpha type, 3 PSMA3 1-255 100 0.0E+00 
C 23a NP_002779.1 Proteasome (proteasome, macropain) subunit, alpha type, 3 PSMA3 1-255 100 0.0E+00 
C 28a NP_002779.1 Proteasome (proteasome, macropain) subunit, alpha type, 3 PSMA3 1-255 99 0.0E+00 
C 29a NP_002779.1 Proteasome (proteasome, macropain) subunit, alpha type, 3 PSMA3 1-255 100 0.0E+00 
C 31a NP_002779.1 Proteasome (proteasome, macropain) subunit, alpha type, 3 PSMA3 1-255 100 2.0E-175 
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C 32a NP_002779.1 Proteasome (proteasome, macropain) subunit, alpha type, 3 PSMA3 1-255 99 0.0E+00 
C 46a NP_002779.1 Proteasome (proteasome, macropain) subunit, alpha type, 3 PSMA3 1-255 99 0.0E+00 
C 50a NP_002779.1 Proteasome (proteasome, macropain) subunit, alpha type, 3 PSMA3 1-255 99 0.0E+00 
C 54b NP_002779.1 Proteasome (proteasome, macropain) subunit, alpha type, 3 PSMA3 1-240 99 4.0E-173 
C 55a NP_002779.1 Proteasome (proteasome, macropain) subunit, alpha type, 3 PSMA3 1-222 94 5.0E-149 
C 90a NP_056176.2 R3H domain containing 1 R3HDM1 238-344 99 5.0E-63 
C 7a NP_000970.1 Ribosomal protein L18  RPL18 2-188 100 2.0E-132 
C 85a NP_001019.1 Ribosomal protein S25 RPS25 8-125 100 1.0E-77 
C 51a NP_001076048.1 RNA binding protein, fox-1 homolog (C. elegans) 2 RBFOX2 61-214 97 2.0E-103 
C 26a NP_054878.5 SET domain containing 2 SETD2 2260-2539 99 1.0E-178 
C 48a NP_054878.5 SET domain containing 2 SETD2 2260-2541 99 1.0E-178 
C 53b NP_054878.5 SET domain containing 2 SETD2 2260-2517 100 9.0E-163 
C 75a NP_054878.5 SET domain containing 2 SETD2 2093-2186 100 2.0E-59 
C 79b NP_054878.5 SET domain containing 2 SETD2 2093-2369 95 0.0E+00 
C 41a NP_689699.2 Sterile alpha motif domain containing 11 SAMD11 413-653 100 1.0E-163 
C 43a NP_689699.2 Sterile alpha motif domain containing 11 SAMD11 304-572 100 0.0E+00 
C 2a NP_689699.2 Sterile alpha motif domain containing 11 SAMD11 413-681 100 0.0E+00 
C 8a NP_689699.2 Sterile alpha motif domain containing 11 SAMD11 413-621 98 3.0E-137 
C 25b NP_689699.2 Sterile alpha motif domain containing 11 SAMD11 n/a  n/a  n/a  
C 33a NP_689699.2 Sterile alpha motif domain containing 11 SAMD11 n/a  n/a  n/a  
C 49a  NP_689699.2 Sterile alpha motif domain containing 11 SAMD11 n/a  n/a  n/a  
C 60c NP_055959.1 Zinc finger, CCHC domain containing 14 ZCCHC14 664-942 100 0.0E+00 
 
Table 3.1 The putative ZNF804A-interactors identified in Y2H screens using a human foetal brain cDNA library. The prey plasmid DNA was isolated 
from clones which putatively interacted with ZNF804A and the cDNA sequence was obtained by 5’ sequencing using a vector primer. Protein sequence 
alignments were made using the standard protein BLAST program. The amino acid alignment and the % identity and E score for each alignment is shown. A 
value of ‘n/a’ is given when the identity of the clone was confirmed using colony PCR. (N = N-terminal ZNF804A bait; C = C-terminal ZNF804A bait.) 
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reviewed. The proteins were sorted into categories based on their common known and/or 
predicted roles in biological processes (Table 3.2). This analysis showed that the Y2H 
screens identified multiple proteins implicated in the regulation of transcription or pre-mRNA 
processing. These data were consistent with the results of additional Y2H screening using the 
N- and C- terminus ZNF804A baits and a mouse brain cDNA library (Table 3.3) (mouse 
brain cDNA library screening performed by C.L. Tinsley). For instance, RNA binding 
protein, fox-1 homolog (C. elegans) 2 (RBFOX2) and RNA binding protein S1, serine-rich 
domain (RNPS1) were identified as putative ZNF804A-interactors in both of the screens. 
Consistent with their functions in transcription regulation or pre-mRNA processing, many of 
the putative ZNF804A-interactors contain protein domains with the capacity to bind nucleic 
acids; these include RNA recognition motifs (RRM), KH-1 domains, ZAS domains and ZnF 
domains (Table 3.4).  
 
In order to identify potential enrichment of the putative ZNF804A-interactors for specific 
biological processes, enrichment analysis for gene ontology (GO) processes was performed 
using GeneGo MetaCore™ software (section 2.10). The enrichment analysis was performed 
against the default background list of genes in GeneGo MetaCore™ as the composition of the 
cDNA libraries was unknown. The results are presented as a ratio of the number of genes 
within the Y2H dataset annotated to a particular GO process compared to the total number of 
genes in that GO process, alongside a P value for the enrichment. Figure 3.2A shows genes 
belonging to the GO terms ‘mRNA metabolic process’ (5/675 P=4.08 x 10-5) and ‘gene 
expression’ (9/3834 P=1.17 x 10-4) were significantly enriched among the putative 
ZNF804A-interactors identified in the human foetal brain cDNA library Y2H screen. The 
interactors identified in the mouse brain cDNA library Y2H screens were also significantly 
enriched for the GO term ‘mRNA metabolic process’ (5/675 P=2.69 x 10-5), in addition to 
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Biological process Protein name Symbol Accession Number of clones Bait References 
Transcription 
regulation 
Zinc finger protein 40 ZNF40 NP_002105.2 9 N (1); C (8)  Otsuka et al., 1995 
  Amino-terminal enhancer of split  AES NP_001121.2 1 C  Tetsukati, 2000 
 SET domain containing 2 SETD2 NP_054878.5 5 C  Edmunds, 2008 
Pre-mRNA processing 
RNA binding protein S1, serine-
rich domain 
RNPS1 NP_006702.1 6 N  Sakashita et al., 2004 
  
Neuro-oncological ventral 
antigen 2 
NOVA2 NP_002507.1 1 C Ule et al., 2005 
  
RNA binding protein, fox-1 
homolog (C. elegans) 2 
RBFOX2 NP_001076048.1 1 C  Yeo et al., 2009 
Translation Ribosomal protein S25 RPS25 NP_001019.1 1 C Marion and Marion, 1988 
  Ribosomal protein L18  RPL18 NP_000970.1 1 C  Tsurugi et al., 1978 
  
Eukaryotic translation elongation 
factor 1 gamma 
EEF1G NP_001395.1 1 C Riis et al., 1990 
Cell adhesion Fibulin 2 FBLN2 NP_001989.2 1 N  Pfaff et al., 1995 
 NEL-like 2 (chicken) isoform a NELL2 NP_001138579.1 3 N  Aihara et al., 2003 
Protein degradation 
Proteasome (proteasome, 
macropain) subunit, alpha type, 
3 
PSMA3 NP_002779.1 11 C  Fedorova et al., 2011 
Proteins of unknown 
function 
R3H domain containing 1 R3HDM1 NP_056176.2 1 C 
 
  
Sterile alpha motif domain 
containing 11 
SAMD11 NP_689699.2 7 C 
 
  
Zinc finger, CCHC domain 
containing 14 
ZCCHC14 NP_055959.1 1 C 
 
Table 3.2 The identity of putative ZNF804A-interacting proteins identified in Y2H screens using a human foetal brain cDNA library 
The proteins are grouped according to their common known and/or predicted roles in biological processes, according to the current literature. (N = N-terminal 
ZNF804A bait; C = C-terminal ZNF804A bait).   
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Biological process Protein name Symbol Accession Number of clones Bait 
 
References 
Transcription regulation Trans-acting transcription factor 1 Sp1 NP_038700.2 1 C 
 
Li et al., 2004 
  
Basic helix-loop-helix family, member 
e40  
Bhlhe40 NP_035628.1 1 C 
 Yamada and 
Miyamoto, 2005 
  
Glucocorticoid modulatory element 
binding protein 1  
Gmeb1 NP_064669.2 1 N 
 
Kaul et al., 2000 
 Melanoma antigen, family D, 1 Maged1 NP_062765.1 8 C 
 
Mouri et al., 2012 
Pre-mRNA processing 
RNA binding protein, fox-1 homolog (C. 
elegans) 1 
Rbfox1 NP_899011.2 1 C 
 
Yeo et al., 2009 
  
RNA binding protein, fox-1 homolog (C. 
elegans) 2 
Rbfox2 NP_780596.1 2 C 
 
Jin et al., 2003 
  CUGBP, Elav-like family member 4  Celf4 NP_573458.2 1 C 
 
Ladd et al., 2001 
  Ribonucleic acid binding protein S1 Rnps1 NP_001073597.1 1 N 
 
Sakashita et al., 2004 
Protein degradation 
Proteasome (proteasome, macropain) 
subunit, alpha type 3 
Psma3 NP_035314.3 26 C 
 
Fedorova et al., 2011 
  Tetratricopeptide repeat domain 3 Ttc3 NP_033467.2 3 C 
 
Suizu et al., 2009 
 
DnaJ (Hsp40) homolog, subfamily A, 
member 3 
Dnaja3 NP_076135.3 3 C 
 
Rowley et al., 1994 
Proteins of unknown 
function 
G patch domain-containing 8 Gpatch8 NP_001152964.1 1 C 
  
 
Table 3.3 The identity of putative ZNF804A-interacting proteins identified in Y2H screens using a mouse brain cDNA library, grouped according to 
biological process 
The proteins are grouped according to their common known and/or predicted roles in biological processes, according to the current literature. (N = N-terminal 
ZNF804A bait; C = C-terminal ZNF804A bait.)  (The mouse brain cDNA library screen was performed by C. L. Tinsley.)  
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Table 3.4 The putative ZNF804A-interactors contain a number of conserved protein domains that can bind to DNA or RNA  
The details of the predicted protein domains were obtained from the RefSeq on the NCBI database.   
Domain name Domain function ZNF804A-interactors containing this domain 
RNA recognition motif (RRM) binds RNA RNPS1; RBFOX2; Rbfox1; Celf4 
K homology RNA-binding domain, type 
1(KH-1) 
binds ssRNA or DNA NOVA2 
K homology RNA-binding domain, 
PCBP_like (PCBP_like_KH) 
binds ssRNA or DNA NOVA2 
zinc finger (ZnF) domain  binds RNA, DNA and protein  Gpatch8; Sp1; ZCCHC14 
ZAS domain binds DNA ZNF40 
R3H_encore_like (R3H) predicted to bind ssDNA or ssRNA R3HDM1 
G patch domain predicted to bind RNA Gpatch8 
heterogeneous nuclear ribonucleoprotein 
R, Q family (hnRNP-R-Q) 
binds RNA Rbfox1 
helix-loop-helix domain (HLH) binds DNA Bhlhe40 
SAND domain binds DNA Gmeb1 
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‘RNA splicing’ (4/339 P=3.43 x 10-5) and ‘regulation of alternative nuclear mRNA splicing, 
via splicesome’ (2/20 P=5.98 x 10-5) (Figure 3.2B). The combined list of ZNF804A-
interactors was enriched for genes in the GO term ‘gene expression’ (14/3834 P = 1.35 x 10-
5) and ‘negative regulation of transcription, DNA dependent’ (7/1026 P = 1.02 x 10-4) (Figure 
3.2C). These enrichments survived 5% FDR correction, as determined by GeneGo 
MetaCore™. The uncorrected P values are shown.  
 
Often, it is possible to use Y2H data to identify a putative minimal binding region between 
two interacting proteins. However, this requires the identification of multiple clones for the 
same interactor. The majority of putative ZNF804A-interactors that were identified 
corresponded to only a single clone and as such, identifying a minimal binding region was 
not possible. However, multiple clones corresponding to zinc finger protein 40 (ZNF40) and 
RNPS1 were identified. Analysing the sequence of these clones suggests that the minimal 
binding region of ZNF804A to ZNF40 was upstream of ZNF40’s C-terminal C2H2 type ZnF 
domains (Figure 3.3A) and that the minimal binding region of ZNF804A to RNPS1 included 
the RRM domain (Figure 3.3B).   
 
3.3. Validation of Y2H results 
The Y2H system may identify false-positive results which can be ‘technical’ false positives, 
that cannot be reproduced under identical experimental conditions; or ‘biological’ false 
positives, which do not occur in vivo (Huang and Bader, 2009). Therefore, true interactors 
must be confirmed using an alternative method; traditionally co-immunoprecipitation is used. 
Co-immunoprecipitation involves transiently expressing epitope tagged-proteins in 
mammalian cell lines and precipitating the proteins using an antibody raised against the 
epitope tag.   
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Figure 3.2 GO processes that were enriched for the putative ZNF804A-interactors 
The list of putative ZNF804A-interactors identified in the Y2H screens using either (A) a human 
foetal brain cDNA library, (B) a mouse brain cDNA library or (C) the combined list of putative 
interactors were imported into GeneGo MetaCore™ and analysed using the enrichment analysis 
workflow for GO processes. The top five statistically significant GO processes are presented. These 
enrichments survived 5% FDR correction, as determined by GeneGo MetaCore™. The uncorrected P 
values are shown.  
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Figure 3.3 The distribution of the ZNF40 and RNPS1 clones  
The distribution of the ZNF40 and RNPS1 clones isolated from a human foetal brain cDNA library 
screen using ZNF804A as the bait. The 5’ cDNA sequence was obtained by sequencing of the cDNA 
clones identified in the Y2H screen (solid line). The remainder of the sequence was inferred from the 
size of insert obtained by restriction digest of the prey plasmid using the enzyme BSRG1 (dashed 
line). The locations of the sequences encoding predicted protein domains are indicated.   
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3.3.1.  Detecting exogenous ZNF804A in cultured mammalian cells  
At the outset of this study, attempts to synthesise tagged-ZNF804A in cultured mammalian 
cells using ZNF804A expression vectors had proved unsuccessful (C. L. Tinsley, personal 
communication; the vectors and cell lines used are summarised in Appendix 2). It was 
hypothesised that the inability to detect tagged-ZNF804A may indicate that over-expression 
of ZNF804A was cytotoxic or that ZNF804A was produced at extremely low levels. An 
alternative hypothesis was that few cells took up the vector cDNA. Previous studies have 
used conditional, stable cell lines to successfully overcome these difficulties (Reeves et al., 
2002). Therefore, I generated a tetracycline-inducible, stable cell line expressing myc-
ZNF804A (Chapter Five). Data presented in Chapter Five show the myc-ZNF804A Flp-In 
TREx cell line produced very low but detectable levels of myc-ZNF804A protein (section 
5.2). Myc-ZNF804A was not detected after immunoprecipitation using anti-myc antibody 
(9E10) -conjugated beads, and was not detected by immunocytochemistry (section 5.2). The 
unsuccessful attempts to immunoprecipitate myc-ZNF804A from the myc-ZNF804A Flp-In 
TREx cell line meant that the cell line could not be used in co-immunoprecipitation 
experiments to validate the Y2H data.   
 
While my studies were in progress, Girgenti and colleagues presented immunocytochemistry 
data which showed that transiently expressed myc-tagged ZNF804A localised to the nucleus 
in rat neural progenitor cells (Girgenti et al., 2012). Girgenti and colleagues also used 
subcellular fractionation and western blots probed with an anti-ZNF804A antibody (Santa 
Cruz) to evaluate the localisation of endogenous ZNF804A. These data showed endogenous 
ZNF804A was predominantly detected in the nuclear fraction and migrated to 136 kDa 
(Girgenti et al., 2012). To investigate whether our expression constructs were ineffective at 
producing ZNF804A, I obtained this vector cDNA (a kind gift from M. Girgenti). Please note 
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that, although this vector was designated pCAG-hZNF804A-myc by Girgenti and colleagues, 
DNA sequence analysis showed that the myc epitope tag was at the N-terminus of ZNF804A 
(data not shown).  
 
To determine the utility of the pCAG-hZNF804A-myc expression vector, HEK293T cells 
were transfected with pCAG-hZNF804A-myc and the following day, protein lysates were 
prepared (section 2.6.1). ZNF804A protein levels were analysed by western blotting 
alongside a protein lysate prepared from cells transfected with our myc-ZNF804A expression 
vector (pCMV-myc-ZNF804A) (section 2.6.3). A lysate prepared from cells transfected with 
a myc-TCF4 expression vector (pCMV-myc-TCF4) served as a positive control for the utility 
of the anti-myc antibody (9E10). The blots were incubated with the 9E10 antibody and our 
four custom anti-ZNF804A antibodies: 3078, 3077, 001 and 002 (C. L. Tinsley designed and 
characterised the custom anti-ZNF804A antibodies; these antibodies are described in 
Appendix 3). The western blot incubated with the 9E10 antibody showed myc-ZNF804A was 
not detected in protein lysates prepared from cells transfected with pCAG-hZNF804A-myc or 
pCMV-myc-ZNF804A (Figure 3.4). Myc-TCF4 was clearly detected in the protein lysate 
prepared from cells transfected with pCMV-myc-TCF4, confirming the utility of the 9E10 
antibody. The blot probed with the 3078 antibody showed that a product (labelled A) which 
migrated to 175 kDa was detected all of the samples - including the negative controls - but 
appeared more abundant in the pCMV-myc-ZNF804A sample. However, the control blot 
incubated with the anti-α-tubulin antibody suggested that the pCMV-myc-ZNF804A sample 
had greater overall protein abundance. Furthermore, a product of this size was not detected on 
the blot probed with the 9E10 antibody. Therefore, it was concluded that this product was 
unlikely to be ZNF804A. The blot incubated with the 3077 antibody showed that a very faint 
product (labelled B) which migrated to 150 kDa was detected in the pCMV-myc-ZNF804A 
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sample. This product was not detected on the blot probed with the 9E10 antibody. Therefore, 
it was concluded that this product was unlikely to be ZNF804A.  
 
In summary, these data suggest that pCAG-hZNF804A-myc did not produce detectable levels 
of myc-ZNF804A in HEK293T cells. Consistent with these findings, immunocytochemistry  
using the 9E10 antibody showed COS-7 cells transfected with pCAG-hZNF804A-myc did 
not produce detectable levels of myc-ZNF804A (section 2.8.1) (data not shown).  
 
3.3.2. Degradation of myc-ZNF804A by the proteasome  
Many intracellular proteins are degraded by the ubiquitin-proteasome system (UPS) 
following post-translational modification with ubiquitin or SUMO (small ubiquitin-related 
modifier) (Guo et al., 2012). Degradation by the UPS regulates a protein’s half-life; this is a 
particularly important consideration for regulatory proteins, such as transcription factors 
(Desterro et al., 2000; Muratani and Tansey, 2003; Wang et al., 2008; Wang et al., 2011). The 
ubiquitin or SUMO modifiers facilitate interaction between the target protein, E3 ligases and 
the proteasome (Wang et al., 2008). Interestingly, the Y2H data presented in Table 3.3 shows 
that ZNF804A putatively interacted with an E3 ubiquitin ligase, Ttc3 (Suizu et al., 2009), and 
Mage-d1, which has been implicated in protein degradation (Mouri et al., 2012). 
Furthermore, additional Y2H data suggest that the ZNF804A paralog, GPATCH8, may 
interact with an E2 conjugating enzyme, Ubc9 (unpublished Y2H screening performed by 
C.L. Tinsley using a mouse brain cDNA library and a GPATCH8 bait), which transfers 
SUMO to the substrate (Desterro et al., 1997; Johnson and Blobel, 1997). Therefore, it was 
tempting to speculate that myc-ZNF804A protein was not detected after transient expression 
of myc-ZNF804A because the protein was post-translationally modified and targeted to the  
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Figure 3.4 Western blot analysis of myc-ZNF804A  
Protein lysates were prepared from HEK293T cells transfected with the plasmids indicated. Proteins 
were detected with either the anti-myc antibody (9E10) only or one of the four custom anti-ZNF804A 
antibodies raised against human ZNF804A (3077 and 3078) or the mouse homolog Zfp804a (002 and 
001). The custom anti-ZNF804A antibodies are described in Appendix 3. A control protein lysate was 
prepared from cells transiently expressing myc-TCF4 to indicate the utility of the 9E10 antibody. On 
a separate but identical blot, the detection of endogenous α-tubulin was used as an internal loading 
control. The antibody dilutions used are given in Table 2.5. Single colour blots are shown. For 
imaging, the highest infrared fluorescence detection was used. The labels ‘A’ and ‘B’ indicate 
potential proteins of interest.  
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proteasome for degradation. To investigate this possibility, HEK293T cells were transfected 
with the pCMV-myc- ZNF804A expression vector and after 24h, the cells were treated with a 
proteasome inhibitor (lactacystin) for a further 18h (section 2.3.7). The hypothesis was that 
treating the cells with a proteasome inhibitor would prevent the putative degradation of 
ZNF804A. The abundance of myc-ZNF804A present in cells treated with a proteasome 
inhibitor and in cells left untreated was analysed by western blotting. The blots were probed 
with either the 9E10 antibody and a goat polyclonal anti-ZNF804A (D-14) antibody (Santa 
Cruz); or the 3077 antibody and an anti-ubiquitinylated proteins antibody (FK2). The blot 
probed with the FK2 antibody showed that the abundance of ubiquitinylated proteins 
increased after treatment with a proteasome inhibitor; this confirmed that the proteasome was 
successfully inhibited (Figure 3.5). The blots probed with the D-14, 9E10 and 3077 
antibodies each showed a product that migrated to 175 kDa was detected in transfected cells 
only when the proteasome was inhibited (Figure 3.5). It is highly likely this product was 
myc-ZNF804A because it was detected by all three antibodies. These data are consistent with 
the hypothesis that myc-ZNF804A was targeted to the proteasome for degradation.  
 
Having established that proteasome inhibition enabled myc-ZNF804A to be detected, a 
further two commercial anti-ZNF804A antibodies, P-13 and S-16 (Santa Cruz) were 
assessed. P-13, which was raised against mouse and rat Zfp804a, detected a very faint 
product that migrated to 175 kDa and was likely to be myc-ZNF804A (data not shown). S-16, 
which was also raised against mouse and rat Zfp804a, did not detect myc-ZNF804A (data not 
shown).  
 
To evaluate whether the subcellular localisation of ZNF804A could be determined following 
proteasome inhibition, COS-7 cells expressing myc-ZNF804A were treated with lactacystin.  
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Figure 3.5 Western blot analysis of myc-ZNF804A after proteasome inhibition   
Cultured HEK293T cells were transfected with a myc-ZNF804A expression vector. The following 
day, the cells were treated with a proteasome inhibitor (lactacystin; 10 µM). 18h after treatment, 
protein lysates were prepared and ZNF804A levels were analysed by western blotting. (A) Two-
colour western blot probed with an anti-myc antibody (9E10) and an anti-ZNF804A (D-14) antibody 
(Santa Cruz). The blot was imaged using the same infrared fluorescence detection signal intensity (5) 
for the individual red and green channels. The merged image is shown to illustrate that the two 
antibodies detect the same product. (B) Two-colour western blot probed with a custom anti-ZNF804A 
(3077) antibody (described in Appendix 3.1) and the anti-ubiquitin (FK2) antibody which served as a 
control for successful proteasome treatment. Black and white images are shown for clarity. The 
antibody dilutions used are given in Table 2.5.   
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Myc-ZNF804A was detected using the 9E10 antibody while the nucleus was counter-stained 
using Hoechst. Consistent with the findings reported above, myc-ZNF804A was readily 
detected when the proteasome was inhibited whereas myc-ZNF804A was only detected in an 
extremely small number of cells when the proteasome was not inhibited. Myc-ZNF804A was 
localised homogenously throughout the nucleus and, in some cells, myc-ZNF804A was also 
evident in the cytoplasm (Figure 3.6). 
 
3.4. Assessing the cellular localisation of transiently expressed GPATCH8  
Paralogs may be used to provide insight into the biological role of a protein of unknown 
function because paralogs may be preserved in the genome by so-called 
‘subfunctionalisation’ (Force et al., 1999; Lynch and Force, 2000). The molecular functions 
of the proteins encoded by the two ZNF804A paralogs: GPATCH8 and ZNF804B, have not 
been elucidated. However, consistent with the possibility that ZNF804A and GPATCH8 may 
co-operate to share the same function as the protein encoded by their ancestral gene, data 
presented in Table 3.3 suggest these proteins putatively interact. Therefore, investigating the 
subcellular localisation of GPATCH8 may provide insight into the function of ZNF804A. 
Alignment of human GPATCH8 and ZNF804A amino acid sequences using ClustalW 
showed that they share 23% identity (Figure 3.7). Notably, the amino acid sequences showed 
homology in the region surrounding the C2H2 type ZnF domain. To determine the 
subcellular localisation of GPATCH8, COS-7 cells expressing GPATCH8-enhanced yellow-
fluorescent protein (-EYFP) were processed for confocal microscopy. The nuclei were 
counter-stained using Hoechst and nuclear speckles were detected using the anti-SC35 
antibody. The nuclear speckle marker was used because the Y2H data suggest ZNF804A may 
interact with factors involved in pre-mRNA processing (Tables 3.2 and 3.3), and nuclear 
speckles are enriched for pre-mRNA splicing factors (Perraud et al., 1979). Figure 3.8 shows  
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Figure 3.6 Localisation of myc-ZNF804A in COS-7 cells  
Cultured COS-7 cells were transfected with a myc-ZNF804A expression vector. The following day, 
the cells were treated with proteasome inhibitor (lactacystin; 10 µM). 18h after treatment the cells 
were stained with an anti-myc antibody (9E10) and a marker for the nucleus (Hoechst; 1 µg/ml). 
Scale bar 10µm. The antibody dilutions used are given in Table 2.5.  
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ZNF804A    1 ------------------------------------------------------------ 
GPATCH8    1 MADRFSRFNEDRDFQGNHFDQYEEGHLEIEQASLDKP IESDNIGHRLLQKHGWKLGQGLG  
 
 
ZNF804A    1 ------MECYYIVISSTHLSNGHF-------------RNIKGVFRGPLSKNGNKTLDYAE 
GPATCH8   61 KSLQGRTDPIPIVVKYDVMGMGRM EMELDYAEDATERRRVLEVEKEDTEELRQKYKDYVD 
 
 
ZNF804A   42 KENTIAKALEDLKAN FYCELCDKQYYKHQEFDNH INSYDHAHKQRLKELKQREFARNVAS 
GPATCH8  121 KEKAIAKALEDLRAN FYCELCDKQYQKHQEFDNH INSYDHAHKQRLKDLKQREFARNVSS 
 
 
ZNF804A  102 KSRKDERKQEKALQRLHKLAELRKETVCAPGSGPMFKSTTVTVRENCNEISQRVVVDSVN 
GPATCH8  181 RSRKDEKKQEKALRRLHELAEQRKQAECAPGSGPMFKPTTVAVDEEGGEDDKDESATNSG 
 
 
ZNF804A  162 NQQDFKYTL----------IHSEENTKDATTVAEDPESAN---NYTAKNNQVGDQAQGIH 
GPATCH8  241 TGATASCGLGSEFSTDKGGPFTAVQITNTTGLAQAPGLASQGISFGIKNN------LGTP 
 
 
ZNF804A  209 RHKIGFSFAFPKKASVKLESSAAAFSEYSDDASVGKGFSRKSRFVPSACHLQQSSPTDVL 
GPATCH8  295 LQKLGVSFSFAKKAPVKLESIASVFKDHAEEGTSEDGTKPDEK--SSDQGLQKVGDSDGS 
 
 
ZNF804A  269 LSSEEKTNSFHPPE------AMCRDKETVQTQEIKEVSSEKDALLLPSFCK------FQL 
GPATCH8  353 SNLDGKKEDEDPQDGGSLASTLSKLKRMKREEGAGATEPEYYHYIPPAHCKVKPNFPFLL 
 
 
ZNF804A  317 QLSSDADNCQNSVPLADQIPLESVVINEDIPVSGNSFELLGNKSTVLDMSNDCISVQATT 
GPATCH8  413 FMRASEQMDGDNTTHPKNAPESKKGSSPKPKSCIKAAASQGAEKTVSEVSEQPKETSMTE 
 
 
ZNF804A  377 EENVKHNEASTTEVENKNGPETLAP-----SNTEEVNITIHKKTNFC-----------KR 
GPATCH8  473 PSEPGSKAEAKKALGGDVSDQSLESHSQKVSETQMCESNSSKETSLATPAGKESQEGPKH 
 
 
ZNF804A  421 QCEPFVPVLNKHRSTVLQWPSEMLVYTTTKPSISYSCNPLCFDFKSTKVNNNLDKNKPDL 
GPATCH8  533 PTGPFFPVLSKDESTALQWPSELLIFTKAEPSISYSCNPLYFDFKLSRNKDARTKGTEKP 
 
 
ZNF804A  481 KDLCSQQKQ--EDICMGPLSDYKDVSTEGLTDYEIG-----SSKNKCSQVTPLLADDILS 
GPATCH8  593 KDIGSSSKDHLQGLDPGEPNKSKEVGGEKIVRSSGGRMDAPASGSACSGLNKQEPGGSHG 
 
 
ZNF804A  534 SSC-DSGKNENTGQRYKNISCKIRETEKYNFTKSQIKQDTLDEKYNKIRLKETHEYWFHK 
GPATCH8  653 SETEDTGRSLPSKKERSGKSHRHKKKKKHKKSSKHKRKHKADTEEKSSKAESGEK---SK 
 
 
ZNF804A  593 SRRKKKRKK--------------------------------------------------- 
GPATCH8  710 KRKKRKRKKNKSSAPADSERGPKPEPPGSGSPAPPRRRRRAQDDSQRRSLPAEEGSSGKK 
 
 
ZNF804A  602 ------------------------LCQHHH-MEKTKESETRCKMEAENSYTENAGKYLLE 
GPATCH8  770 DEGGGGSSSQDHGGRKHKGELPPSSCQRRAGTKRSSRSSHRSQPSSGDEDSDDASSHRLH 
 
 
ZNF804A  637 PISEKQYLAAEQLLDS------------HQLLDKRPKSESISLSDN---EEMCKTWNTEY 
GPATCH8  830 QKSPSQYSEEEEEEDSGSEHSRSRSRSGRRHSSHRSSRRSYSSSSDASSDQSCYSRQRSY 
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ZNF804A  682 --NTYDTIS--SKNHCKKNTILLNGQSNATMIHSGKHNLTYSR---TYCCW--------- 
GPATCH8  890 SDDSYSDYSDRSRRHSKRSHDSDDSDYASSKHRSKRHKYSSSDDDYSLSCSQSRSRSRSH 
 
 
ZNF804A  726 ---------KTKMSSCSQDHRSLVLQNDMKHMSQNQAVKRGYN-----SVMNESERFYRK 
GPATCH8  950 TRERSRSRGRSRSSSCSRSRSKRRSRSTTAHSWQRS---RSYSRDRSRSTRSPSQRSGSR 
 
 
ZNF804A  772 RRQHSHSYSSDESLNRQNHLPEEFLRPPSTSV-------APCKPKKKRRRKRGRFHPGFE 
GPATCH8 1007 KRSWGHESPEERHSGRRDFIRSKIYRSQSPHYFRSGRGEGPGKKDDGRGDDSKATGPPSQ 
 
 
ZNF804A  825 TLELKENT----DYPVKDNSSLNP---LDRLISEDKKEKMKPQEVAKIERNSEQTN---- 
GPATCH8 1067 NSNIGTGRGSEGDCSPEDKNSVTAKLLLEKI--QSRKVERKPSVSEEVQATPNKAGPKLK 
 
ZNF804A  874 -------------QLRNKLSFHPNNLLPSETNGETEHLEMETTSG---ELSDVSNDP--T 
GPATCH8 1125 DPPQGYFGPKLPPSLGNKPVLPLIGKLPATRKPNKKCEESGLERGEEQEQSETEEGPPGS 
 
 
ZNF804A  916 TSVCVASAPTKEAIDNTLLE---HKERSENINLNEKQIPFQVPNIERNF--RQSQPKSYL 
GPATCH8 1185 SDALFGHQFPSEETTGPLLDPPPEESKSGEATADHPVAPLGTPAHSDCYPGDPTISHNYL 
 
 
ZNF804A  971 CHYELAEALPQGKMNETPTEWLRYNSGILNTQPPLPFKEAHVSGHTFVTAEQILAPLALP 
GPATCH8 1245 PDPSDGDTLESLDSSSQPGP---VESSLLPIAPDL----EHFPSYAPPSGDPSIESTDGA 
 
 
ZNF804A 1031 EQALLIPLENH---------DKFKNVPCEVYQHILQPNMLANKVKFTFPPAALPPPSTP- 
GPATCH8 1298 EDASLAPLESQPITFTPEEMEKYSKLQQAAQQHI-QQQLLAKQVK-AFPASAALAPATPA 
 
 
ZNF804A 1081 LQPLPLQQ--SLCSTSVTTIHHTVLQQHAAAAAAAAAAAAAGTFKVLQPHQQFLSQIPAL 
GPATCH8 1356 LQPIHIQQPATASATSITTVQHAILQHHAAAAAAAIGIHP-------HPHPQPLAQVHHI 
 
 
ZNF804A 1139 TRTSLPQLSVGPVGPRLCPGNQPTFVAPPQMPIIPASVLHPSHLAFPSLPH-ALFPSLLS 
GPATCH8 1409 PQPHLTPISLSHLTHSIIPGHPATFLASHPIHIIPASAIHPGPFTFHPVPHAALYPTLLA 
 
 
ZNF804A 1198 PHP-----TVIPLQPLF----------------- 
GPATCH8 1469 PRPAAAAATALHLHPLLHPIFSGQDLQHPPSHGT 
 
 
Key 
XXXX   – C2H2 type ZnF domain  X XXXX  – G-patch domain     
X – Identical residue  X – Similar residue  
 
Figure 3.7 Alignment of human ZNF804A and GPATCH8 amino acid sequences  
The human ZNF804A and GPATCH8 amino acid sequences were aligned using ClustalW, Kalign 
and Boxshade servers (section 2.11). The proteins shared 23% amino acid similarity. The regions of 
identity are coloured black whereas similar residues are highlighted in grey. The conserved C2H2 
type ZnF domain is highlighted yellow on the alignment. The alignment indicated that the C2H2 type 
ZnF domain was highly conserved between these two proteins.  
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Figure 3.8 Localisation of GPATCH8-EYFP in COS-7 cells.  
(A) Cultured COS-7 cells were transfected with a GPATCH8-EYFP expression vector. 24h post-
transfection cells were stained markers for the nucleus (Hoechst; 10 µM) and nuclear speckles (anti-
SC35). The cells were imaged by confocal microscopy using a 63x lens (top row) and a 100x lens 
(second row). Scale bar 10 µm. (B) Schematic representation of the change in nuclear speckle 
morphology in GPATCH8-EYFP transfected cells. This change in morphology was not observed in 
untransfected cells or cells transfected with an EYFP vector only (data not shown). The antibody 
dilutions used are given in Table 2.5.    
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GPATCH8-EYFP formed punctae within the nucleus. Some GPATCH8- EYFP punctae 
appeared to localise within atypical ring tori formed by nuclear speckles. The examination of 
untransfected cells (Figure 3.8) and cells transfected with EYFP vector only (data not shown) 
suggest that the nuclear speckles only formed ring tori when GPATCH8-EYFP was over-
expressed. 
 
3.5. Discussion 
The principle aim of the work described in this Chapter was to provide the first insights into 
the biological function of ZNF804A by identifying its protein binding partners. The binding 
partners of ZNF804A were determined using Y2H screens with N- and C-terminal ZNF804A 
baits and human foetal and mouse brain cDNA libraries. Proteins belonging to the GO 
processes ‘gene expression’ and ‘RNA splicing’ were enriched among the putative 
ZNF804A-interactors. Thus, these data may suggest a functional role for ZNF804A as a 
regulator of gene expression at the level of transcription and/or pre-mRNA processing.  
 
The suggestion that ZNF804A may be involved in transcriptional regulation is consistent 
with the current literature. For example, studies have reported ZNF804A interacted directly 
with the promoter/enhancer regions of COMT and PRSS16, which are known schizophrenia 
susceptibility genes, and up-regulated expression of these genes (Girgenti et al., 2012). 
Additionally, using a hypothesis-free, genome-wide microarray approach Hill and colleagues 
(2012) showed that knockdown of ZNF804A in human neural progenitor cells led to changes 
in expression of genes implicated in cell adhesion. Recently, studies have reported that 
ZNF804A over-expression in HEK293 cells altered the expression of genes involved in 
TGFβ signalling (Umeda-Yano et al., 2013).  
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The data presented in this Chapter expand on the current understanding of ZNF804A’s 
potential role in transcriptional regulation by providing evidence that ZNF804A may interact 
with proteins which have known roles in pre-mRNA processing. Pre-mRNA processing (also 
known as ‘splicing’) is the process by which intronic sequences in the primary transcript (the 
pre-mRNA) are excised and the exonic sequences are joined together to produce a mature, 
translatable mRNA (Black, 2003). This process is catalysed by the spliceosome; a large 
structure in which numerous proteins co-operate to mediate the splicing reaction, and is 
directed by sequences at the intron/exon junctions called splice sites (Wahl et al., 2009). 
Alterations in splice site choice, via skipping of exons, retention of introns or the use of 
alternative splice sites, promoters or poly-A tails can change the resulting mRNA sequence; 
such changes are broadly termed ‘alternative splicing’ (Figure 3.9) (Black, 2003; Chen and 
Manley, 2009). Alternative splicing gives rise to changes in the mature mRNA sequence and 
consequently, can result in different protein products that may have different functions. As 
such, alternative splicing is considered to contribute greatly to proteomic diversity. The 
decision as to which exon is excised and which is included in the mature mRNA is complex 
and involves RNA sequence elements and many protein regulators. Several of the putative 
ZNF804A-interactors identified here are known pre-mRNA splicing regulators. For instance, 
ZNF804A interacted with RNPS1, a SR-protein which localises to nuclear speckles and 
regulates constitutive pre-mRNA splicing (Loyer et al., 1998; Mayeda, 1999; Sakashita et al., 
2004). ZNF804A also interacted with CUGBP, Elav-like family member 4 (Celf4), a member 
of the Bruno/CELF (CUG-BP- and Etr-3-like factor) family of proteins which have multiple 
roles in post-transcriptional regulation, including roles in alternative splicing and mRNA 
translation (Barreau et al., 2006).  
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Figure 3.9 Patterns of alternative splicing 
The primary transcripts from a gene can undergo many patterns of alternative splicing. The 
constitutive exons that are present in all mature mRNAs are represented as grey boxes. The 
alternatively spliced exons which may or may not be included in the mature mRNA are represented as 
blue boxes. The most common form of alternative splicing is a cassette exon, in which the whole exon 
may or may not be included in the mature mRNA. Paired cassette exons may be mutually exclusive, 
in which one exon or the other is included, but not both. The exons may be lengthened or shortened 
using different 5’ or 3’ splice sites. The transcriptional initiation at different promoters, or the start of 
polyadenylation (poly-A) at alternative sites, can lead to changes in the mature mRNA sequence. The 
exclusion of an intronic sequence may also be repressed, such that the intron is retained. A single gene 
may have many different alternative splicing patterns; this generates proteomic diversity. (Black, 
2003)  
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In addition, ZNF804A interacted with tissue-specific alternative splicing factors (NOVA2, 
Rbfox1 and RBFOX2). In mouse brain, Nova2 is present exclusively in neurons and localises 
to the nucleus (Bemmo et al., 2008; Jensen et al., 2000; Yang et al., 1998). Using cross-
linking and immunoprecipitation, Ule and colleagues showed that Nova2 binds RNAs that 
function at the neuronal synapse and are involved in neuronal inhibition (Ule, 2003). 
Subsequently, using splicing sensitive microarrays Ule and colleagues demonstrated that 
Nova2 regulated the splicing of targets which form an interaction module at the synapse (Ule 
et al., 2005). The Rbfox family of splicing factors comprises of three members, Rbfox1-3. 
The Y2H results indicate that ZNF804A interacted with both Rbfox1 and RBFOX2. Rbfox1 
and Rbfox2 regulate splicing of many neuronal transcripts by binding to the consensus 
sequence (U)GCAUG in introns flanking alternatively spliced exons (Gehman et al., 2011; 
Yeo et al., 2009). The location of the binding sequence, either upstream or downstream of the 
alternative exon, determines whether the result of alternative exon usage will be increased or 
repressed exon inclusion (Jin et al., 2003; Underwood et al., 2005; Yeo et al., 2009). It is 
interesting to note that the only putative ZNF804A-interactor identified at the outset of this 
study, ATXN1, has also been implicated in pre-mRNA processing (Lim et al., 2006; Orr, 
2010). Although no interaction between ATXN1 and ZNF804A was identified here, it is 
possible an interaction may be detected if more clones were screened. 
 
Several proteins (including RNPS1 and RBFOX2) were identified in both the human foetal 
and mouse brain cDNA library Y2H screens. These data support the notion that these 
proteins are true ZNF804A-interactors. However, it would have been preferable to confirm 
the Y2H data in cultured mammalian cells using co-immunoprecipitation. This required 
ZNF804A over-expression in mammalian cells; yet at the outset of this study, transiently 
expressed ZNF804A could not be detected in mammalian cells. Data presented here support 
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these findings and show that transiently expressed ZNF804A was degraded by the 
proteasome (section 3.3.2). Proteins, particularly those involved in regulating gene 
expression, are targeted for degradation by post-translational modifications such as 
ubiquitination and SUMOylation (Desterro et al., 2000; Muratani and Tansey, 2003). 
Therefore, these data may be consistent with a role for ZNF804A in the regulation of gene 
expression. The finding that ZNF804A is only reliably detected after proteasome inhibition is 
inconsistent with the literature which suggests transiently expressed myc-ZNF804A has been 
readily detected in rat neural progenitor cells (Girgenti et al., 2012) and HEK293 cells 
(Umeda-Yano et al., 2013) without inhibiting the proteasome. To further understand 
ZNF804A’s biological function, it will be useful to establish the nature of the post-
translational modifications that target ZNF804A to the proteasome for degradation and under 
what cellular conditions these post-translational modifications occur. Having established that 
myc-ZNF804A migrated to 175 kDa (rather than 136 kDa as reported (Girgenti et al., 2013)), 
it is feasible that data presented in Figure 3.4 show that the 3078 antibody detected very low 
levels of myc-ZNF804A when the proteasome was not inhibited. Further experiments using 
proteasome inhibitors are needed to confirm this hypothesis.  
 
Preliminary attempts have been made to immunoprecipitate exogenously synthesised myc-
ZNF804A in the presence of a proteasome inhibitor using anti-myc antibody-conjugated 
beads. To date, immunoprecipitation of myc-ZNF804A has been unsuccessful; therefore 
these experiments require further optimisation. These experiments are important to enable 
validation of the Y2H data in mammalian cells.  
 
To facilitate the understanding of ZNF804A’s function in mammalian cells in vitro, the 
paralog of ZNF804A, GPATCH8, was used. GPATCH8-EYFP localised in punctae in the 
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nucleus within rings formed by nuclear speckles, suggesting GPATCH8 may have a role in 
pre-mRNA splicing (Figure 3.8). As ZNF804A and GPATCH8 are paralogs and putatively 
interact, it is tempting to interpret these data as further evidence that ZNF804A may function 
in the regulation of gene expression and particularly, pre-mRNA splicing. However, Figure 
3.6 shows myc-ZNF804A localised homogenously throughout the nucleus and did not form 
punctae. It is possible that proteasome inhibition may have affected nuclear architecture and 
consequently altered the localisation of ZNF804A. Alternatively, accumulation of myc-
ZNF804A following proteasome inhibition may have altered its nuclear localisation 
compared with endogenous levels. The potential inability of ZNF804A to localise to nuclear 
speckles does not preclude its involvement in pre-mRNA processing as little is understood 
about where in the nucleus splicing takes place (Han et al., 2011).  
 
Notably, anti-SC35 staining showed that the nuclear speckles underwent a change in 
morphology from an orb-shape to a ring-torus shape when GPATCH8-EYFP was over-
expressed. Using fluorescent microscopy, nuclear speckles are visible as punctae which vary 
in size and shape (Misteli, 2000; Spector and Lamond, 2011). However, electron microscopy 
shows that nuclear speckles are in fact composed of two morphologically distinct structures: 
a central region consisting of interchromatin granules, and a peripheral region containing 
nascent transcripts (Fakan, 1994). Interestingly, previous literature suggests that knockdown 
of a G-patch domain-containing protein called Son in HeLa cells led to a comparable change 
in nuclear speckle morphology (Sharma et al., 2010). Consequently, Sharma and colleagues 
proposed that Son has a role in maintaining the correct nuclear speckle structure. It is 
tempting to speculate that GPATCH8 may also have a role in maintaining nuclear speckle 
structure.  
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In summary, the results presented in this Chapter suggest ZNF804A putatively interacts with 
a range of proteins involved in regulating gene expression, including transcription factors and 
regulators of pre-mRNA processing. These data imply that, via interactions with its binding 
partners, ZNF804A may influence gene transcription and splicing of pre-mRNA transcripts. 
Consistent with a potential role for ZNF804A in pre-mRNA processing, the ZNF804A 
paralog and putative interactor, GPATCH8, localised in punctate within nuclear speckles 
enriched for pre-mRNA splicing factors (Spector and Lamond, 2011). Having established 
ZNF804A may have a role in the regulation of transcription and pre-mRNA splicing, human 
exon arrays were used to investigate the effects of knocking down and over-expressing 
ZNF804A on the cellular transcriptome (Chapters Four and Five). The working hypothesis 
was that manipulating ZNF804A mRNA levels would alter the expression and pre-mRNA 
splicing of transcripts regulated, directly or indirectly, by ZNF804A. Data presented in 
Chapters Four and Five are consistent with a role for ZNF804A in transcription and pre-
mRNA processing. In particular, the data show that knockdown of ZNF804A altered splicing 
of a known target of RBFOX2 called enabled homolog (ENAH) (section 4.6.2). 
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Chapter 4: Investigating the effects of depleting ZNF804A on the cellular 
transcriptome 
 
4.1. Introduction  
In Chapter Three, Y2H screening was used to identify the putative protein binding partners of 
ZNF804A. Data presented in Chapter Three suggest ZNF804A putatively interacts with a 
range of proteins involved in regulating gene expression including transcription factors and 
regulators of pre-mRNA processing, such as RNPS1, members of the RBFOX family and 
NOVA2. Fluorescent microscopy showed the ZNF804A paralog and putative interactor, 
GPATCH8, localised in punctate within nuclear speckles enriched for pre-mRNA splicing 
factors (Spector and Lamond, 2011). These data imply that, via interaction with its protein 
binding partners, ZNF804A may influence transcription and pre-mRNA processing.  
 
RNA interference (RNAi) is a mechanism by which double stranded RNA (dsRNA) can 
trigger the sequence-specific suppression of mRNA (Fire et al., 1998). The task of specific 
gene knockdown in vitro has been facilitated by the development of small interfering RNAs 
(siRNAs) (Elbashir et al., 2001). RNAi is a useful tool to investigate gene function, 
particularly when combined with systematic analysis of the downstream consequences of 
mRNA knockdown. For example, transcriptional targets of transcription factors can be 
identified by depleting the endogenous transcription factor and analysing any subsequent 
changes in gene expression using microarrays (Yu et al., 2010). The combination of siRNA 
and splicing-sensitive microarray technologies (known as exon arrays; Figure 4.1) has also 
proved useful in identifying the targets of predicted regulators of pre-mRNA splicing 
(Cheung et al., 2009; Hung et al., 2008a; Warzecha et al., 2009). The aim of the experiments 
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described in this Chapter was to investigate the role of ZNF804A in the regulation of 
transcription and pre-mRNA processing using a combination of siRNA, exon array 
technologies and pathway analysis. The workflow is shown in Figure 4.2 and is described as 
follows: siRNA was used to knockdown endogenous ZNF804A in the human neuroblastoma 
cell line SH-SY5Y (Ross and Biedler, 1985). The SH-SY5Y cell line was chosen because it 
endogenously expresses ZNF804A and it has many of the properties of mature neurons 
(Pahlman et al., 1990; Vaughan et al., 1995). Subsequently, the Affymetrix GeneChip human 
exon 1.0 ST array was used to profile changes in the cellular transcriptome and the data was 
analysed in the context of biological pathways.  
 
The hypothesis was that knockdown of endogenous ZNF804A would lead to changes in the 
expression and pre-mRNA splicing of transcripts regulated, directly or indirectly, by 
ZNF804A. Yet, because very few studies have analysed the effects of depleting a splicing 
regulator on genome-wide pre-mRNA processing (Cheung et al., 2009; Hung et al., 2008a; 
Warzecha et al., 2009), it was difficult to predict how knockdown of ZNF804A would 
influence splicing if ZNF804A was a true regulator of pre-mRNA processing. Therefore, to 
establish a benchmark comparison, siRNA was used to deplete the mRNA of a gene 
(glyceraldehyde 3-phosphate dehydrogenase (GAPDH)) which has no known role in pre-
mRNA processing. It was predicted that there would be relatively more changes in pre-
mRNA splicing in ZNF804A-depleted cells than in GAPDH-depleted cells when compared to 
mock transfections.  
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Figure 4.1 Schematic overview of the exon array design, method and data interpretation  
The Affymetrix GeneChip human exon 1.0 ST array is used to evaluate changes in gene expression 
and splicing. (A) Pre-mRNA is composed of exons and introns. The array is a comprehensive 
platform that contains approximately 5.4 million probes grouped into 1.4 million probe sets 
interrogating over 1 million exon clusters. (B) The RNA samples are prepared for exon array by 
reverse transcription (RT), fragmentation and labelling. The cDNA is then hybridised to the chip. (C) 
The signal intensity data from each individual probe is summarised to the probe set-level. The probe 
set level (exon-level) signal intensity data can be virtually assembled into transcript clusters (gene-
level) using a meta-probe set list. The assembly of exon-level data into transcript clusters allows 
accurate quantification of changes in pre-mRNA splicing (Whistler, 2010) and gene expression 
(Kapur et al., 2007). In example 1 there is no difference in the log2 signal intensities for any of the 
probe sets across the gene, implying there is no difference in transcript abundance or splicing between 
the sample groups. In example 2 all of the probe sets in sample A have smaller log2 signal intensities, 
implying the transcript cDNA is less abundant in sample A. In example 3 the log2 signal intensities of 
the probe sets in the second exon (blue) suggest this exon is less abundant in sample A, but the log2 
signal intensities of the probe sets in the first and third exons are unchanged between the two samples. 
Therefore, it is likely the second exon is alternatively spliced in sample A.  
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Figure 4.2 Flowchart illustrating the experimental design   
Short interfering RNAs (siRNAs) were used to knockdown the mRNA of interest in SH-SY5Y cells. 
RNA was prepared and exon arrays were performed by Central Biotechnology Services (CBS), 
Cardiff University. The raw .CEL files which contained the signal intensity information were 
imported into the Partek Genomics Suite (PGS) using the core metaprobe set annotation file. The 
robust multiarray averaging (RMA) algorithm was used to summarise the probe-level data to a single 
value for each probe set. Two parallel analyses were performed to identify changes in gene expression 
and pre-mRNA splicing. The results were filtered to reduce false-positives, and a selection of changes 
was empirically confirmed.  
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4.2. The knockdown of wildtype ZNF804A mRNA using siRNA-mediated RNAi 
The aim of these experiments was to examine the effects of ZNF804A knockdown. Therefore, 
to ensure that only specific on-target effects of ZNF804A knockdown were analysed, two 
siRNA duplexes were designed to target exons two and three of ZNF804A and the signal 
intensity files from these samples were pooled to give a ‘ZNF804A-knockdown’ group for the 
analysis (Jackson, Bartz et al. 2003, Berns, Hijmans et al. 2004). Appendix 5.1 depicts the 
location of the sites of siRNA directed cleavage, in the context of ZNF804A’s structure. 
C.L.Tinsley designed and optimised the siRNA duplexes used to knockdown ZNF804A 
(designated siZNFA and siZNFB) and GAPDH (designated siGAP) and performed the 
knockdown experiments (section 2.3.8). Mock transfections were also performed to control 
for any changes in the transcriptome in response to exposure to the transfection reagent. To 
ensure that any changes in gene expression or pre-mRNA splicing reported were robust and 
reproducible; four independent biological replicates were performed. Reverse transcription 
(RT) reactions were performed to generate 1
st
 strand cDNA and the level of transcript 
knockdown was assessed using quantitative-PCR (Q-PCR) analysis in collaboration with 
C.L. Tinsley (sections 2.9.1 and 2.3.6). The Q-PCR primer sequences used are listed in 
Appendix 1.4. Appendix 5.1 illustrates the location of the Q-PCR primers, in the context of 
the gene’s structure and in relation to the sites of siRNA directed cleavage. Figure 4.3A 
shows ZNF804A was depleted to a mean average of 18.7% (sd = 8.4) and a mean average of 
23.1% (sd = 8.8) of endogenous levels using siZNFA and siZNFB respectively. Figure 4.3B 
shows GAPDH was depleted to 14.3% (sd = 3.2) of endogenous levels using siGAP. These 
RNA samples were used for the subsequent exon array (n = 4 for each condition). The quality 
of the RNA was assessed on the Agilent 2100 bioanalyser (Central Biotechnology Services 
(CBS), Cardiff University). The RNA integrity number (RIN) for each sample was 10. This 
meant that the RNA was intact and suitable for gene expression analysis. 
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Figure 4.3 ZNF804A and GAPDH were depleted after siRNA treatment  
In four independent experiments (A-D), SH-SY5Y cells were treated twice at 48h intervals with either 
a siRNA duplex designed to target ZNF804A (siZNFA or siZNFB) or a siRNA duplex designed to 
target GAPDH (siGAP). The following day, RNA was prepared. (A) Q-PCR to quantify ZNF804A 
knockdown was performed in triplicate. The raw Ct values were normalised to GAPDH levels. (B) Q-
PCR to quantify GAPDH knockdown was performed in triplicate. The raw Ct values were normalised 
to ACTB levels. The error bars represent the standard deviation of the three raw Ct values. These RNA 
samples were used for the subsequent exon array experiments.  
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4.3. Processing of the exon array chips and quality assessment 
The exon arrays were performed by CBS, Cardiff University (section 2.9.1). Briefly, the 
RNA samples were converted into labelled cDNA, hybridised to the Affymetrix GeneChip 
human exon array 1.0 ST plate and scanned. I received and analysed the resulting .CEL files 
which contained the raw signal intensity information for each probe set. To eliminate non-
specific effects of siRNA treatment, the differentially expressed and alternatively spliced 
transcripts in ZNF804A-depleted cells were identified relative to the GAPDH-depleted cells 
(Jackson, Bartz et al. 2003, Berns, Hijmans et al. 2004). Therefore, the .CEL files were 
imported into the Partek Genomics Suite (PGS) and analysed in three groups: 1) pooled 
siZNF-treated samples (n = 8) versus siGAP-treated samples (n = 4); 2) pooled siZNF-treated 
samples (n = 8) versus mock samples (n = 4); and 3) siGAP-treated samples (n = 4) versus 
mock samples (n = 4). The .CEL files were imported using the core metaprobe set and robust 
multiarray averaging (RMA) algorithm (section 2.9.2). RMA is a model-based method that 
generates robust signal estimates by down-weighing probes that perform poorly (Irizarry et 
al., 2003b; Lockstone, 2011). Supplementary data provided in Appendices 4A and B show 
quality assessment metrics performed in the PGS confirmed RMA normalisation was 
successful. To identify related samples, agglomerative hierarchical clustering was performed 
(section 2.9.3), and the resulting cluster dendrograms are shown in Figures 4.4 and 4.5. The 
clustering was performed using the gene-summarised expression values from the top 100, 
1000 and 5000 most differentially expressed genes. The clustering patterns correlated with 
ZNF804A knockdown. These data suggest that ZNF804A-depleted cells were systematically 
different to the control cell lines.  
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Figure 4.4 Hierarchical clustering of the most differentially expressed genes between siZNF-
treated and siGAP-treated samples 
Hierarchical clustering of the (A) 100, (B) 500 and (C) 1000 most differentially expressed genes 
between siZNF-treated samples (red) and siGAP-treated samples (blue). The heatmap colours are 
artificial: green = relative up-regulation and red = relative down-regulation black = no difference.  
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Figure 4.5 Hierarchical clustering of the most differentially expressed genes between the siZNF-
treated and the mock samples 
Hierarchical clustering of the (A) 100, (B) 500 and (C) 1000 most differentially expressed genes 
between siZNF-treated samples (red) and mock samples (blue). The heatmap colours are artificial: 
green = relative up-regulation and red = relative down-regulation black = no difference.  
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4.4. The PGS ‘geneview’ of ZNF804A  
The PGS represents exon array data graphically in the form of a ‘geneview’. A geneview 
contains three key pieces of information: 1) the mean log2 signal intensity for each probe set 
assigned to the gene for each sample group 2) the fold change in log2 signal intensity for each 
probe set between sample groups and 3) the known mRNA transcript variants. Figure 4.6A 
shows the geneview for ZNF804A. This geneview shows that only probe sets in exon four of 
ZNF804A had reduced log2 signal intensity after ZNF804A knockdown. This implies only 
exon four of ZNF804A was depleted after siZNF treatment. These data contradict the Q-PCR 
analysis of ZNF804A knockdown which was performed using a primer/probe pair designed 
complementary to the 5’ end of ZNF804A (Figure 4.3; Appendix 5.1). Figure 4.6B shows the 
GAPDH geneview was consistent with a reduction in log2 signal intensity across every probe 
set complementary to GAPDH. Therefore, it is unlikely that the ZNF804A geneview reflects 
the RNAi method used to deplete ZNF804A. The most parsimonious explanation for the 
ZNF804A geneview is that non-specific mRNA cross-hybridised with the probe sets 
complementary to exons 1-3 of ZNF804A on the exon array and artificially increased the 
signal intensity readings for these probe sets. However, further experiments using RNA-
sequencing or northern blotting are required to explore the possibility that there may be more 
than one transcript variant of ZNF804A.  
 
4.5. Identifying genes with altered expression after ZNF804A knockdown  
To identify genes with altered expression in ZNF804A-depleted cells, a one-way ANOVA 
was performed on the gene-summarised expression values, between the pooled siZNF-treated 
samples and the siGAP-treated samples (section 2.9.4). The expression of 579 genes differed 
significantly (FDR 0.01; Table 4.1). Of these genes, 263 had a fold change of greater than 1.5 
or less than -1.5 and 66 had a fold change of greater than 2 or less than -2. The top 10  
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Figure 4.6 The geneviews of ZNF804A and GAPDH 
(A) There was reduced ZNF804A mRNA abundance in ZNF804A-depleted cells (P = 2.13 x 10
-8
; FC 
= -2.01; one-way ANOVA). The geneview of ZNF804A was the same when either siGAP-treated or 
mock samples were used as the control. (B) There was reduced GAPDH mRNA abundance in 
GAPDH-depleted cells compared to the mock samples. FC = fold change. 
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Table 4.1 The most significantly differentially expressed genes after ZNF804A knockdown  
The .CEL files were imported into the PGS using the core metaprobe set and RMA normalisation. 
The .CEL files were assigned as either siZNF- or siGAP-treatment. A one-way ANOVA was 
performed on the gene-summarised expression values, using treatment as the candidate variable in the 
ANOVA model. The expression of 579 genes differed significantly (FDR 0.01). The top 35 genes 
ranked by P value are shown. FC = fold change.  
Gene name Gene symbol P value FC 
alanyl (membrane) aminopeptidase  ANPEP 1.17E-09 -2.53 
inositol polyphosphate-5-phosphatase INPP5A 1.54E-09 2.04 
retinal degeneration 3 RD3 6.93E-09 2.15 
protocadherin beta 14  PCDHB14 1.65E-08 2.50 
zinc finger protein 804A  ZNF804A 2.13E-08 -2.01 
caspase 3 CASP3 2.27E-08 -2.81 
MARVEL domain containing 1 MARVELD1 3.28E-08 2.17 
F-box and leucine-rich repeat protein 2  FBXL2 3.31E-08 2.00 
calcium channel, voltage-dependent, T type, alpha 
1G subunit 
CACNA1G 3.45E-08 -1.94 
solute carrier family 36  SLC36A1 5.68E-08 1.84 
notch 3 NOTCH3 8.22E-08 -2.02 
protein tyrosine phosphatase domain containing 1 PTPDC1 8.64E-08 1.39 
ATPase, H+ transporting, lysosomal 42kDa, V1 
subunit C1 
ATP6V1C1 1.01E-07 3.37 
tribbles homolog 2 (Drosophila) TRIB2 1.03E-07 1.97 
placental growth factor  PGF 1.07E-07 -1.69 
bone morphogenetic protein 2 BMP2 1.56E-07 1.62 
solute carrier family 9 (sodium/hydrogen exchanger) SLC9A6 2.30E-07 -2.00 
protein S (alpha)  PROS1 2.44E-07 1.65 
T-cell leukemia translocation altered gene  TCTA 2.48E-07 2.25 
EPH receptor A6 EPHA6 2.50E-07 2.16 
sestrin 3 SESN3 2.77E-07 -3.11 
connector enhancer of kinase suppressor of Ras 2  CNKSR2 3.19E-07 -1.56 
salt-inducible kinase 2  SIK2 3.36E-07 -1.88 
vasoactive intestinal peptide VIP 3.52E-07 3.15 
LAG1 homolog, ceramide synthase 2 LASS2 3.99E-07 2.29 
nidogen 2 (osteonidogen) NID2 4.29E-07 -1.51 
Kruppel-like factor 7 (ubiquitous)  KLF7 5.41E-07 1.53 
sphingomyelin phosphodiesterase 3, neutral 
membrane (neutral sphingomyelinase II) 
SMPD3 6.76E-07 -2.32 
potassium voltage-gated channel, shaker-related 
subfamily, member 3 
KCNA3 6.95E-07 1.61 
chromosome 12 open reading frame 53 C12orf53 7.16E-07 1.63 
chromosome 6 open reading frame 48 C6orf48 8.02E-07 1.53 
tissue factor pathway inhibitor (lipoprotein-associated 
coagulation inhibitor) 
TFPI 8.74E-07 -1.45 
adrenergic, alpha-2C-, receptor  ADRA2C 8.85E-07 1.50 
MYST histone acetyltransferase 1  MYST1 1.05E-06 -1.39 
GDNF family receptor alpha 2 GFRA2 1.09E-06 2.13 
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positive and negative fold changes are shown in Table 4.2.  
 
Using siRNA to initiate the RNAi pathway can result in off-target effects (Jackson, Bartz et 
al. 2003, Berns, Hijmans et al. 2004). To negate these off-target effects, the siGAP-treated 
samples were used as the negative control condition. To ensure using the siGAP-treated 
samples as the negative control condition did not alter the conclusions drawn from the study, 
a one-way ANOVA was performed on the gene-summarised expression values between the 
siGAP-treated samples and the untreated, mock samples, and the list was compared to the 
579 genes identified as differentially expressed between siZNF-treated samples and siGAP-
treated samples. Using a 1% FDR, the expression of 47 genes differed significantly between 
the siGAP-treated samples and mock samples (gene list provided in Appendix 5.2). There 
was an overlap of only 10 genes between these 47 genes and the 579 identified as 
differentially expressed between siZNF-treated and siGAP-treated samples. This suggests 
that the overwhelming majority of the 579 differentially expressed genes were true 
ZNF804A-related events.  
 
4.5.1. Enrichment analysis of the genes with altered expression after ZNF804A 
knockdown  
Some of the genes that were differentially expressed in ZNF804A-depleted cells relative to 
the GAPDH-depleted cells have been consistently implicated in neuropsychiatric disease 
using a range of genetics and post-mortem studies, including reelin (RELN), neuropeptide Y 
(NPY) and components of glutamate signalling, such as glutamate receptor 7 (GRM7) (Table 
4.3).  
 
While it was tempting to place emphasis on these individual genes, it was more informative 
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Table 4.2 The genes with the largest fold changes in expression after ZNF804A knockdown   
The .CEL files were imported into the PGS using the core metaprobe set and RMA normalisation. 
The .CEL files were assigned as either siZNF- or siGAP-treatment. A one-way ANOVA was 
performed on the gene-summarised expression values, using treatment as the candidate variable in the 
ANOVA model. The expression of 579 genes differed significantly (FDR 0.01). The top 10 positive 
and negative fold changes in expression are shown. (FC = fold change.) 
 
 
 
 
 
 
 
Gene name Gene symbol P value FC 
Up-regulated genes 
EGF-like repeats and discoidin I-like domains 3 EDIL3 2.49E-04 4.11 
reelin  RELN 1.03E-05 3.91 
LY6/PLAUR domain containing 1  LYPD1 2.28E-06 3.56 
ATPase, H+ transporting, lysosomal 42kDa, V1 subunit 
C1 
ATP6V1C1 1.01E-07 3.37 
vasoactive intestinal peptide VIP  3.52E-07 3.15 
Rho GTPase activating protein 36  ARHGAP36 3.11E-05 3.11 
histone cluster 1, H4h HIST1H4H 3.59E-06 2.83 
cyclin-dependent kinase inhibitor 1A (p21, Cip1) CDKN1A 2.13E-06 2.69 
ER degradation enhancer, mannosidase alpha-like 2 EDEM2 1.40E-06 2.59 
achaete-scute complex homolog 1 (Drosophila) ASCL1 2.25E-04 2.54 
Down-regulated genes 
hepatocyte growth factor (hepapoietin A; scatter factor) HGF 4.30E-05 -12.43 
cellular retinoic acid binding protein 2  CRABP2 1.04E-04 -4.04 
ADAM metallopeptidase with thrombospondin type 1 
motif, 3 
ADAMTS3 8.69E-06 -3.24 
decorin DCN  2.09E-05 -3.11 
sestrin 3  SESN3 2.77E-07 -3.11 
serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, 
pigment epithelium derived factor), member 1 
SERPINF1 2.38E-06 -2.91 
fms-related tyrosine kinase 1 (vascular endothelial 
growth)  
FLT1 6.79E-05 -2.84 
caspase 3, apoptosis-related cysteine peptidase CASP3 2.27E-08 -2.81 
transmembrane protein with EGF-like and two follistatin-l TMEFF1 2.89E-05 -2.58 
coiled-coil domain containing 80  CCDC80 6.86E-05 -2.57 
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to use a systematic, statistical approach to identify particular biological processes which were 
enriched for ZNF804A-related target genes. Therefore, enrichment analysis was performed 
using GeneGo MetaCore™ software (section 2.10). GeneGo MetaCore™ was chosen as the 
analysis software because it utilises both GO processes and GeneGo’s manually curated 
processes and pathways. To ensure that only genes that could be detected as differentially 
expressed in the exon array were included in the enrichment analysis, the background 
comparison was set as the Affymetrix GeneChip human exon array 1.0 ST-v2. Of the 579 
differentially expressed genes, 544 were represented in GeneGo MetaCore™. Numerous GO 
process terms were identified as significantly enriched among the differentially expressed 
genes including ‘neuron projection development’ (72/774 P = 3.35 x10-15), ‘cell projection 
organisation’ (82/986 P = 1.96 x 10-14) and ‘nervous system development’ (142/2250 P = 
2.66 x 10
-14
) (Figure 4.7A). These enrichments survived 5% FDR correction for multiple 
testing. Genes belonging to GeneGo process networks ‘synaptic contact as an element of cell 
adhesion’ (21/167 P = 8.39 x 10-6) and ‘axonal guidance as an element of neurogenesis and 
development’ (21/219 P = 4.5 x 10-4) were significantly enriched among the differentially 
expressed genes (Figure 4.7B). These enrichments survived 5% FDR correction for multiple 
testing. The differentially expressed genes belonging to ‘synaptic contact as an element of 
cell adhesion’ included neuroligin 2 (NLGN2), neurofascin (NFASC) and regulating synaptic 
membrane exocytosis 1 (RIMS1). There was no apparent difference in the enrichment 
categories of the up-regulated and down-regulated genes (data not shown).   
 
4.5.2. GWAS enrichment analysis  
If the genes with altered expression after ZNF804A knockdown represent the causal effects of 
ZNF804A’s contribution to disease, it was hypothesised that these genes may show genetic 
associations with neuropsychiatric disease. Many secondary studies of GWAS data use gene-
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Gene name 
Gene 
symbol 
Evidence for involvement in pathophysiology of 
schizophrenia 
siZNF vs. siGAP siZNF vs. mock 
   P value         FC          P value          FC 
Neuroligin 2 NLGN2 
Rare mutations in NLGN2 are associated with disease (Sun et al., 
2011).  
1.51E-04 -1.29 3.86E-03 -1.25 
Caspase 3 CASP3 
Decreased expression in oligodendrocytes in schizophrenia patients 
(Kerns et al., 2010). 2.27E-08 -2.81 5.39E-07 -2.05 
Reelin RELN 
Post-mortem brain studies show a decrease in RELN expression in 
schizophrenia (Guidotti et al., 2000; Impagnatiello et al., 1998); 
genetics analysis identified association between common variation in 
RELN and disease (Kahler et al., 2008; Shifman et al., 2008) and 
disruptions in RELN signalling cascade have been associated with 
disease (Costa et al., 2002).  
1.03E-05 3.91 8.86E-04  2.35 
Ephrin B2 EFNB2 
Genetic analysis identified association with schizophrenia (Zhang et 
al., 2010). Also, EFNB2 is an essential component of RELN pathway 
and regulates neuronal migration (Senturk et al., 2011) 
3.88E-06 -2.14 1.87E-04 -1.61 
Neuropeptide Y NPY 
Post-mortem brain studies of schizophrenia and bipolar disorder 
patients show decrease in NPY expression in frontal cortex 
(Kuromitsu et al., 2001) and disorganisation of NPY containing 
neurons in DPFC (Ikeda et al., 2004). Additionally, impaired NPY 
signalling is implicated in pathophysiology of psychiatric disorders 
(Caceda et al., 2007; Eaton et al., 2007).  
8.13E-06 2.05 3.36E-05  1.86 
Glutamate receptor 7 GRM7 
GRM7 encodes a G-protein-coupled receptor for glutamate. 
Glutamate dysfunction has been implicated in pathophysiology of 
schizophrenia (Carlsson et al., 2001). CNVs in GRM7 have been 
found in schizophrenia patients (Saus et al., 2010). 
4.85E-06 1.26 6.72E-06  1.26 
Neurotensin NTS 
NTS is implicated in dopamine and NMDA interactions (Li et al., 2010; 
Tanganelli et al., 2012). 
4.31E-06 1.95 1.11E-07  2.80 
 
Table 4.3 The literature implicates some of the differentially expressed genes in the neurobiology of schizophrenia. (FC = fold change.)
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Figure 4.7 Biological processes that were significantly enriched for genes showing differential 
expression after ZNF804A knockdown  
The list of genes showing differential expressed between siZNF-treated and siGAP-treated samples 
using a 1% FDR (section 4.5.1) was imported into GeneGo MetaCore™. Of the 579 differentially 
expressed genes, 544 were represented in GeneGo MetaCore™. The enrichment analysis was 
performed using Affymetrix GeneChip human exon array 1.0 ST v-2 as the background list. The bar 
charts show the top statistically significant (A) GO processes and (B) GeneGo process networks 
identified by the enrichment analysis. The enrichments presented were statistically significant when 
5% FDR correction was applied, as determined by GeneGo MetaCore™. The uncorrected P values 
are shown.  
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based tests rather than information from individual SNP markers to assess whether a group of 
genes are genetically associated with disease. Gene-based association P values (also known 
as gene-wide P values) are calculated by combining the information from several SNP 
markers (Moskvina et al., 2011). Here, gene-wide P values from the schizophrenia and 
bipolar disorder psychiatric GWAS consortium (PGC) datasets (kindly provided by V. 
Moskvina) were used to test the hypothesis that there were more genes significantly 
associated with disease (gene-wide P < 0.05) in the differentially expressed gene list than 
would be expected by chance. The significance of the over-representation was tested using a 
normal distribution. The results show that more genes that have a gene-wide significant 
association with disease were differentially expressed in ZNF804A-depleted cells (FDR 0.05) 
than expected by chance (P = 0.03 for schizophrenia and P = 0.04 for bipolar disorder) (Table 
4.4). Manual inspection of the genomic location of the differentially expressed genes which 
were genetically associated with disease suggested they were not in close proximity to one 
another (data not shown). Therefore, it is unlikely that this result reflects LD between the 
SNPs. This finding suggests that the genes with altered expression after ZNF804A 
knockdown are moderately enriched for genes genetically associated with disease. These data 
provide independent support for a causal link between the genes with altered expression after 
ZNF804A knockdown and neuropsychiatric disease. When a more stringent cut-off for 
differential expression was used (FDR 0.01), there was no significant difference from the 
normal distribution (P = 0.23 for schizophrenia and P = 0.22 for bipolar disorder; Table 4.4). 
However, there were more genes genetically associated with disease observed than expected, 
suggesting that these data did follow the same trend.  
 
To establish whether the genes with altered expression after ZNF804A knockdown were more 
strongly associated with disease than genes which did not show altered expression, a Mann 
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Whitney U test was used. The null hypothesis of this test was that the gene-wide P values of 
the differentially expressed genes had the same distribution as the gene-wide P values of the 
non-differentially expressed genes. The results showed there was no significant difference in 
the distribution of the gene-wide P values for differentially expressed and non-differentially 
expressed genes for either the schizophrenia dataset (P = 0.868) or the bipolar disorder 
dataset (P = 0.808) (data not shown).  
 
 
Table 4.4 Enrichment analysis of the genes significantly associated with neuropsychiatric 
disease (gene-wide P < 0.05) in the lists of genes which were differentially expressed after 
ZNF804A knockdown  
The PGC datasets were filtered using the gene symbols of the genes differentially expressed after 
ZNF804A knockdown relative to the siGAP-treated samples. The number of overlapping gene 
symbols is shown after ZNF804A was removed from the analysis. A filter was applied to retain only 
the genes with a gene-wide association P < 0.05. The expected number of retained genes was 
calculated using a significance level of 0.05. The significance of the over-representation was tested 
using a normal distribution. (PGC = Psychiatric GWAS consortium; sd = standard deviation.)  
 
 
 
 
 
 
PGC dataset 
exon array 
significance 
cut-off 
number of 
overlapping 
gene symbols 
(PGC/exon array) 
number of genes 
significantly associated with 
disease (P < 0.05) in the list 
of differentially expressed 
genes 
sd       P value 
  
  
  
observed expected   
  
schizophrenia 
FDR 0.05 1367/1755 85 68.35 8.91 0.03 
FDR 0.01 446/578 26 22.3 5.09 0.23 
bipolar 
disorder   
FDR 0.05 1367/1755 85 69.45 8.98 0.04 
FDR 0.01 446/578 28 23.85 5.26 0.22 
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4.5.3.  Q-PCR validation of gene expression changes after ZNF804A knockdown 
Currently, there is no ‘gold standard’ for analysing gene expression measurements therefore, 
it is important to consider the reliability of the array results by validating a selection of the 
identified target genes experimentally (Allison et al., 2006; Chuaqui et al., 2002). Here, Q-
PCR was used to validate the gene expression data from the exon array. Please note, only one 
biological replicate used in the exon array was analysed using Q-PCR. Q-PCR was chosen as 
the validation method due to its ability to detect small changes in fold change and its 
excellent target specificity (section 2.9.5).  
 
For validation, eight genes were selected from the list of genes differentially expressed 
between siZNF-treated and siGAP-treated samples based on: 1) the magnitude of fold 
change, where a large fold change was preferred; 2) the number of known transcript variants, 
where a single transcript variant was preferred; and 3) the DNA sequence, where sequences 
with 40-60% GC content which were amenable to Q-PCR were preferred. The array data was 
considered verified if the Q-PCR results demonstrated a statistically significant difference in 
the abundance of mRNA between the pooled siZNF-treated samples and both of the control 
samples, with the fold change in the same direction as the array data. Of the eight genes 
selected for validation, all eight were verified as true results (Figure 4.8A). For example, 
NPY, chemokine (C-C motif) ligand 2 (CCL2), secreted protein acidic and rich in cysteine 
(SPARC), transmembrane protein with EGF-like and two follistatin-like domains 2 
(TMEFF2) and early growth response 1 (EGR1) showed up-regulation after ZNF804A 
knockdown while pyruvate dehydrogenase lipoamide kinase isozyme 1 (PDK1), follistatin-
like 4 (FSTL4), ephrin-B2 (EFNB2) showed down-regulation after ZNF804A knockdown. 
Comparison of the Q-PCR data with the exon array data showed that the magnitude of fold 
change calculated by Q-PCR was very similar to that calculated by exon array analysis 
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Figure 4.8 Q-PCR assessment of gene expression changes after ZNF804A knockdown  
To assess a selection of the gene expression changes using Q-PCR, RNA from one biological 
replicate used for the exon array was treated with DNase and cDNA was prepared. The cDNA from 
each condition was run by Q-PCR in triplicate for each primer set (primer sequences are given in 
Appendix 1.4). The mean average raw Ct value was normalised to ACTB and the data was analysed 
using the ∆Ct method. The data from the siZNFA- and siZNFB-treated sample was pooled to reflect 
the exon array analysis. (A) Bar graphs presenting the target mRNA abundance as a percentage of the 
target mRNA abundance in the siGAP-treated sample. The error bars represent the standard deviation 
of the raw Ct values (three technical replicates for each condition). (B) The statistical analysis was 
carried out on the ΔCt values using one-way ANOVA and Tukey post-hoc. The fold change was 
calculated by dividing the siGAP-treated ∆∆Ct value by the pooled siZNF-treated ∆∆Ct value. When 
this number was less than one, indicating a negative fold change, the reciprocal fold change is listed. 
The summary statistics from the exon array are listed for comparison. * = P < 0.05 ** = P < 0.001 
compared to both siGAP-treated and mock samples. (FC = fold change.)    
 
 
 
 
 
 
 Gene symbol Exon array Q-PCR 
 P value FC P value FC 
SPARC 1.25E-04 2.29 >0.001 2.32 
FSTL4 8.32E-03 -2.06 6.00E-03 -2.70 
NPY 8.14E-06 2.05 1.00E-03 3.31 
PDK1 5.28E-03 -2.04 >0.001 -2.13 
EGR1 4.49E-04 2.65 2.00E-03 3.68 
TMEFF2 6.80E-04 2.37 >0.001 2.80 
CCL2 4.96E-03 3.64 1.20E-02 6.29 
EFNB2 3.87E-06 -2.14 3.00E-03 -1.90 
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(Figure 4.8B). These data imply that the exon array analysis was able to accurately determine 
changes in gene expression in ZNF804A-depleted cells.  
 
4.6. Investigating changes in pre-mRNA splicing after ZNF804A knockdown  
Since the advent of exon arrays, several algorithms have been proposed to identify alternative 
splicing events. These algorithms include the alternative splicing ANOVA in the PGS, the 
microarray detection of alternative splicing (MIDAS) (Affymetrix, 2006), the splicing index 
(SI) (Srinivasan et al., 2005) and the microarray analysis of differential splicing (MADS) 
(Xing et al., 2008). In this Chapter, two analysis approaches using the statistical tests 
available in the PGS were employed (section 2.9.6). In both approaches, the alternative 
splicing one-way ANOVA was performed on probe set log2 signal intensities using only 
probe set log2 signal intensities which were greater than three to ensure the analysis included 
only probe sets detected in at least one of the sample groups (Whistler, 2010). The output of 
the alternative splicing one-way ANOVA was displayed in the PGS both at the gene-level 
and at the probe set-level. This meant that each gene was attributed an alternative splicing P 
value and each individual probe set was attributed a P value for differential expression. 
Inherently, gene-level analyses of alternative splicing take into consideration any differences 
in gene-wide expression which may influence discovery of true changes in splicing. 
Therefore, most published papers present and validate only the results of gene-level analyses. 
However, the literature suggests that analysis of individual probe set log2 signal intensities at 
the exon-level (equivalent to the probe-set level) may also identify true alternative splicing 
events (Laajala et al., 2009; Warzecha et al., 2009). Therefore, both the gene-level (section 
4.6.1) and the probe set-level (section 4.6.2) output derived from the alternative splicing one-
way ANOVA were used to identify alternative splicing events.  
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4.6.1.  Analysing alternative splicing after ZNF804A knockdown using the alternative 
splicing one-way ANOVA gene-level output 
To reduce the number of false-positive results, the gene list was filtered to exclude any gene 
with less than five probe sets or gene expression changes greater than five-fold and a 
conservative Bonferroni correction for multiple testing was applied. The Bonferroni corrected 
P values are presented here. After Bonferroni correction, an arbitrary cut-off of P < 1 x 10
-6
 
was chosen to generate a manageable list of statistically significant alternatively spliced 
genes (Whistler, 2010). This analysis revealed the splicing of 116 genes was altered after 
ZNF804A knockdown, relative to siGAP-treated samples (Table 4.5). The geneviews of the 
116 alternatively spliced genes detailed in Table 4.5 were viewed alongside the gene 
information in the UCSC genome browser to determine if the statistically significant events 
resembled true changes in splicing (Langer et al., 2010; Whistler, 2010). This analysis is 
presented as supplementary data in Appendix 5.3. Many of the 116 statistically significant 
changes in splicing corresponded to complex changes in transcript usage which would be 
difficult to evaluate empirically. However, 17 of the events corresponded to putative 
alternative splicing of a cassette exon. Three of these cassette exons corresponded to known 
alternative splicing events. Thus, these three events were the focus of the confirmation 
analyses (see below).  
 
Signal induced proliferation-associated 1 like 1 (SIPA1L1) was identified as statistically 
significantly alternatively spliced (Bonferroni corrected P = 2.57 x 10
-11
; alternative splicing 
one-way ANOVA). The geneview for SIPA1L1 showed one probe set had a larger, negative 
fold change following ZNF804A knockdown than the other probe sets (Figure 4.9A). This 
probe set corresponded to exon 13a (chr14:72171438-72171500) of SIPA1L1 which is known 
to be alternatively spliced (Figure 4.9B). Therefore, RT-PCR was used to test the hypothesis  
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Gene name 
Gene 
symbol 
Gene 
expression  
P value 
Bonferroni corrected 
alternative splicing 
P value 
FC 
calcium channel, voltage-
dependent, T type, alpha 1G 
subunit 
CACNA1G 3.43E-08 0.00E+00 -1.97 
laminin, beta 2 (laminin S) LAMB2 2.57E-05 1.98E-35 2.42 
fms-related tyrosine kinase 1  FLT1 6.79E-05 5.39E-34 -2.84 
notch 3 NOTCH3 8.22E-08 1.59E-33 -2.02 
G protein-coupled receptor 64 GPR64 2.75E-04 1.57E-30 3.19 
Rho GTPase activating protein 36 ARHGAP36 3.36E-05 3.18E-30 3.29 
WNK lysine deficient protein kinase 
1 
WNK1 6.48E-05 3.54E-30 -1.29 
myosin X MYO10 6.64E-06 5.39E-30 -1.90 
slit homolog 1 (Drosophila) SLIT1 8.62E-05 9.38E-26 -1.52 
alanyl (membrane) aminopeptidase ANPEP 1.08E-09 1.51E-25 -2.63 
zinc finger protein 804A ZNF804A 2.13E-08 1.98E-22 -2.01 
ATP-binding cassette, sub-family C 
(CFTR/MRP), member 3 
ABCC3 1.03E-03 4.00E-22 1.45 
reelin RELN 1.03E-05 9.25E-22 3.91 
protein tyrosine phosphatase, 
receptor type, E 
PTPRE 2.08E-03 3.22E-20 2.16 
LY6/PLAUR domain containing 1  LYPD1 2.28E-06 3.06E-19 3.56 
protein tyrosine phosphatase, 
receptor type, R 
PTPRR 1.38E-01 3.32E-19 -1.17 
 transforming, acidic coiled-coil 
containing protein 2 
TACC2 1.80E-03 1.17E-18 -1.21 
thrombospondin, type I, domain 
containing 4 
THSD4 1.94E-04 4.01E-17 2.05 
sestrin 3 SESN3 2.77E-07 8.38E-17 -3.11 
leucine rich repeat containing 7 LRRC7 3.32E-06 1.28E-16 1.73 
glutamate decarboxylase 1 (brain, 
67kDa) 
GAD1 2.53E-01 4.18E-16 -1.07 
integrin, alpha 5  ITGA5 1.18E-02 4.81E-15 -1.20 
decorin DCN 2.09E-05 6.16E-15 -3.11 
ATP-binding cassette, sub-family C 
(CFTR/MRP), member 5  
ABCC5 5.57E-01 1.79E-14 -1.06 
family with sequence similarity 184, 
member A  
FAM184A 8.33E-05 2.35E-14 -1.31 
PALM2-AKAP2 readthrough 
PALM2-
AKAP2 
1.38E-01 3.58E-14 -1.11 
protocadherin gamma subfamily C, 
5 
PCDHGC5 2.51E-04 5.98E-14 1.23 
polymerase (DNA directed), theta POLQ 2.54E-04 1.35E-13 -1.42 
elastin  ELN 1.16E-05 3.10E-13 1.45 
laminin, alpha 1 LAMA1 5.49E-02 4.22E-13 -1.17 
T-box 3 TBX3 3.83E-04 5.35E-13 2.30 
 ATPase, Ca++ transporting, 
ubiquitous 
ATP2A3 4.37E-04 6.40E-13 -1.18 
U-box domain containing 5  UBOX5 4.88E-04 8.14E-13 -1.25 
 kinesin family member 21A KIF21A 5.66E-03 8.32E-13 -1.41 
retinoic acid induced 14  RAI14 4.15E-04 9.43E-13 -2.51 
B-cell CLL/lymphoma 11A (zinc 
finger protein) 
BCL11A 1.53E-05 9.80E-13 -1.62 
caspase 4, apoptosis-related 
cysteine peptidase  
CASP4 2.91E-06 1.07E-12 1.80 
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G protein-coupled receptor 162 GPR162 1.00E+00 1.16E-12 -1.00 
vasoactive intestinal peptide  VIP 3.52E-07 1.26E-12 3.15 
 reticulon 4 RTN4 9.15E-01 1.50E-12 1.01 
aspartate beta-hydroxylase ASPH 1.84E-05 2.29E-12 -1.79 
 fibroblast growth factor receptor-
like 1 
FGFRL1 1.77E-05 3.92E-12 -1.62 
matrilin 2 MATN2 8.59E-03 4.83E-12 2.27 
 immunoglobulin superfamily, 
member 1 
IGSF1 3.65E-06 6.02E-12 2.47 
topoisomerase (DNA) II alpha 
170kDa 
TOP2A 1.77E-04 8.31E-12 -1.99 
Rho GTPase activating protein 28  ARHGAP28 2.55E-03 8.35E-12 -2.20 
chimerin (chimaerin) 1 CHN1 5.03E-01 1.03E-11 -1.12 
pre-B-cell leukemia homeobox 
interacting protein 1  
PBXIP1 3.67E-03 2.35E-11 -1.63 
signal-induced proliferation-
associated 1 like 1 
SIPA1L1 2.46E-04 2.57E-11 -1.43 
complement factor H CFH 9.35E-02 2.59E-11 1.20 
lipid phosphate phosphatase-
related protein type 3 
LPPR3 5.19E-05 2.89E-11 -1.31 
 immunoglobulin superfamily, 
member 9 
IGSF9 1.44E-05 3.36E-11 -1.32 
signal-induced proliferation-
associated 1 
SIPA1 4.74E-05 4.59E-11 -1.39 
RNA binding protein with multiple 
splicing 
RBPMS 6.73E-04 1.03E-10 -1.77 
collagen, type XXVII, alpha 1 COL27A1 4.09E-01 1.04E-10 1.06 
active BCR-related gene  ABR 6.56E-02 1.19E-10 1.18 
phosphodiesterase 11A  PDE11A 3.68E-05 1.77E-10 1.74 
CD44 molecule (Indian blood 
group)  
CD44 2.51E-03 2.04E-10 1.83 
tissue factor pathway inhibitor 2 TFPI2 1.54E-04 2.87E-10 1.72 
serpin peptidase inhibitor, clade F   SERPINF1 2.38E-06 3.56E-10 -2.91 
MAX interactor 1 MXI1 1.87E-06 3.87E-10 -1.55 
matrix metallopeptidase 15 MMP15 1.12E-04 6.60E-10 2.01 
E1A binding protein p400 EP400 5.87E-02 7.31E-10 -1.12 
phosphatidylinositol-3,4,5-
trisphosphate-dependent Rac 
exchange factor 1 
PREX1 2.16E-06 1.13E-09 -1.22 
neuron navigator 2  NAV2 3.51E-02 1.21E-09 -1.30 
tight junction protein 2 (zona 
occludens 2)  
TJP2 2.81E-03 1.48E-09 -1.76 
nuclear transcription factor Y, 
alpha 
NFYA 9.45E-03 1.50E-09 -1.39 
 BR serine/threonine kinase 2 BRSK2 2.71E-05 1.64E-09 -1.13 
ryanodine receptor 1 (skeletal) RYR1 3.86E-02 2.03E-09 1.13 
WD repeat and SOCS box-
containing 1  
WSB1 7.90E-01 2.43E-09 -1.02 
C1q and tumor necrosis factor 
related protein 6 
C1QTNF6 1.10E-04 3.58E-09 1.84 
Sema domain, immunoglobulin 
domain (Ig), short basic domain, 
secreted, (semaphorin) 3F 
SEMA3F 1.86E-03 3.72E-09 -1.19 
metastasis suppressor 1 MTSS1 4.15E-05 4.49E-09 -1.32 
cytochrome b5 reductase 2 CYB5R2 2.82E-03 5.13E-09 -1.22 
transcription elongation factor A 
(SII), 2  
TCEA2 3.66E-03 6.25E-09 -1.52 
Chapter Four: Investigating the effects of depleting ZNF804A on the cellular transcriptome  
 126 
microtubule associated 
serine/threonine kinase 1  
MAST1 4.29E-04 6.39E-09 -1.24 
LIM homeobox 8 LHX8 1.90E-04 7.41E-09 -1.30 
pyruvate kinase, muscle PKM2 2.30E-03 7.76E-09 -1.23 
collagen, type IV, alpha 2 COL4A2 1.90E-03 8.55E-09 -1.27 
beta-1,4-N-acetyl-galactosaminyl 
transferase 4 
B4GALNT4 1.03E-05 1.60E-08 -1.28 
sphingomyelin phosphodiesterase 
3, neutral membrane (neutral 
sphingomyelinase II) 
SMPD3 6.77E-07 1.64E-08 -2.32 
extra spindle pole bodies homolog 
1 (S. cerevisiae)  
ESPL1 5.57E-03 1.68E-08 -1.36 
KIAA0649 KIAA0649 1.07E-05 2.45E-08 -1.27 
transmembrane protein with EGF-
like and two follistatin-like domains 
2 
TMEFF2 6.80E-06 3.08E-08 2.37 
ankyrin repeat domain 12  ANKRD12 3.65E-04 3.13E-08 -1.55 
casein kinase 2, alpha prime 
polypeptide 
CSNK2A2 4.45E-06 3.25E-08 -1.39 
glutamine-fructose-6-phosphate 
transaminase 2  
GFPT2 3.18E-04 3.47E-08 -1.39 
 prostaglandin F receptor (FP) PTGFR 6.88E-05 3.65E-08 1.72 
zinc finger protein 395 ZNF395 5.56E-06 3.68E-08 -1.44 
astrotactin 1 ASTN1 8.86E-04 4.56E-08 1.75 
anoctamin 3 ANO3 1.69E-04 5.14E-08 1.56 
platelet-derived growth factor 
receptor, alpha polypeptide 
PDGFRA 5.34E-03 5.20E-08 -1.27 
family with sequence similarity 190, 
member B 
FAM190B 1.86E-05 5.60E-08 -1.47 
sulfatase 2 SULF2 1.30E-04 7.43E-08 2.02 
SRSF protein kinase 2 SRPK2 8.56E-04 7.61E-08 -1.53 
chromosome 1 open reading frame 
85  
C1orf85 4.74E-03 9.78E-08 -1.40 
cellular retinoic acid binding protein 
2 
CRABP2 1.04E-04 1.01E-07 -4.04 
tripartite motif-containing 9 TRIM9 8.56E-05 1.14E-07 -1.25 
plexin D1 PLXND1 5.28E-01 1.23E-07 -1.03 
DENN/MADD domain containing 
5B 
DENND5B 3.63E-05 1.26E-07 -1.61 
potassium large conductance 
calcium-activated channel, 
subfamily M, alpha member 1 
KCNMA1 3.08E-04 1.43E-07 1.42 
regulator of G-protein signalling 9  RGS9 1.17E-06 2.35E-07 1.80 
cadherin 2, type 1, N-cadherin 
(neuronal) 
CDH2 4.58E-04 2.66E-07 -1.44 
EPH receptor B2 EPHB2 5.25E-06 2.78E-07 -1.66 
protein kinase C and casein kinase 
substrate in neurons 3 
PACSIN3 6.98E-04 2.89E-07 -1.82 
potassium channel tetramerisation 
domain containing 12  
KCTD12 4.44E-04 3.65E-07 1.74 
DIX domain containing 1 DIXDC1 1.52E-04 3.81E-07 -1.62 
small nuclear RNA activating 
complex, polypeptide 3, 50kDa 
SNAPC3 2.02E-03 3.95E-07 -1.40 
insulin-like growth factor 2 
(somatomedin A) 
IGF2 1.86E-03 5.23E-07 -1.83 
spectrin repeat containing, nuclear 
envelope 1 
SYNE1 7.72E-04 6.20E-07 1.26 
coiled-coil domain containing 50 CCDC50 4.15E-06 6.56E-07 -1.73 
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spondin 1, extracellular matrix 
protein 
SPON1 2.71E-02 7.09E-07 1.30 
WEE1 homolog (S. pombe) WEE1 1.24E-04 7.10E-07 -1.37 
chromosome 9 open reading frame 
86  
C9orf86 1.14E-01 8.32E-07 1.07 
brain-derived neurotrophic factor  BDNF 1.97E-03 8.37E-07 1.37 
chromosome 20 open reading 
frame 117  
C20orf117 3.78E-01 9.51E-07 -1.04 
 
Table 4.5 The genes showing alternative splicing after ZNF804A knockdown  
The .CEL files were imported into the PGS using the core metaprobe set and RMA normalisation. 
The .CEL files were assigned as either siZNF- or siGAP-treatment. To identify alternatively spliced 
transcripts, an alternative splicing one-way ANOVA was performed on the probe set log2 signal 
intensities greater than three. Treatment was chosen as the candidate variable in the ANOVA model. 
The gene list was filtered to exclude genes containing fewer than five markers or a fold change greater 
than five. Alternative splicing ANOVA P values were corrected using the conservative Bonferroni 
method. After Bonferroni correction, an arbitrary cut-off of P < 1 x 10
-6
 was chosen to generate a 
manageable list of statistically significant alternatively spliced genes. Using this threshold, the 
splicing of 116 genes was altered after ZNF804A knockdown. (FC = fold change.) 
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Figure 4.9 Exon 13a of SIPA1L1 was alternatively spliced when ZNF804A was depleted 
SIPA1L1 was identified as alternatively spliced (Bonferroni corrected P = 2.57 x 10
-11
; alternative 
splicing one-way ANOVA). The splicing event was confirmed empirically. (A & B) The geneview of 
SIPA1L1 showed increased exclusion of the known cassette exon 13a when ZNF804A was depleted. 
(C) RT-PCR using primers complementary to the constitutive exons flanking exon 13a. Calmodulin 
(CaM) was used as a loading control. (D) Q-PCR using primers complementary to exon 13a (blue 
arrows) and a ‘control’ pair complementary to another region on the transcript (grey arrows). Please 
note, one biological replicate used in the exon array was analysed using Q-PCR. The expression of 
exon 13a was compared between the conditions using the ∆∆Ct method with the control primer set as 
the endogenous normaliser. The bar graph presented shows the percentage abundance of exon 13a in 
each condition relative to its abundance in the siGAP-treated sample. Q-PCR was performed in 
triplicate (three technical replicates) for each condition. The error bars represent the standard 
deviation of the three raw Ct values. The significance was assessed using one-way ANOVA, Tukey 
post-hoc. ** P < 0.05.  
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that there was increased exclusion of exon 13a of SIPA1L1 in ZNF804A-depleted cells 
(section 2.9.7). RT-PCR showed that there was less of the longer transcript of SIPA1L1 (the 
transcript including exon 13a) in siZNF-treated samples (Figure 4.9C). Q-PCR showed that 
there was statistically significantly less of exon 13a present after ZNF804A knockdown 
(Figure 4.9D). These data were consistent with the exon array analysis. These data suggest 
that knockdown of ZNF804A altered the splicing of exon 13a of SIPA1L1.  
 
Figure 4.10A shows that there was increased exclusion of exon 9a of pyruvate kinase, muscle 
(PKM2) (chr15: 72495363-72495529) after ZNF804A knockdown (Bonferroni corrected P 
=7.76 x 10
-9
; alternative splicing one-way ANOVA). Exon 9a of PKM2 is known to be 
alternatively spliced (Figure 4.10B). RT-PCR analysis showed less of the longer transcript of 
PKM2 was present in the siZNF-treated samples compared to the controls (Figure 4.10C). 
While this result was consistent with the exon array data, subsequent Q-PCR analysis showed 
that there was no significant difference in the abundance of exon 9a between the siZNF-
treated samples and the siGAP-treated sample (Figure 4.10D). Therefore, the alternative 
splicing of exon 9a of PKM2 after ZNF804A knockdown was not validated by the empirical 
analysis. 
 
The third gene containing an alternatively spliced cassette exon was nuclear transcription 
factor Y, alpha (NFYA) (Bonferroni corrected P = 1.5 x 10
-9
; alternative splicing one-way 
ANOVA). The geneview of NFYA showed exon 1a (chr6:41048550-41048636) was excluded 
significantly more after ZNF804A knockdown (Figures 4.11A and B). RT-PCR showed that 
there was a reduced amount of the longer transcript and a reciprocal increase in the amount of 
the shorter transcript following ZNF804A knockdown (Figure 4.11C). This was consistent  
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Figure 4.10 The empirical assessment of alternative splicing of exon 9a in PKM2 
PKM2 was identified as alternatively spliced (Bonferroni corrected P = 7.76 x 10
-9
; alternative 
splicing one-way ANOVA) however; this splicing event was not confirmed empirically. (A & B) The 
PKM2 geneview suggested increased exclusion of a known cassette exon 9a when ZNF804A was 
depleted. (C) RT-PCR using primers complementary to the constitutive exons flanking exon 9a. Beta 
actin (ACTB) was used as a loading control. (D) Q-PCR using primers complementary to exon 9a 
(blue arrows) and a ‘control’ pair complementary to amplify another region on the transcript (grey 
arrows). Please note, one biological replicate used in the exon array was analysed using Q-PCR. The 
expression of exon 9a between the conditions was assessed using the ∆∆Ct method with the control 
primer set as the endogenous normaliser. The bar graph presented shows the percentage abundance of 
exon 9a in each condition relative to its abundance in the siGAP-treated sample. Q-PCR was 
performed in triplicate (three technical replicates) for each condition. The error bars represent the 
standard deviation of the three raw Ct values. 
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Figure 4.11 Validation of splicing of a cassette exon in NFYA 
NFYA was identified as alternatively spliced (Bonferroni corrected P = 1.5 x 10
-9
; alternative splicing 
one-way ANOVA) however; this splicing event was not confirmed empirically. (A & B) In 
ZNF804A-depleted cells, there was increased exclusion of the known cassette exon 1a in NFYA (C) 
RT-PCR using primers complementary to the constitutive exons flanking exon 1a. Calmodulin (CaM) 
was used as a loading control. (D) Q-PCR using primers complementary to exon 1a (blue arrows) and 
a ‘control’ pair complementary to another region on the transcript (grey arrows). Please note, one 
biological replicate used in the exon array was analysed using Q-PCR. The expression of exon 1a was 
compared between the conditions using the control primer set as the endogenous normaliser in the 
∆∆Ct method. The bar graph presented shows the percentage abundance of exon 1a in each condition 
relative to its abundance in the siGAP-treated sample. (E) Q-PCR using the ‘control’ pair of NFYA 
primers. Please note, one biological replicate used in the exon array was analysed using Q-PCR. The 
expression of NFYA was compared between the conditions using the ∆∆Ct method with beta actin 
(ACTB) set as the endogenous normaliser. The bar graph presented shows the percentage abundance 
of NFYA relative in each condition relative to its abundance in the siGAP-treated sample. Q-PCR was 
performed in triplicate (three technical replicates) for each condition. The error bars represent the 
standard deviation of the three raw Ct values.   
Chapter Four: Investigating the effects of depleting ZNF804A on the cellular transcriptome  
 135 
with increased exclusion of exon 1a when ZNF804A was depleted. Q-PCR showed that there 
was less of exon 1a in the siZNFB-treated sample, relative to the siGAP-treated and mock 
samples (Figure 4.11D). However, there was no difference in the amount of exon 1a of NFYA 
in siZNFA-treated sample. Further inspection of the Q-PCR data showed that the expression 
of NFYA transcript was decreased after ZNF804A knockdown relative to the controls (Figure 
4.11E). As the level of exon 1a was normalised to the amount of total NFYA transcript in 
each of the samples, this may explain the discrepancy between the exon array and Q-PCR 
data. In summary, the alternative splicing of exon 1a of NFYA was not confirmed.   
 
The visual inspection of the PGS geneviews revealed very few of the 116 alternative splicing 
events corresponded to known cassette exons in the UCSC genome browser. Consequently, 
the number of events which were selected for empirical validation was restricted. To increase 
the number of putative alternative splicing events evaluated alongside the UCSC genome 
browser, a less stringent significance cut-off of P < 0.05 rather than P < 1 x 10
-6
 was used. 
This gave a list of 448 genes which were putatively alternatively spliced. As previously, the 
geneviews were assessed alongside the UCSC genome browser.  Three genes containing 
cassette exons that were putatively alternatively spliced in ZNF804A-depleted cells were 
selected. These genes, and the corresponding alternatively spliced exons, were: bromodomain 
adjacent to zinc finger domain, 1A (BAZ1A; exon 12a; chr14:35255332-35255427); mitogen-
activated protein kinase kinase 5 (MAP2K5; exon 18; chr15:68040569-68040595); and REST 
corepressor 2 (RCOR2; exon 11; chr11:63679777-63680006). An alternative 5’ prime splice 
site (chr17:75137137-75137189) in SEC14-like 1 (S. cerevisiae) (SEC14L1) was also chosen 
for validation. RT-PCR primers were designed to amplify the transcript variants of each gene 
(primer sequences are given in Appendix 1.7). Data presented in Figure 4.12 show 
knockdown of ZNF804A led to putative increased exclusion of known alternatively spliced  
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Figure 4.12 RT-PCR assessment of alternative splicing events 
BAZ1A, MAP2K5, RCOR2 and SEC14L1 were identified as alternatively spliced after ZNF804A 
knockdown (alternative splicing one-way ANOVA; Bonferroni corrected P < 0.05). Manually 
annotation of the geneviews alongside the UCSC genome browser showed BAZ1A (A), MAP2K5 (D) 
and RCOR2 (G) had increased exclusion of a known cassette exon (B; E; H respectively). The 
SEC14L1 geneview (J) showed alternative 5’ splice site usage (K). RT-PCR primers were designed to 
amplify the constitutive exons flanking the spliced exon. None of the empirical validations was 
conclusive (C; F; I; L). 
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exons in BAZ1A, MAP2K5 and RCOR2. However, RT-PCR showed that there was no 
obvious difference in the transcript variant abundance in the siZNF-treated samples relative 
to siGAP-treated and mock samples for each of these genes (Figure 4.12). The geneview for 
SEC14L1 showed an alternative 5’ splice site was used; however, RT-PCR showed no 
difference in the abundance of the two transcript variants. Therefore, alternative splicing of 
these four transcripts was not validated, however further Q-PCR analysis of exon levels is 
required to conclude confidently that these are not true splicing events.   
 
4.6.2. Analysing alternative splicing after ZNF804A knockdown using the alternative 
splicing one-way ANOVA probe set-level output 
To identify changes in splicing using the log2 signal intensities for each individual probe set, 
the probe set-level list derived from the alternative splicing one-way ANOVA was filtered to 
retain probe sets with differential expression (FDR 0.05) and to remove any probe sets 
present in differentially expressed genes (P > 0.05). The log2 signal intensity of 566 
individual probe sets differed in genes without differential expression after ZNF804A 
knockdown (Table 4.6). The probe sets were ranked according to fold change in log2 signal 
intensity. The top 30 positive and top 30 negative ranked probe sets were manually annotated 
alongside the UCSC genome browser; four alternative splicing events were selected for 
empirical confirmation: enabled homolog (Drosophila) (ENAH), GTPase activating protein 
(SH3 domain) binding protein 2 (G3BP2), ATPase, class VI, type 11C (ATP11C) and 
syntaxin binding protein 1 (STXBP1).  
 
The geneview of ENAH showed that there was increased exclusion of the known alternatively 
spliced exon 11a (chr1:225692693-225692755) after ZNF804A knockdown (P = 8.2 x 10
-4
; 
FC = -2.69; one-way ANOVA), although the ENAH transcript was not differentially  
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Gene name Gene Symbol Probe set ID Probe set Gene 
      P value FC P value FC 
protease, serine, 22 PRSS22 3677272 4.11E-04 1.90 1.27E-01 1.08 
guanylate cyclase activator 1A (retina) GUCA1A 2907084 7.54E-04 1.93 5.72E-02 1.27 
centrosomal protein 41kDa TSGA14 3072581 2.76E-04 1.94 6.25E-01 1.04 
mechanistic target of rapamycin 
(serine/threonine kinase) 
MTOR 2396609 5.16E-05 1.96 1.09E-01 1.22 
DDB1 and CUL4 associated factor 11 DCAF11 3529551 1.08E-03 1.96 1.16E-01 1.08 
kinesin family member 13B KIF13B 3129597 1.46E-04 1.97 4.96E-01 1.04 
prolyl 4-hydroxylase, alpha polypeptide II P4HA2 2875234 1.40E-04 1.98 1.20E-01 1.24 
phosphoserine phosphatise PSPH 3051872 3.07E-05 2.02 3.54E-01 1.09 
TIMP metallopeptidase inhibitor 3 TIMP3 3943508 9.70E-04 2.02 1.05E-01 1.15 
solute carrier family 35, member F3 SLC35F3 2386041 1.10E-04 2.03 1.59E-01 1.13 
mevalonate (diphospho) decarboxylase MVD 3704307 5.14E-04 2.03 4.91E-01 1.05 
leucyl/cystinyl aminopeptidase LNPEP 2821467 1.14E-03 2.17 5.31E-02 1.19 
dual specificity phosphatase 19 DUSP19 2518732 4.72E-04 2.17 5.07E-01 -1.04 
homeodomain interacting protein kinase 3 HIPK3 3325929 4.91E-05 2.28 5.78E-02 1.43 
transmembrane channel-like 4 TMC4 3870551 1.17E-03 2.36 1.02E-01 1.16 
protein tyrosine phosphatase, receptor type, R PTPRR 3461943 4.44E-06 2.37 1.38E-01 -1.17 
Smad nuclear interacting protein 1 SNIP1 2407184 6.12E-04 2.39 1.83E-01 1.10 
active BCR-related ABR 3740042 5.29E-05 2.40 6.56E-02 1.18 
KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum 
protein retention receptor 3 
KDELR3 3945319 5.42E-05 2.54 7.18E-02 1.52 
trinucleotide repeat containing 6B TNRC6B 3946327 2.02E-06 2.56 3.89E-01 1.08 
salt-inducible kinase 1 SIK1 3934129 8.50E-04 2.57 1.07E-01 1.16 
lipocalin 8 LCN8 3230419 3.03E-04 2.60 7.91E-02 1.11 
ankyrin repeat domain 10 ANKRD10 3525703 4.69E-05 2.63 5.44E-02 -1.18 
protein phosphatase 4, regulatory subunit 4 PPP4R4 3549607 1.13E-03 2.78 9.61E-02 1.12 
fucosyltransferase 8 (alpha (1,6) 
fucosyltransferase) 
FUT8 3540553 2.03E-04 2.80 5.53E-01 1.04 
sialic acid binding Ig-like lectin 1, sialoadhesin SIGLEC1 3895653 6.48E-07 3.01 5.85E-02 1.13 
ataxin 3 ATXN3 3576899 2.25E-04 3.57 7.90E-02 1.29 
G protein-coupled receptor 162 GPR162 3402829 6.60E-07 3.77 1.00E+00 -1.00 
ATP-binding cassette, sub-family C 
(CFTR/MRP), member 5 
ABCC5 2708339 4.59E-05 4.51 5.57E-01 -1.06 
complement factor H CFH 2373397 9.77E-04 5.63 9.62E-02 1.18 
A 
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Table 4.6 Probe sets with changes in log2 signal intensity after ZNF804A knockdown  
To identify changes in splicing, the probe set-level list derived from the alternative splicing one-way 
ANOVA was filtered to retain probe sets with altered log2 signal intensity (FDR 0.05) and to remove 
any probe sets present in differentially expressed genes (P > 0.05). The top 30 (A) positive and (B) 
negative fold changes in probe set log2 signal intensity are shown.  
Gene name Gene Symbol Probe set ID Probe set Gene 
      P value FC P value FC 
mitochondrial calcium uptake 2 EFHA1 3504794 1.08E-03 -3.80 8.68E-02 -1.64 
mastermind-like domain containing 1 MAMLD1 3994752 1.72E-04 -2.97 4.12E-01 -1.07 
tetratricopeptide repeat domain 39B TTC39B 3199695 2.29E-04 -2.76 1.72E-01 -1.10 
WNK lysine deficient protein kinase 1 WNK1 3400127 1.06E-05 -2.74 1.15E-01 -1.45 
enabled homolog (Drosophila) ENAH 2458376 8.23E-04 -2.69 5.48E-02 -1.35 
coiled-coil-helix-coiled-coil-helix domain 
containing 5 
CHCHD5 2500878 4.82E-05 -2.68 9.34E-02 -1.18 
ATPase, class VI, type 11C ATP11C 4024164 6.83E-04 -2.67 1.78E-01 -1.16 
glutamate decarboxylase 1 (brain, 
67kDa) 
GAD1 2515021 1.83E-04 -2.66 2.50E-01 -1.07 
coiled-coil domain containing 68 CCDC68 3808749 2.06E-04 -2.58 4.73E-01 -1.05 
reticulon 4 RTN4 2553630 9.09E-04 -2.46 9.15E-01 1.01 
GTPase activating protein (SH3 domain) 
binding protein 2 
G3BP2 2773765 7.34E-04 -2.43 1.64E-01 -1.26 
F-box protein 36 FBXO36 2531135 5.61E-04 -2.36 8.13E-02 -1.20 
CKLF-like MARVEL transmembrane 
domain containing 4 
CMTM4 3695161 4.83E-04 -2.28 2.83E-01 -1.15 
frizzled family receptor 4 FZD4 3385518 6.05E-04 -2.26 3.12E-01 -1.08 
plexin D1 PLXND1 2694864 6.57E-04 -2.23 5.35E-01 -1.03 
Kv channel interacting protein 2 KCNIP2 3304096 7.82E-04 -2.21 9.47E-01 -1.00 
collagen, type XXVII, alpha 1 COL27A1 3185987 7.89E-06 -2.21 4.27E-01 1.06 
 semaphorin 6B SEMA6B 3846887 2.81E-06 -2.18 6.43E-01 1.03 
LUC7-like (S. cerevisiae) LUC7L 3674992 6.69E-04 -2.15 6.96E-02 -1.25 
leucine rich repeat (in FLII) interacting 
protein 1 
LRRFIP1 2534476 9.97E-04 -2.14 5.76E-01 1.07 
kinesin family member 24 KIF24 3203937 5.26E-04 -2.08 2.97E-01 -1.05 
gamma-aminobutyric acid (GABA) B 
receptor, 1 
GABBR1 2947928 5.22E-04 -2.07 1.55E-01 -1.11 
microtubule-associated protein 2 MAP2 2525534 2.44E-04 -2.06 3.57E-01 -1.07 
caspase 8 associated protein 2 CASP8AP2 2916983 5.90E-04 -2.03 5.15E-02 -1.24 
galactose mutarotase (aldose 1-
epimerase) 
GALM 2477959 5.87E-04 -2.02 9.04E-02 -1.30 
latent transforming growth factor beta 
binding protein 3 
LTBP3 3335309 6.89E-04 -2.01 2.10E-01 1.10 
collagen, type XVI, alpha 1 COL16A1 2404672 5.61E-07 -1.99 7.47E-01 1.02 
autism susceptibility candidate 2 AUTS2 3006703 5.69E-04 -1.97 1.38E-01 -1.23 
syntaxin binding protein 1 STXBP1 3189965 9.70E-04 -1.96 9.09E-02 -1.06 
supervillin SVIL 3283067 8.38E-04 -1.92 9.81E-01 1.00 
B 
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expressed (P = 0.055; one-way ANOVA) (Figures 4.13A and B). Consistent with this result, 
RT-PCR showed that there was less of the longer transcript of ENAH in siZNF-treated 
samples (Figure 4.13C). Q-PCR confirmed that there was less of the spliced exon present in 
ZNF804A-depleted cells relative to both of the siGAP-treatment and mock samples (one-way 
ANOVA and Tukey post-hoc P < 0.01; Figure 4.13D). Therefore, the empirical results for 
ENAH were consistent with the exon array analysis. These data suggest that ZNF804A may 
have a role in regulating the inclusion of exon 11a of ENAH.   
 
The geneview of G3BP2 showed that there was alternative splicing of the known cassette 
exon 7a (chr4:76579167-76579265) when ZNF804A was depleted (P = 7.3 x 10
-4
; FC = -
2.43; one-way ANOVA), although the G3BP2 transcript was not differentially expressed (P = 
0.164; one-way ANOVA) (Figures 4.14A and B). RT-PCR and Q-PCR suggested that there 
was less of the longer transcript in the siZNFB-treated sample, but there was no change in the 
abundance of the longer transcript in the siZNFA-treated sample (Figures 4.14C and D). 
These data were inconsistent with the exon array results and therefore, the alternative splicing 
of exon 7a of G3BP2 was not validated. 
 
Confirming the two remaining selected alternative splicing events proved problematic. 
Firstly, the gene ATP11C showed increased exon exclusion of a known alternatively spliced 
exon, exon 29a (chrX: 138813810-138813914), when ZNF804A was depleted (P = 6.8 x 10
-4
; 
FC = -2.67; one-way ANOVA) (Figure 4.15A). RT-PCR showed the abundance of the longer 
transcript of ATP11C decreased and that there was a reciprocal increase in the abundance of 
the shorter transcript in siZNF-treated samples (Figure 4.15B). This was consistent with the 
hypothesis that there was increased exclusion of exon 29a after ZNF804A knockdown. 
However, it proved impossible to design Q-PCR primers for exon 29a that satisfied the  
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Figure 4.13 Exon 11a of ENAH was alternatively spliced when ZNF804A was depleted  
Analysis of the probe set-level list generated from the alternative splicing ANOVA identified a probe 
set in ENAH as differentially expressed (P = 8.2 x 10
-4
; FC = -2.69; one-way ANOVA) although the 
ENAH transcript was not differentially expressed (P = 0.055; one-way ANOVA). This splicing event 
was confirmed empirically. (A & B) The geneview for ENAH showed that after ZNF804A knockdown 
there was increased exclusion of the known cassette exon 11a. (C) RT-PCR using primers 
complementary to the constitutive exons flanking exon 11a. Beta actin (ACTB) was used as a loading 
control. (D) Q-PCR using primers complementary to exon 11a (blue arrows) and a ‘control’ pair 
complementary to another region on the transcript (grey arrows). Please note, one biological replicate 
used in the exon array was analysed using Q-PCR. The expression of exon 11a was compared 
between the conditions using the ∆∆Ct method with the control primer set as the endogenous 
normaliser. The bar graph presented shows the percentage abundance of exon 11a in each condition 
relative to the siGAP-treated sample. Q-PCR was performed in triplicate (three technical replicates) 
for each condition. The error bars represent the standard deviation of the three raw Ct values. The 
significance was assessed using a one-way ANOVA and Tukey post-hoc. ** P < 0.05.  
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Figure 4.14 The assessment of alternative splicing of exon 7a in G3BP2 
Analysis of the probe set-level list generated from the alternative splicing ANOVA identified a probe 
set in G3BP2 as differentially expressed (P = 7.3 x 10
-4
; FC = -2.43; one-way ANOVA) although the 
G3BP2 transcript was not differentially expressed (P = 0.164). This alternative splicing event was not 
validated using empirical methods. (A & B) The PGS geneview showed this corresponded to 
increased exclusion of the known cassette exon 7a when ZNF804A was depleted. (C) RT-PCR using 
primers complementary to the constitutive exons flanking exon 7a. (D) Q-PCR using primers 
complementary to exon 7a (blue arrows) and a ‘control’ pair complementary to another region on the 
transcript (grey arrows). Please note, one biological replicate used in the exon array was analysed 
using Q-PCR. The expression of exon 7a was compared between the conditions using the ∆∆Ct 
method with the control primer set as the endogenous normaliser. The bar graph presented shows the 
percentage abundance of exon 7a in each condition relative to the siGAP-treated sample. Q-PCR was 
performed in triplicate (three technical replicates) for each condition. The error bars represent the 
standard deviation of the three raw Ct values.  
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desired amplification efficiencies required to use the comparative ΔΔCt method. Therefore, 
the splicing of exon 29a was not examined by Q-PCR. However, the RT-PCR showed 
convincing evidence that ZNF804A knockdown altered the inclusion of exon 29a of ATP11C. 
Therefore, it is likely that ZNF804A has a role in regulating the splicing of this exon. 
 
The second gene containing a splicing event which was problematic to confirm was STXBP1. 
The geneview analysis of STXBP1 showed that there was alternative inclusion of exon 18a 
when ZNF804A was depleted (P = 9.7 x 10
-4
; FC = -1.96; one-way ANOVA), although the 
STXBP1 transcript was not differentially expressed (P = 0.178; one-way ANOVA) (Figure 
4.15C). RT-PCR demonstrated that the amount of the longer transcript was markedly reduced 
in the siZNF-treated samples (Figure 4.15D). However, RT-PCR amplified three bands, 
rather than the predicted two bands. This suggests that these RT-PCR primers may amplify a 
novel splice variant of STXBP1. The splicing of exon 18a of STXBP1 was not validated by Q-
PCR as the Q-PCR primers also amplified more than one product. However, as the RT-PCR 
showed convincing evidence of alternative splicing in STXBP1, it is highly likely that the 
splicing of exon 18a of STXBP1 was altered in ZNF804A-depleted cells.  
 
In summary, knockdown of ZNF804A led to numerous statistically significant changes in 
splicing. Of the 11 splicing events selected for validation, two were unequivocally validated 
(SIPA1L1 and ENAH), two were validated by RT-PCR only (ATP11C and STXBP1), three 
events were not validated (PKM2, NFYA, G3BP2) and four were inconclusive (BAZ1A, 
MAP2K5, RCOR2 and SEC14L1). 
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Figure 4.15 Validation of alternative splicing in ATP11C and STXBP1 
Analysis of the probe set-level list generated from the alternative splicing ANOVA identified a probe 
set in ATP11C as differentially expressed (P = 6.8 x 10
-4
; FC = -2.67; one-way ANOVA) although the 
ATP11C transcript was not differentially expressed (P = 0.178; one-way ANOVA). (A) The ATP11C 
PGS geneview showed increased exclusion of a known cassette exon 29a (B) when ZNF804A was 
depleted. (C) RT-PCR using primers complementary to the constitutive exons flanking exon 29a 
confirmed the alternative splicing event. Analysis of the probe set-level list generated from the 
alternative splicing ANOVA identified a probe set in STXBP1 as differentially expressed (P = 9.7  10
-
4
; FC = -1.96; one-way ANOVA) although the STXBP1 transcript was not differentially expressed (P 
= 0.099; one-way ANOVA). (D) The STXBP1 PGS geneview showed increased exclusion of known 
cassette exon 18a (E) when ZNF804A was depleted. (D) RT-PCR using primers complementary to the 
constitutive exons confirmed alternative splicing of exon 18a.   
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4.6.3. Investigating a change in transcription start site usage   
In addition to changes in cassette exon splicing, the alternative splicing one-way ANOVA 
identified changes in transcript variant use after ZNF804A knockdown. Many of these events 
involved multiple transcript variants and were too complex to confirm empirically. However, 
the geneview of PTPRR demonstrated that there was a simple switch in transcript variant 
usage when ZNF804A was depleted (Figure 4.16A). This switch in transcript variant usage 
was confirmed using Q-PCR (Figure 4.16B). The isoforms of PTPRR arise from the 
differential use of distinct transcription start sites and promoters (Chirivi et al., 2004). 
Therefore, this result suggests ZNF804A may also have a role in determining transcription 
start site or promoter site choice.  
 
4.6.4. Enrichment analysis of genes showing alternative splicing after ZNF804A 
knockdown  
To identify particular biological processes which were enriched for ZNF804A-related 
alternative splicing events, enrichment analysis was performed using GeneGo MetaCore™ 
software. To ensure that only genes which could be detected as alternatively spliced in the 
exon array were included in the enrichment analysis, the background comparison was set as 
the Affymetrix GeneChip human exon array 1.0 ST-v2. Enrichment by GeneGo pathway map 
showed genes belonging to the term ‘cell adhesion_extracellular matrix (ECM) remodelling’ 
(4/52 P = 2.93 x 10
-4
) were significantly enriched among the 116 putatively alternatively 
spliced genes (section 4.6.1). This was the only pathway map enrichment which survived 5% 
FDR correction for multiple testing. The four genes belonging to this pathway map were 
insulin-like growth factor 2 (somatomedin A) (IGF2); CD44 molecule (Indian blood group) 
(CD44), matrix metallopeptidase 15 (membrane-inserted) (MMP15) and collagen, type IV, 
alpha 1 (COL4A1). Consistent with these data, enrichment by GeneGo process network 
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Figure 4.16 Empirical validation of alternative transcript usage in PTPRR after ZNF804A 
knockdown PTPRR was identified as alternatively spliced by alternative splicing one-way ANOVA 
(P = 3.32 x 10
-19
). (A) The PTPRR geneview showed a potential switch in transcript variant use in 
ZNF804A-depleted cells. (B) PTPRR has five RefSeq transcript variants. (C) Q-PCR using primers 
complementary to NM_130846.2 and NM_002849 (illustrated by arrows on the geneview). Please 
note, one biological replicate used in the exon array was analysed using Q-PCR. The expression of 
each PTPRR transcript was compared between the conditions using the ∆∆Ct method with beta actin 
(ACTB) as the endogenous normaliser. The bar graph presented shows the percentage abundance of 
each PTPRR transcript in each condition relative to the abundance of NM_130846.2 in the siGAP-
treated sample. Q-PCR was performed in triplicate (three technical replicates) for each condition. The 
error bars represent the standard deviation of the three raw Ct values. The significance was assessed 
between the ZNF804A-depleted samples and both of the control samples using a one-way ANOVA 
and Tukey post-hoc test on ∆Ct ; ** = P < 0.001; * = P < 0.05.   
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identified ‘cell adhesion_cell-matrix interactions’ (13/211 P = 7.95 x 10-5) as significantly 
enriched (Figure 4.17A). Genes belonging to the GeneGo process network term 
‘development_neurogenesis_axonal guidance’ (12/230 P = 1.19 x 10-5) were also enriched 
among the 116 putatively alternatively spliced genes. The 10 active genes annotated to this 
term were reticulon 4 (RTN4); plexin D1 (PLXND1); EPH receptor B2 (EPHB2); reelin 
(RELN); brain-derived neurotrophic factor (BDNF); sema domain, immunoglobulin domain 
(Ig), short basic domain, secreted, (semaphorin) 3F (SEMA3F); slit homolog 3 (Drosophila) 
(SLIT3); slit homolog 1 (Drosophila) (SLIT1); cadherin 2, type 1, N-cadherin (neuronal) 
(CDH2) and ryanodine receptor 1 (skeletal) (RYR1). EPHB2 was assigned to more than one 
node in the network. Enrichment by GO process showed the most significantly enriched 
terms related to neurodevelopment (Figure 4.17B). For example, ‘neurogenesis’ (52/1649 P = 
9.03 x 10
-24) and ‘nervous system development’ (59/2400 P 8.36 x 10-22).  
 
The biological processes enriched among the alternatively spliced genes are consistent with 
those enriched among the differentially expressed genes (section 4.5.1). For instance, genes 
belonging to the GO process term ‘nervous system development’ and the GeneGo process 
network ‘development_neurogenesis_axonal guidance’ were significantly enriched among 
both datasets. It was hypothesised that genes which were alternatively spliced but were not 
differentially expressed may belong to different biological processes from those which were 
both alternatively spliced and differentially expressed. To test this hypothesis, the list of 116 
alternatively spliced genes was filtered to exclude the 59 genes showing differential 
expression (FDR 0.01; corresponding to uncorrected P > 0.00026). Enrichment analysis 
identified genes belonging to GO process terms ‘neurogenesis’ (20/1649 P = 4.97 x 10-9), 
‘nervous system development’ (23/2400 P = 2.13 x 10-8) and the GeneGo process network 
‘development_neurogenesis_axonal guidance’ (6/230 P = 7.72 x 10-4) as the top biological  
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Figure 4.17  Biological processes significantly enriched for genes showing alternative splicing in 
ZNF804A-depleted cells 
(A) The top statistically significant GeneGo process networks and (B) GO processes among the 116 
alternatively spliced genes (section 4.6.1). (C) The top statistically significant GO processes among 
the 566 non-differentially expressed genes containing a differentially expressed probe set (section 
4.6.2). Enrichment analysis was performed using GeneGo MetaCore™ with Affymetrix GeneChip 
human exon array 1.0 ST v-2 as the background list. These enrichments survived multiple test 
correction, as determined at a 5% FDR by GeneGo MetaCore™.  
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processes significantly enriched among the 57 alternatively spliced genes with no differential 
expression (data not shown). These enrichments survived 5% correction for multiple testing. 
These data imply that ZNF804A may influence both the expression and splicing of genes 
implicated in processes underlying nervous system development. Consistent with this 
interpretation, enrichment by GO process of the 566 non-differentially expressed genes 
containing a differentially expressed probe set (section 4.6.2) showed genes belonging to the 
term ‘neuron projection development’ (57/813 P = 5.76 x 10-10) were significantly over-
represented among these genes (Figure 4.17C). 
 
4.6.5. Comparing the relative number of alternative splicing events after ZNF804A or 
GAPDH knockdown  
It was difficult to predict the number of alternative splicing events which would be expected 
following ZNF804A knockdown, if it was a true regulator of pre-mRNA processing. 
Therefore, to provide a benchmark with which to compare the effects of knocking down 
ZNF804A on splicing, the number of alternatively spliced genes after ZNF804A or GAPDH 
knockdown relative to the mock samples was determined using the same parameters as 
above. The splicing of 177 genes was altered after ZNF804A knockdown relative to the mock 
samples (in the interest of brevity, these data are not shown). The splicing of 13 genes was 
altered after GAPDH knockdown relative to the mock samples (presented as supplementary 
data in Appendix 5.4). This result suggests that knockdown of ZNF804A led to many more 
changes in splicing than would be expected if ZNF804A had no role in pre-mRNA 
processing. 
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4.7. Discussion 
Data presented in Chapter Three implicate a role for ZNF804A in the regulation of 
transcription and pre-mRNA splicing. The aim of the experiments described in this Chapter 
was to investigate the role of ZNF804A in the regulation of transcription and pre-mRNA 
processing using a combination of siRNA, exon array technologies and pathway analysis. 
The hypothesis was that knockdown of endogenous ZNF804A would lead to changes in the 
expression and pre-mRNA splicing of transcripts regulated, directly or indirectly, by 
ZNF804A. The findings presented in this Chapter provide convincing evidence to support 
this hypothesis.  
 
The knockdown of ZNF804A resulted in numerous statistically significant changes in gene 
expression. A selection of these gene expression changes were empirically validated using Q-
PCR. Among the most differentially expressed genes were genes which have been implicated 
in schizophrenia pathology, including RELN, NPY and NLGN2 (Table 4.3). Whilst it was 
tempting to place emphasis on these gene expression changes, based on a priori knowledge 
of schizophrenia genetics, it was more informative to use enrichment analysis to determine 
biological processes enriched for ZNF804A-related target genes. Enrichment analysis 
indicated that genes belonging to GO process ‘nervous system development’ and the GeneGo 
network process ‘cell adhesion_synaptic contact’ were significantly over-represented in the 
genes with altered expression in ZNF804A-depleted cells. These biological processes have 
been implicated in the neurobiology of schizophrenia (Bourgeron, 2009; Melom and 
Littleton, 2011; Zoghbi, 2003). Further, recent genetic data suggests risk genes for 
schizophrenia converge at the synapse (see section 1.6.3.4) (O’Dushlaine et al., 2011; Kirov 
et al., 2012; Glessner et al., 2010). Therefore, these data may reflect candidate mechanisms 
for ZNF804A’s function in disease. Consistent with the notion that the genes with altered 
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expression after ZNF804A knockdown represent the causal effects of ZNF804A’s 
contribution to disease, the differentially expressed genes were moderately enriched for genes 
with genetic association with schizophrenia and bipolar disorder (section 4.5.2).   
 
The knockdown of endogenous ZNF804A led to a number of statistically significant changes 
in pre-mRNA processing. Importantly, the knockdown of endogenous ZNF804A resulted in 
remarkably more statistically significant alternative splicing events than the knockdown of 
endogenous GAPDH (section 4.6.5). These data are consistent with a potential role for 
ZNF804A in pre-mRNA processing. The empirical confirmation of the exon array data was 
successful for five of the eleven events selected for validation. Although this number seems 
small, it is comparable with data obtained by previous groups when evaluating the targets of 
known pre-mRNA splicing factors using exon arrays. For example, knockdown of 
heterogeneous nuclear ribonucleoprotein L (hnRNP L), which encodes an abundant nuclear 
protein that is a known global regulator of alternative splicing, gave only 11 validated 
alternative splicing events across the genome (Hung et al., 2008).  
 
Interestingly, knockdown of ZNF804A altered the splicing of exon 11a of ENAH, a known 
target of the putative ZNF804A-interactor, RBFOX2 (Chapter Three) (Yeo et al., 2009). It is 
tempting to speculate that ZNF804A and RBFOX2 may interact to co-regulate splicing of 
exon 11a of ENAH (Figure 4.18). ENAH is a member of the enabled (Ena)/vasodilator-
stimulated phosphoprotein (VASP) family of proteins which are involved in a range of 
processes dependent on cytoskeleton remodelling and cell polarity, such as axon guidance 
and growth cone dynamics in migrating cells (Lebrand et al., 2004). Studies suggest that the 
two transcript variants, including and excluding exon 11a of ENAH, have different functional 
roles in the cell, possibly arising from additional serine and tyrosine phosphorylation sites  
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Figure 4.18 Models of ZNF804A/RBFOX2 mediated splicing of exon 11a of ENAH  
(A) RBFOX2 and ZNF804A may interact with one another and both bind directly to RNA upstream 
of exon 11a of ENAH to promote its inclusion. (B) Alternatively, interaction between RBFOX2 and 
ZNF804A may be necessary for binding of RBFOX2 to RNA upstream of exon 11a to promote its 
inclusion. In each of these models, knockdown of either RBFOX2 or ZNF804A would result in 
exclusion of exon 11a of ENAH.  
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within the alternatively spliced exon (Barzik et al., 2005; Di Modugno et al., 2007). 
Therefore, aberrant splicing of exon 11a of ENAH may have downstream consequences on 
axonal guidance and nervous system development which may increase risk for 
neuropsychiatric disease. Support for this hypothesis comes from recent post-mortem  
transcriptome analyses of brain tissue which showed a statistically significant increase in the 
exclusion of exon 11a of ENAH in the Brodmann Area 10 and caudate of schizophrenia 
patients compared to controls (Cohen, 2012). Furthermore, this hypothesis is consistent with 
the data presented by Kahler and colleagues that showed that haplotypes of ENAH were 
associated with increased risk for schizophrenia (Kahler et al., 2008).  
 
In addition to ENAH, splicing of exon 18a of STXBP1 was altered in ZNF804A-depleted 
cells. STXBP1 (also known as MUNC18-1) is a member of the Sec1/munc18-like protein 
family. These proteins are highly conserved between species and are essential components of 
synaptic vesicle fusion protein complexes. There are two known isoforms of STXBP1 of 
which only the longer isoform is expressed in neural tissues, suggesting it has a role specific 
for synaptic transmission (Swanson et al., 1998; Tellam et al., 1995). The results presented 
here show that when ZNF804A was depleted, there was reduced expression of the neural-
specific transcript variant. Interestingly, the splicing of a different family member, STXBP2, 
has been shown to be regulated by NOVA2 (Ule et al., 2005), a putative ZNF804A-interactor 
(Chapter Three). It is tempting to speculate that NOVA2 may also mediate splicing of 
STXBP1, potentially through interactions with ZNF804A. Aberrant splicing of STXBP1 may 
contribute to susceptibility for schizophrenia via changes to neurotransmitter release and 
vesicle trafficking.  
 
Chapter Four: Investigating the effects of depleting ZNF804A on the cellular transcriptome  
 157 
There is little functional information regarding the genes SIPA1L1 and ATP11C and as such, 
it is not possible to infer the consequences of alternative splicing of these transcripts on the 
protein’s function. However, deep sequencing of SIPA1L1 in 138 schizophrenia patients and 
285 controls identified a nonsense mutation in SIPA1L1 in a schizophrenia case (Myers et al., 
2011). Therefore, it is conceivable that alternative splicing in SIPA1L1 may contribute to 
increased risk for schizophrenia.    
 
The alternative splicing analysis identified a switch in transcript variant usage in PTPRR 
which was empirically confirmed. The isoforms of PTPRR arise from the differential use of 
distinct transcription start sites and promoters (Chirivi et al., 2004). PTPRR is an enzyme 
expressed predominantly in the brain (Augustine et al., 2000a). There are four known human 
protein isoforms of PTPRR (Augustine et al., 2000b), of which the mRNAs coding for 
PTPPBSα and PTPPBSγ were identified as differentially expressed in this Chapter. Studies in 
mice show PTPPBSα is a receptor-type protein tyrosine phosphatase (PTP) whereas 
PTPPBSγ is a cytosolic type PTP (van den Maagdenberg 1999). Each of these isoforms 
exhibits a different expression pattern in specific neural cell subtypes during development, 
suggesting that they have diverse roles in neurodevelopment (van den Maagdenberg 1999). 
Further, the predicted ligands of PTPPBSα suggest that this receptor is involved in neuronal 
development and synaptic plasticity (Chesini et al., 2011). This suggests that aberrant 
transcript variant usage of PTPRR may contribute to disease susceptibility via functional 
consequences on nervous system development. The alternative transcript usage of PTPRR 
after ZNF804A knockdown may suggest that ZNF804A has roles in the regulation of 
transcription start site and promoter site choice.  
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For PKM2, NFYA and G3BP2, the exon array data were not validated. It is important to 
consider the reasons behind this and what this infers about the methods used. Firstly, these 
three events may represent false-positive alternative splicing calls in the exon array analysis. 
For instance, the assessment of NFYA suggests that rather than alternative splicing of exon 
1a, there was a change in transcript expression of the whole gene (Figure 4.12E). This may 
suggest that the alternative splicing ANOVA might not be sensitive enough to correct for 
small changes in transcript expression. Secondly, some or all of these three events may 
represent false-negative findings of the empirical analyses. The primary caveat of the 
empirical analyses is that only one of the independent biological replicates used in the exon 
array was evaluated by Q-PCR. It is possible that if all four of the biological replicates were 
evaluated by Q-PCR the increase in statistical power may support replication of the exon 
array data. Further Q-PCR experiments are required to investigate this possibility. In 
addition, there may be unknown transcript variants of these three genes which may impact 
the empirical assessment of the exon usage using RT-PCR and Q-PCR. Future experiments 
using northern blotting or RNA sequencing analysis may provide a more comprehensive 
assessment of the possible nature of alternative splicing of these genes after ZNF804A 
knockdown. Interestingly, both the RT-PCR and Q-PCR data appeared to suggest that the 
siRNA duplexes used to deplete ZNF804A may have had different effects on the splicing of 
exon 9a of PKM2 (Figure 4.10) and exon 7a of G3BP2 (Figure 4.14). However further 
inspection of the geneviews on the exon array showed that both siRNA duplexes influenced 
the splicing of the exons to the same extent (data not shown). Therefore, it is unlikely that the 
siRNA duplexes had different effects on splicing. It is important to note that the empirical 
analysis focused on known alternative splicing events because previous investigations 
showed that this filter reduces the number of false positives (Whistler, 2010). The bias to 
known pre-mRNA splicing events precludes the discovery of novel pre-mRNA splicing 
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events and as such, the estimates of empirically validated alternative splicing are very 
conservative.  
 
The enrichment analysis indicated the alternatively spliced genes were enriched for genes 
involved in biological processes implicated in schizophrenia, such as nervous system 
development and axonal guidance (Amann-Zalcenstein et al., 2006; Ingason et al., 2007). 
These data may indicate alternative splicing of ZNF804A-related target genes could increase 
risk for disease. These data are consistent with enrichment by biological process of the genes 
differentially expressed after ZNF804A knockdown. Importantly, these data suggest 
ZNF804A may influence both the expression and splicing of genes implicated in processes 
underlying nervous system development. 
 
Recent studies have reported knockdown of wildtype ZNF804A in human neural progenitor 
cells led to nominally significant differential expression of 151 genes; these genes were 
enriched for genes belonging to the GO term ‘cell adhesion’ (Hill et al., 2012a). Data 
presented in this Chapter also indicate a significant effect of ZNF804A knockdown on genes 
involved in cell adhesion, particularly synaptic contact. Only 20 genes were identified as 
differentially expressed in both studies (supplementary data presented in Appendix 5.5). The 
relatively small overlap between the datasets, and the finding that more genes showed altered 
expression in our study, may be explained by the difference in the level of knockdown 
achieved using the siRNA duplexes. Specifically, Hill and colleagues (2012) chose to 
knockdown wildtype ZNF804A to 60% to emulate unpublished observations of the cis-
regulatory effects of the disease-associated SNP in ZNF804A, while siZNFA or siZNFB 
mediated knockdown of ZNF804A to an average of 18.7% (sd = 8.4) and 23.1% (sd = 8.8) of 
endogenous levels respectively.  
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In summary, the results presented in this Chapter are consistent with the hypothesis that 
ZNF804A plays a role in the regulation of gene expression and pre-mRNA processing 
(Chapter Three). Notably, ZNF804A-related targets were enriched for biological processes 
implicated in neuropsychiatric diseases and genes which are genetically associated with 
schizophrenia and bipolar disorder. The alternative splicing analysis showed knockdown of 
ZNF804A altered the splicing of exon 11a of ENAH which is regulated by RBFOX2 (Yeo et 
al., 2009), a putative interactor of ZNF804A (Chapter Three). This is consistent with the 
hypothesis that ZNF804A may interact with RNA-binding proteins to mediate splicing 
(Chapter Three). Further investigation is required to define the mechanisms of ZNF804A-
related gene expression and pre-mRNA splicing and to develop an appreciation of how the 
disease-associated SNP in ZNF804A impacts on its function and increases risk for 
schizophrenia.  
Chapter Five: Investigating the effects of over-expressing myc-ZNF804A on the cellular transcriptome  
 161 
Chapter 5: Investigating the effects of over-expressing myc-ZNF804A on 
the cellular transcriptome  
 
5.1. Introduction 
The findings presented in Chapter Three suggest a role for ZNF804A in the regulation of 
transcription and pre-mRNA processing. Consistent with these findings, data presented in 
Chapter Four show that ZNF804A-depleted cells displayed numerous changes in gene 
expression and pre-mRNA splicing. Often, to complement knockdown experiments, over-
expression experiments are used to study gene function in heterologous cells. For example, 
fibroblasts can be converted to induced pluripotent stem (iPS) cells through reprogramming 
by heterologous expression of four transcription factors (Oct4, Sox2, c-Myc and Klf4) 
(Takahashi and Yamanaka, 2006; Wernig et al., 2007). In addition, a recent paper by Wilbert 
and colleagues elucidated the role of LIN28 in mRNA regulation using splicing arrays in 
cells stably over-expressing LIN28 and in LIN28-depleted cells (Wilbert et al., 2012). 
Therefore, the aim of this Chapter was to over-express myc-ZNF804A in mammalian cells 
and profile the ensuing genome-wide changes in gene expression and pre-mRNA splicing 
using Affymetrix GeneChip human exon 1.0 ST arrays (Figure 5.1). The hypothesis was that 
over-expression of myc-ZNF804A would lead to changes in the expression and pre-mRNA 
splicing of transcripts regulated, directly or indirectly, by ZNF804A.  
 
5.2. Characterisation of the myc-ZNF804A Flp In-TREx cell line 
At the outset of this project, our data suggested that transient transfection of ZNF804A-
expression vectors into mammalian cells did not produce detectable levels of exogenous 
ZNF804A (C.L. Tinsley, personal communication, the vectors and cell lines used are 
summarised in Appendix 2). Data presented in Chapter Three support these findings and 
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Figure 5.1 A flowchart illustrating the experimental design  
The Flp-In TREx expression system was used to generate a stable, inducible cell line expressing myc-
ZNF804A. Cultured myc-ZNF804A Flp-In TREx cells were induced to over-express myc-ZNF804A 
and RNA was prepared. Exon arrays were performed by Central Biotechnology Services (CBS), 
Cardiff University using Affymetrix GeneChip human exon array 1.0 ST. The raw .CEL files which 
contained the signal intensity information were imported into Partek Genomics Suite (PGS) using the 
core metaprobe set annotation file. The robust multiarray averaging (RMA) algorithm was used to 
summarise the probe-level data to a single value for each probe set. Two parallel analyses were 
performed to identify changes in either gene expression or pre-mRNA splicing. Differentially 
expressed gene lists were generated using a cut-off P value only or P value and fold change. A list of 
alternatively spliced genes was generated using a cut-off P value. Enrichment analysis was performed 
to identify biological processes enriched for ZNF804A-associated target genes. A selection of changes 
was empirically confirmed.  
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show that transiently expressed myc-ZNF804A was only reliably detected after proteasome 
inhibition (section 3.5.2). Prior to this discovery, it was hypothesised that the inability to 
detect exogenous ZNF804A may indicate that over-expression of ZNF804A was cytotoxic or 
that ZNF804A may be produced at extremely low levels. An alternative hypothesis is that the 
cDNA was only taken-up by a few cells. Previous studies have used tetracycline-inducible 
stable cell lines to successfully overcome such difficulties (Reeves et al., 2002). Therefore to 
express ZNF804A in a regulatable manner, a tetracycline-inducible, stable cell line 
expressing myc-ZNF804A was generated (section 2.8.2). Myc-ZNF804A was cloned into the 
pcDNA5/FRT/TO expression vector, co-transfected into Flp-In TREx -293 cells with the 
pOG44 vector and four successful transformants were selected. In control experiments, I also 
generated an inducible cell line expressing GFP-TCF4. TCF4 can be transiently expressed in 
mammalian cells and its cognate protein can be readily detected by western blotting and 
immunocytochemistry (Forrest et al., 2012).  
 
RT-PCR analysis confirmed that the tetracycline-induced myc-ZNF804A and GFP-TCF4 
Flp-In TREx cell lines expressed myc-ZNF804A or GFP-TCF4 respectively (Figure 5.2A) 
(section 2.3.1). However, Figure 5.2A also shows that myc-ZNF804A and GFP-TCF4 mRNA 
was detected in the uninduced sample. Q-PCR analysis showed the expression of ZNF804A 
was significantly increased in tetracycline-induced samples relative to the uninduced samples 
(Figure 5.2B) (section 2.3.6). Endogenous ZNF804A was not detected in wildtype HEK293T 
cells by Q-PCR (data not shown). Therefore, the ZNF804A detected in the uninduced samples 
was likely to be myc-ZNF804A. These data indicate that there was some myc-ZNF804A 
expression from the pCMV/TetO2 promoter in the absence of tetracycline. This may occur 
through leaky repression or if there was small amounts of tetracycline present in the cell 
culture media, for example in the foetal calf serum used to supplement the media.  
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Figure 5.2 PCR analysis of myc-ZNF804A and GFP-TCF4 expression  
Cultured myc-ZNF804A or GFP-TCF4 Flp-In TREx cells were either treated with 1 µg/ml 
tetracycline to induce expression of the gene of interest (induced) or left untreated (uninduced). RNA 
was prepared at 8h intervals (0h uninduced; 8h post-induction; 16h post-induction and 24h post-
induction). Reverse transcription (RT) reactions were performed to generate cDNA. As a control for 
genomic DNA contamination (gDNA), RT reactions were performed without reverse transcriptase (-
RT) using myc-ZNF804A Flp-In TREx clone one as the template. (A) RT-PCR was performed using 
a forward primer complementary to the myc epitope tag and a reverse primer complementary to the 
gene of interest. Primer sequences are given in Appendices 1.1 and 1.5. (B) Q-PCR was performed in 
triplicate using a Solaris probe and primer pair designed complementary to ZNF804A. Primer and 
probe sequences are given in Appendix 1.4. The mean Ct value for each sample was normalised to 
GAPDH levels. The bar graph represents the fold change in ZNF804A mRNA abundance between the 
samples, relative to the abundance of ZNF804A mRNA in the uninduced sample of clone number one. 
The error bars represent the standard deviation of the three raw Ct values. (* denotes P < 0.05, paired 
t-test on ∆Ct values).  
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Figure 5.3 Western blot analyses of myc-ZNF804A and GFP-TCF4  
Cultured myc-ZNF804A and GFP-TCF4 Flp-In TREx cells were induced with tetracycline at the 
concentrations shown. The following day, protein lysates were prepared. (A) The protein lysates were 
western blotted and the blot was incubated with an anti-myc antibody. A protein lysate prepared from 
HEK293T cells transiently expressing myc-TCF4 served to confirm that the anti-myc antibody 
detected the myc epitope tag. (B) The protein lysates were western blotted and the blot was incubated 
with an anti-GFP antibody. Incubating a separate, but identical, blot with an anti-α-tubulin antibody 
confirmed the presence of similar amounts of protein in each sample. The antibody dilutions used are 
given in Table 2.5.   
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To evaluate whether myc-ZNF804A protein could be detected, protein lysates were prepared 
from tetracycline-induced myc-ZNF804A Flp-In TREx cells and western blotted (section 
2.6). The blots were probed for the presence of myc-tagged proteins using an anti-myc 
antibody (9E10). Myc-ZNF804A migrated at 175 kDa and was only detected very weakly in 
induced myc-ZNF804A Flp-In TREx cells (Figure 5.3). These data are consistent with those 
presented in Chapter Three which show myc-ZNF804A was degraded by the proteasome and 
the abundance of myc-ZNF804A was extremely low. In control experiments, GFP-TCF4 was 
readily detected in induced GFP-TCF4 Flp-In TREx cells. This confirmed the utility of the 
Flp-In TREx expression system (Figure 5.3B).  
 
To determine whether the subcellular location of myc-ZNF804A could be visualised, induced 
myc-ZNF804A Flp-In TREx cells were processed for immunocytochemistry using the 9E10 
antibody while the nucleus was counter-stained using Hoechst (section 2.8.1). Consistent 
with the extremely low levels of myc-ZNF804A detected by western blot, myc-ZNF804A 
was not detected by immunocytochemistry (data not shown). The utility of the Flp-In TREx 
expression system for immunocytochemistry was confirmed using the tetracycline-induced 
GFP-TCF4 Flp-In TREx cell line (data not shown). Consistent with published findings, GFP-
TCF4 localised homogenously throughout the nucleus (Forrest et al., 2012).  
 
Having established that the myc-ZNF804A Flp-In TREx cells produced detectable levels of 
myc-ZNF804A protein, I wanted to determine if the cell line could be used to validate the 
Y2H data presented in Chapter Three using co-immunoprecipitation. To determine the utility 
of the myc-ZNF804A Flp-In TREx cells for immunoprecipitation, large-scale 
immunoprecipitation experiments were performed (section 2.7.2). The myc-ZNF804A Flp-In 
TREx cells were seeded in thirty 10 cm dishes and myc-ZNF804A expression was induced 
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with 1 µg/ml tetracycline. The following day, the cells were lysed in RIPA buffer and myc-
ZNF804A was immunoprecipitated from the RIPA lysate using anti-myc antibody (9E10) -
conjugated protein A beads. Transient transfection of a myc-TCF4 expression vector into 
four 10 cm dishes of HEK293T cells served as a control for immunoprecipitation of myc-
tagged protein with 9E10-conjugated protein A beads. The immunoprecipitated proteins were 
western blotted and the blots were probed with the 9E10 antibody. Figure 5.4A shows that 
myc-ZNF804A was not detected; however myc-TCF4 was enriched after 
immunoprecipitation. The successful immunoprecipitation of myc-TCF4 indicates that the 
9E10-conjugated protein A beads could immunoprecipitate myc-tagged proteins.  
 
5.3. Preparation of samples for exon array 
Having demonstrated that the ZNF804A transcript could be over-expressed in myc-ZNF804A 
Flp-In TREx cells, the cell line could be used to investigate potential changes in the cellular 
transcriptome in cells over-expressing myc-ZNF804A using exon array technology. Data 
presented in Figure 5.2A show uninduced myc-ZNF804A Flp-In TREx samples expressed 
myc-ZNF804A; therefore these samples were not appropriate negative controls. Instead, the 
preliminary exon array analysis was performed using wildtype HEK293T cells as the control 
sample because Q-PCR analysis showed that these cells did not express ZNF804A. 
Examination of these data suggested that the antibiotics used to maintain and/or induce the 
myc-ZNF804A Flp-In TREx cell line may influence pre-mRNA splicing. Therefore, a 
control, transformed Flp-In TREx cell line that expressed the hygromycin B resistance (H
R
) 
and blasticidin resistance (B
R
) genes was generated using an empty, circular pcDNA5/FRT 
expression vector. This cell line is referred to as the ‘negative control’. In parallel, a further 
four clonal myc-ZNF804A Flp-In TREx cell lines were generated to control for any potential 
effects of the experimental conditions used to generate the stable cell lines on the cellular  
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Figure 5.4 Immunoprecipitation of myc-tagged proteins  
Expression of myc-ZNF804A was induced in myc-ZNF804A Flp-In TREx cells using 1 µg/ml of 
tetracycline. HEK293T cells transiently expressing myc-TCF4 served as a positive control for the 
immunoprecipitation. The following day, RIPA extracts were prepared. Myc-ZNF804A and myc-
TCF4 were immunoprecipitated from RIPA extracts using anti-myc antibody (9E10) -conjugated 
Protein A beads. A portion of the eluted immune complexes was western blotted alongside a ‘Protein 
A only’ control and pre- and post-IP samples. The blots were incubated with the 9E10 antibody. The 
antibody dilutions used are given in Table 2.5.   
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transcriptome.  
 
To prepare the samples for exon array, the four clonal myc-ZNF804A Flp-In TREx cell lines 
and the four clonal negative control cell lines were seeded and 24h later, the cells were 
treated with 1 µg/ml tetracycline (section 2.9.1). The following day, RNA was extracted from 
the induced cells and 1
st
 strand cDNA was prepared. In control reactions, the reverse 
transcriptase was excluded from the reaction mix to determine the levels of residual genomic 
DNA in the RNA samples. RT-PCR confirmed that myc-ZNF804A and H
R
 were expressed 
when the cells were treated with tetracycline (Figure 5.5). After 40 cycles of PCR, there was 
a very faint product in the no reverse transcriptase (-RT) control sample which may suggest 
that there was very low levels of residual genomic DNA in the RNA samples. The quality of 
the RNA was assessed on the Agilent 2100 bioanalyser (Central Biotechnology Services 
(CBS), Cardiff University). The RNA integrity number (RIN) for each sample was 10; this 
meant that the RNA was intact and suitable for gene expression analysis.  
 
5.4. Processing of exon array chips and quality assessment 
The RNA samples were converted into labelled cDNA for hybridisation to the Affymetrix 
GeneChip human exon array 1.0 ST and the arrays were processed by CBS. CBS performed 
an assessment of the array quality control parameters using the Affymetrix expression 
console; this assessment showed that all of the arrays met the required parameters for 
labelling and hybridisation. I received and analysed the resulting raw .CEL files which 
contained the signal intensity information for each probe set. The .CEL files were imported 
into the Partek Genomics Suite (PGS) using the core metaprobe set and RMA algorithm 
(section 2.9.2). The quality control metrics performed in the PGS showed that the RMA 
normalisation was successful (Appendix 4C) (section 2.9.3). To identify related samples,  
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Figure 5.5 RT-PCR assessment of myc-ZNF804A and hygromycinR  
Cultured myc-ZNF804A Flp-In TREx and control cells were treated with 1 µg/ml tetracycline to 
induce gene expression. The following day, RNA was prepared. Reverse transcription (RT) reactions 
were performed to generate cDNA. RT reactions performed without reverse transcriptase (-RT) 
served as a control for residual levels of genomic DNA (gDNA). PCR was performed using primers 
complementary to the hygromycin resistance gene (hygromycin
R
) or myc-ZNF804A. Primer sequences 
are given in Appendix 1.1 and 1.5. A representative example of the induced myc-ZNF804A and 
induced control cell line is shown.   
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Figure 5.6 Hierarchical clustering of the most differentially expressed genes between ZNF804A-
myc Flp-In TREx samples and control samples   
Hierarchical clustering of the (A) 100, (B) 1000 and (C) 5000 most differentially expressed genes 
between the induced myc-ZNF804A Flp-In TREx samples (red) and negative control samples (blue). 
The heatmap colours are artificial: green = relative up-regulation and red = relative down-regulation 
black = no difference.  
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agglomerative hierarchical clustering was performed, and the resulting cluster dendrograms 
are shown in Figure 5.6. The clustering was performed using the gene-summarised 
expression values from the top 100, 1000 and 5000 most differentially expressed genes. The 
clustering patterns correlated with the over-expression of myc-ZNF804A. These data suggest 
that the cell lines over-expressing myc-ZNF804A were systematically different to the negative 
control cell lines.  
 
5.5. Identifying genes with altered expression after myc-ZNF804A over-expression  
To identify genes with altered expression in cells over-expressing myc-ZNF804A, a one-way 
ANOVA was performed on the gene-summarised expression values between the myc-
ZNF804A Flp-In TREx and the negative control samples (section 2.9.4). The expression of 
1257 genes differed with a nominally significant P < 0.05 (Table 5.1). Of these 1257 genes, 
951 mapped to known HGNC gene symbols. After correction for multiple testing using a 5% 
FDR, only ZNF804A was statistically significantly differentially expressed (uncorrected P = 
2.58 x 10
-8
; FC = 46.41) (Figure 5.7). However, the literature suggests judging whether a 
gene is differentially expressed by fold change rather than P value gives greater 
reproducibility between microarray platforms (Patterson et al., 2006; Guo et al., 2006). 
Moreover, from a biological perspective, differential gene expression may only be of interest 
if the fold change is biologically significant; this is likely to depend on the gene in question 
and the experimental context (McCarthy and Smyth, 2009). However, measurements of fold 
change do not control for variance between samples therefore, data outliers can have an effect 
of the fold change calculated. As such, many studies use a combination of a modest P value 
and a fold change cut-off to identify differentially expressed genes. For example, Patterson et 
al. (2006) required a gene to satisfy P < 0.01 or P < 0.05 and then used a fold change ranking 
of 1.5, 2 or 4. While Rahimov et al. (2012) required genes to have a fold change of greater  
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Gene name Gene Symbol P value FC 
zinc finger protein 804A  ZNF804A 2.58E-08 46.41 
mitochondrial ribosomal protein L11  MRPL11 2.20E-04 1.19 
chromosome 20 open reading frame 165  C20orf165 2.36E-04 -1.47 
coiled-coil domain containing 142  CCDC142 2.69E-04 -1.21 
tyrosylprotein sulfotransferase 2  TPST2 4.35E-04 1.16 
zinc finger protein 208  ZNF208 4.80E-04 -1.68 
lipase, endothelial  LIPG 5.68E-04 1.56 
 transcription factor 7-like 1 (T-cell specific, HMG-box)  TCF7L1 6.01E-04 -1.15 
S-phase kinase-associated protein 1  SKP1 6.15E-04 -1.19 
chromosome 5 open reading frame 45  C5orf45 8.67E-04 -1.22 
SMAD family member 5 opposite strand  SMAD5OS 9.02E-04 -1.14 
heterogeneous nuclear ribonucleoprotein K  HNRNPK 9.68E-04 1.17 
 family with sequence similarity 83, member D  FAM83D 9.71E-04 -1.07 
thymine-DNA glycosylase  TDG 1.00E-03 1.09 
ventral anterior homeobox 1  VAX1 1.13E-03 1.15 
purinergic receptor P2X, ligand-gated ion channel, 5  P2RX5 1.14E-03 1.66 
 zinc finger protein 793  ZNF793 1.17E-03 -1.32 
family with sequence similarity 40, member A FAM40A 1.22E-03 -1.14 
toll-like receptor adaptor molecule 1 TICAM1 1.29E-03 -1.16 
Niemann-Pick disease, type C1  NPC1 1.52E-03 1.17 
Kv channel interacting protein 4  KCNIP4 1.55E-03 -1.08 
chromosome 3 open reading frame 36  C3orf36 1.58E-03 -1.20 
PIH1 domain containing 2  PIH1D2 1.58E-03 1.26 
aminopeptidase-like 1  NPEPL1 1.60E-03 -1.27 
apolipoprotein L, 6  APOL6 1.60E-03 1.16 
SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin, subfamily c, member 1 
SMARCC1 1.65E-03 1.07 
N-acetylneuraminic acid synthase  NANS 1.68E-03 1.27 
collagen, type XII, alpha 1  COL12A1 1.72E-03 -1.64 
 acyl-CoA binding domain containing 7  ACBD7 1.79E-03 1.56 
 
Table 5.1 The top 30 differentially expressed genes after myc-ZNF804A over-expression 
The .CEL files were imported into the PGS using the core metaprobe set and RMA normalisation. 
The .CEL files were assigned as either myc-ZNF804A Flp-In TREx or negative control. The genes 
with changes in expression associated with myc-ZNF804A over-expression were detected using a one-
way ANOVA with type as the candidate variable in the ANOVA model. The gene list represents the 
top 30 nominally differentially expressed genes (uncorrected P < 0.05) with known HGNC gene 
symbols, sorted by P value.   
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Figure 5.7 The PGS ‘geneview’ of ZNF804A in cells over-expressing myc-ZNF804A 
One-way ANOVA detected differential expression of ZNF804A between myc-ZNF804A Flp-In TREx 
samples and control samples. The individual probe set log2 signal intensities across the ZNF804A 
transcript were plotted in the PGS. The first three 5’ probe sets were unaltered because these probe 
sets fell within the untranslated region of ZNF804A whereas the myc-ZNF804A sequence which was 
cloned into the pcDNA5/FRT/TO vector began at the start codon.   
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Gene name Gene Symbol P value FC 
zinc finger protein 804A  ZNF804A 2.58E-08 46.41 
zinc finger protein 208 ZNF208 4.80E-04 -1.68 
lipase, endothelial  LIPG 5.68E-04 1.56 
purinergic receptor P2X, ligand-gated ion channel, 5  P2RX5 1.14E-03 1.66 
collagen, type XII, alpha 1  COL12A1 1.72E-03 -1.64 
acyl-CoA binding domain containing 7 ACBD7 1.79E-03 1.56 
secreted protein, acidic, cysteine-rich (osteonectin)  SPARC 2.62E-03 5.28 
pentraxin 3, long  PTX3 5.50E-03 1.61 
tetratricopeptide repeat domain 30B  TTC30B 7.37E-03 1.52 
Zic family member 1 (odd-paired homolog, Drosophila)  ZIC1 7.39E-03 -2.43 
hypothetical LOC84856  LOC84856 7.53E-03 -1.83 
inactivation escape 1 (non-protein coding)  INE1 9.64E-03 -1.58 
zinc finger protein, X-linked  ZFX 1.06E-02 -1.52 
PCI domain containing 2  PCID2 1.18E-02 -1.51 
spondin 1, extracellular matrix protein  SPON1 1.82E-02 2.15 
sprouty homolog 4 (Drosophila) SPRY4 2.03E-02 1.87 
NAD(P)H dehydrogenase, quinone 1 NQO1 2.16E-02 1.66 
zinc finger protein 738 ZNF738 3.07E-02 -4.83 
TLC domain containing 1 TLCD1 3.29E-02 1.62 
hairy/enhancer-of-split related with YRPW motif 1  HEY1 3.69E-02 -1.77 
v-myb myeloblastosis viral oncogene homolog (avian)  MYB 3.76E-02 1.60 
ryanodine receptor 2 (cardiac)  RYR2 4.03E-02 -1.63 
interferon regulatory factor 8  IRF8 4.22E-02 1.71 
paired related homeobox 1  PRRX1 4.41E-02 1.67 
chromosome 7 open reading frame 58  C7orf58 4.66E-02 1.58 
 
Table 5.2 The genes that had a fold change in expression greater than +/- 1.5 when myc-
ZNF804A was over-expressed  
The .CEL files were imported into the PGS using the core metaprobe set and RMA normalisation. 
The .CEL files were assigned as either myc-ZNF804A Flp-In TREx or negative control. The genes 
with changes in expression associated with myc-ZNF804A over-expression were detected using a one-
way ANOVA with type as the candidate variable in the ANOVA model. The gene list represents the 
nominally differentially expressed genes (P < 0.05) with known HGNC gene symbols and fold change 
of less than -1.5 or greater than 1.5.   
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Figure 5.8 SPARC was up-regulated in cells over-expressing myc-ZNF804A 
 (A) One-way ANOVA detected differential expression of SPARC between myc-ZNF804A Flp-In 
TREx samples and negative control samples (P = 2.62 x 10
-3
; FC = 5.28). The individual probe set 
log2 signal intensities across the SPARC transcript were plotted in the PGS alongside the fold change 
in log2 signal intensity for each of the probe sets. (B) Q-PCR analysis of SPARC mRNA abundance (n 
= 4). Q-PCR was performed using primers designed complementary to SPARC. The primer sequences 
are given in Appendix 1.6. The Q-PCR reactions were performed in duplicate and the Ct values were 
normalised to beta actin (ACTB). The error bars represent the standard deviation of the raw Ct values. 
** denotes P < 0.001 using independent samples T-test on the ∆Ct values.  
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than 1.2 and a nominal P < 0.01. Therefore, to identify expression changes which did not 
withstand multiple test correction but may still have biological relevance to the over-
expression of myc-ZNF804A, a filter for fold change was applied. Only genes with nominal 
differential expression (P < 0.05) and known HGNC gene symbol were included in the 
analysis. All 951 genes had a fold change greater than 1 or less than -1 so a fold change 
greater than 1.5 or less than -1.5 was used. Twenty-five genes fulfilled these criteria (Table 
5.2). Of these, four genes had a fold change greater than 2 or less than -2: ZNF804A; SPARC; 
Zic family member 1 (odd-paired homolog, Drosophila) (ZIC1) and spondin 1, extracellular 
matrix protein (SPON1). SPARC was up-regulated five-fold in cells over-expressing myc-
ZNF804A (2.62 x 10
-3
; FC = 5.28). Q-PCR analysis confirmed the up-regulation of SPARC 
when myc-ZNF804A was over-expressed (Figure 5.8). The up-regulation of SPARC is 
particularly notable because data presented in Chapter Four show SPARC was also up-
regulated after ZNF804A knockdown (section 4.5.5; Figure 4.11). 
 
5.5.1. Enrichment analysis of  differentially expressed genes after myc-ZNF804A over-
expression 
To identify biological processes which were enriched for ZNF804A-related target genes, 
enrichment analysis was performed using GeneGo MetaCore™ software (section 2.10). Of 
the 1256 differentially expressed genes (excluding ZNF804A), 948 were annotated in 
GeneGo MetaCore™. Genes belonging to the GO processes ‘regulation of RNA biosynthetic 
process’ (250/3710 P = 2.23 x 10-13) and ‘regulation of transcription, DNA-dependent’ 
(249/3692 P = 2.32 x 10
-13
) were significantly enriched among the differentially expressed 
genes (Figure 5.9A). After 5% FDR correction for multiple testing, no GeneGo process 
networks were statistically significantly enriched among the differentially expressed genes. 
However, a number of GeneGo pathway maps were significantly enriched among the 
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differentially expressed genes (Figure 5.9B). GeneGo pathway maps reflect consensus 
knowledge on specific functional components in the intracellular cell signaling, regulatory 
processes, metabolic processes or disease-related processes. The most statistically significant 
GeneGo pathway map was ‘development_regulation of epithelial-to-mesenchymal transition 
(EMT)’ (10/64 P = 2.29 x 10-5) (Figure 5.10A). The differentially expressed genes belonging 
to the top 10 statistically significant GeneGo pathway maps are listed in Table 5.3. This 
shows that of the 10 genes belonging to ‘development_regulation of epithelial-to-
mesenchymal transition (EMT)’, four were also annotated in ‘development_TGF-beta-
dependent induction of EMT via RhoA, PI3K and ILK’ (8/46 P = 6.95 x 10-5; Figure 5.10B). 
Table 5.3 highlights that some of the differentially expressed genes belonged to multiple 
significantly enriched pathway maps. For example, ras homolog gene family, member A 
(RHOA), which encodes a small guanosine triphosphatase (GTPase) protein that is known to 
regulate the actin cytoskeleton, belonged to five pathway maps: ‘cell adhesion_chemokines 
and adhesion’; ‘development_TGF-beta-dependent induction of EMT via RhoA,  PI3K and 
ILK’; ‘development_Role of IL-8 in angiogenesis’; ‘neurophysiological process_receptor-
mediated axon growth repulsion’ and ‘cell adhesion_histamine H1 receptor signaling in the 
interruption of cell barrier integrity’. 
 
5.6. Identifying changes in pre-mRNA splicing after myc-ZNF804A over-expression  
To investigate the effect of over-expressing myc-ZNF804A on pre-mRNA splicing, an 
alternative splicing one-way ANOVA was performed (section 2.9.6). To ensure that only 
transcripts that were expressed in at least one sample group were analysed, only probe sets 
with a log2 signal intensity greater than three were included in the analysis. To reduce the 
number of false-positive results, the gene list was filtered to exclude any gene with less than 
five probe sets or gene expression changes greater than five-fold and a conservative  
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Figure 5.9 The top GO processes and GeneGo pathway maps that were significantly 
enriched for genes showing differential expression in cells over-expressing myc-
ZNF804A 
The list of 1256 genes (excluding ZNF804A) differentially expressed between myc-ZNF804A 
Flp-In TREx samples and negative control samples (one-way ANOVA, nominal P < 0.05) 
was imported into GeneGo MetaCore™. Enrichment analysis was performed as described in 
section 2.10. The bar charts show (A) the top 10 statistically significant GO processes and (B) 
the top 10 statistically significant GeneGo pathway maps identified by the enrichment 
analysis. GeneGo MetaCore™ determined these enrichments to be statistically significant at a 
5% FDR; the uncorrected P values are shown.    
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Figure 5.10 Visual representation of GeneGo pathway maps enriched among the 
differentially expressed genes. Enrichment analysis for GeneGo pathway maps was 
performed using GeneGo MetaCore™ (refer to Figure 5.9 for details). (A) Ten genes 
belonging to the pathway map ‘development_regulation of epithelial-to-mesenchymal 
transition (EMT)’ and (B) eight genes belonging to the pathway map ‘development_TGF-
beta-dependent induction of EMT via RhoA, PI3K and ILK’ were differentially expressed in 
cells over-expressing myc-ZNF804A. The target genes are represented by red (up-regulation) 
or blue (down-regulation) bars. The GeneGo pathway map legend is provided in Appendix 6. 
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GeneGo pathway map Active data  
Development_Regulation of 
epithelial-to-mesenchymal 
transition (EMT) 
hairy/enhancer-of-split related with YRPW motif 1 (HEY1); tropomyosin 1 (alpha) (TPM1), v-rel reticuloendotheliosis viral 
oncogene homolog A (avian) (RELA); tumor necrosis factor receptor superfamily, member 1A (TNFRSF1A); wingless-type 
MMTV integration site family, member 7B (WNT7B); lymphoid enhancer-binding factor 1 (LEF1); serum response factor (c-fos 
serum response element-binding transcription factor) (SRF); frizzled-related protein (FRZB); B-cell CLL/lymphoma 2 (BCL2); 
tumor necrosis factor (TNF) 
Cell adhesion_Chemokines and 
adhesion 
ras homolog gene family, member A (RHOA); G-protein beta/gamma* (guanine nucleotide binding protein (G protein), β 
polypeptide 1 and 2 (GNB1 and GNB2); guanine nucleotide binding protein (G protein), gamma 12 and 13 (GNG13 and 
GNG12)); vascular endothelial growth factor A (VEGF-A);  NFKB activating protein (NKAP); LIM domain kinase 2 (LIMK2); 
collagen, type IV, alpha 4 (COLA4A); moesin (MSN); transcription factor 7-like 1 (TCF7L1); laminin, alpha 4 (LAMA4); syndecan 
2 (SDC2); paxillin (PXN); cofilin 1 (CFL1) 
Development_TGF-beta-
dependent induction of EMT via 
RhoA,  PI3K and ILK.  
RHOA; TPM1; RELA; par-6 partitioning defective 6 homolog alpha (C. elegans) (PARD6A); LIMK2; LEF1; SRF; CFL1 
Immune response_C5a signaling 
G-protein beta/gamma* (GNB1, GNB2, GNG13, GNG12); mitogen-activated protein kinase 9 (MAPK9); NKAP; PKC* (protein 
kinase D3 (PRKD3)); phospholipase C, beta 1 (phosphoinositide-specific) (PLCB1); ribosomal protein S, kinase, 90kDa 
(RPS6KA1); BCL2; TNF 
Development_Role of IL-8 in 
angiogenesis 
RHOA; sterol regulatory element binding transcription factor 1 (SREBF1); janus kinase 2 (JAK2); VEGF-A; ubiquitin-conjugating 
enzyme E2N (UBC13 homolog, yeast) (UBE2N); NKAP; PXN 
Immune response_HSP60 and 
HSP70/ TLR signaling pathway 
CD80 molecule (CD80); MAPK9; UBE2N; NKAP; CD14 molecule (CD14); heat shock 60kDa protein 1 (chaperonin) (HSPD1); 
TNF 
PGE2 pathways in cancer 
prostaglandin E receptor 2 (subtype EP2), 53kDa (PTGER2); G-protein beta/gamma* (GNB1, GNB2, GNG13, GNG12); VEGF-
A; TCF7L1; LEF1; solute carrier organic anion transporter family, member 2A1 (SLCO2A1); TNF 
Neurophysiological 
process_Receptor-mediated axon 
growth repulsion 
RHOA; Ephrin-A receptors* (EPH receptor A6 (EPHA6) and EPH receptor A2 (EPHA2)); microtubule-associated protein tau 
(MAPT); LIMK2; Rho family GTPase 1 (RND1); CFL1 
Cell adhesion_Histamine H1 
receptor signaling in the 
interruption of cell barrier integrity 
RHOA; G-protein beta/gamma* (GNB1, GNB2, GNG13, GNG12); LIMK2; PLCB1; myosin, light chain 9, regulatory (MYL9); PXN; 
CFL1 
Proteolysis_Putative ubiquitin 
pathway 
cullin 1 (CUL1); UBE2N; ubiquitin-like modifier activating enzyme 1 (UBA1); S-phase kinase-associated protein 1 (SKP1); 
parkinson protein 2, E3 ubiquitin protein ligase (parkin) (PARK2) 
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Table 5.3 The active data in the top 10 statistically enriched GeneGo pathway maps  
The differentially expressed genes that correspond to the active data in the top 10 statistically 
significant GeneGo pathway maps (Figure 5.9B). * denotes a protein family that is encoded by more 
than one gene; all differentially expressed genes which relate to the protein family are listed.  
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Bonferroni correction for multiple testing was applied. After Bonferroni correction, an 
arbitrary cut-off of P < 0.05 was chosen to generate a manageable list of statistically 
significant alternatively spliced genes (Whistler, 2010).This analysis identified 27 genes as 
alternatively spliced (Table 5.4). The putative alternative splicing events were manually 
annotated alongside the UCSC genome browser (data presented as supplementary 
information in Appendix 6.2). Four genes were identified as both statistically significantly 
differentially expressed (P < 0.05; FC +/- 1.5; Table 5.2) and alternatively spliced: ZIC1; 
lipase, endothelial (LIPG); hypothetical LOC84856 (LOC84856) and collagen, type XII, 
alpha 1 (COL12A1). Visual inspection of the PGS geneviews alongside the UCSC genome 
browser suggested that there may be potential novel alternative splicing events in COL12A1 
and LIPG and a potential alternative transcription start site in ZIC1. However, there was no 
identifiable alternative splicing in LOC84856. Three of the putative splicing events 
corresponded with known alternatively spliced exons: O- linked N-acetylglucosamine 
(GlcNAc) transferase (OGT), nucleoporin like 1 (NUPL1) and mucosa associated lymphoid 
tissue lymphoma translocation gene 1 (MALT1). However, preliminary RT-PCR analysis 
using primers designed complementary to the constitutive exons flanking the putatively 
spliced exons failed to amplify more than one transcript variant for these genes therefore, 
further empirical analysis is needed to determine if these are true alternative splicing events.  
 
5.6.1. Enrichment analysis of genes showing alternative splicing after myc-ZNF804A 
over-expression 
To identify biological processes for genes differentially spliced after myc-ZNF804A over-
expression, enrichment analysis was performed using GeneGo MetaCore™ software. Of the 
27 genes identified as alternatively spliced (section 5.6), all 27 were annotated in GeneGo 
MetaCore™. Genes belonging to the GeneGo process network ‘cell_adhesion_cell-matrix  
Chapter Five: Investigating the effects of over-expressing myc-ZNF804A on the cellular transcriptome  
 185 
 
 
Table 5.4 Genes identified as alternatively spliced in cells over-expressing myc-ZNF804A 
The .CEL files were imported into the PGS using the core metaprobe set and RMA normalisation. 
The .CEL files were assigned as either myc-ZNF804A Flp-In TREx or negative control. The genes 
with changes in splicing associated with ZNF804A over-expression were detected using an alternative 
splicing one-way ANOVA.  Alternative splicing ANOVA P values were corrected using the 
Bonferroni method. After Bonferroni correction, an arbitrary cut-off of P < 0.05 was chosen to 
generate a manageable list of statistically significant alternatively spliced genes. Using this cut-off, 27 
genes were identified as alternatively spliced.  
Gene name Gene Symbol 
Bonferroni corrected 
alternative splicing 
P value 
collagen, type XII, alpha 1 COL12A1 2.31E-09 
Zic family member 1 (odd-paired homolog, Drosophila)  ZIC1 1.75E-06 
O-linked N-acetylglucosamine (GlcNAc) transferase  OGT 2.53E-06 
ryanodine receptor 2 (cardiac)  RYR2 3.30E-06 
cyclin-dependent kinase 16  CDK16 6.66E-06 
SET domain containing (lysine methyltransferase) 7  SETD7 8.31E-06 
interleukin enhancer binding factor 3, 90kDa  ILF3 1.25E-05 
protein phosphatase methylesterase 1  PPME1 1.88E-05 
nucleoporin like 1  NUPL1 1.83E-04 
LPS-responsive vesicle trafficking, beach and anchor 
containing LRBA 
1.35E-03 
hypothetical LOC84856  LOC84856 1.99E-03 
mucosa associated lymphoid tissue lymphoma 
translocation gene 1 MALT1 
2.76E-03 
NADH dehydrogenase (ubiquinone) Fe-S protein 2, 
49kDa (NADH-coenzyme Q reductase)  NDUFS2 
3.33E-03 
zinc finger protein 536  ZNF536 3.94E-03 
mediator complex subunit 1  MED1 4.30E-03 
feline leukemia virus subgroup C cellular receptor 1 FLVCR1 5.87E-03 
transcription factor 7-like 2 (T-cell specific, HMG-box) TCF7L2 6.00E-03 
collagen, type II, alpha 1  COL2A1 1.39E-02 
kinesin family member 22  KIF22 1.66E-02 
CD44 molecule (Indian blood group)  CD44 2.29E-02 
erythrocyte membrane protein band 4.1-like 2  EPB41L2 2.40E-02 
claudin domain containing 1 CLDND1 2.51E-02 
lipase, endothelial  LIPG 2.63E-02 
myelin expression factor 2 MYEF2 3.30E-02 
GTPase, IMAP family member 7 GIMAP7 3.89E-02 
sprouty homolog 1, antagonist of FGF signalling 
(Drosophila) SPRY1 
3.90E-02 
leucine rich repeat containing 7  LRRC7 4.42E-02 
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interactions’ were significantly enriched among the alternatively spliced genes (6/207 P = 
1.65 x 10
-5
). This was the only GeneGo process network which remained significantly 
enriched after 5% FDR correction for multiple testing. The alternatively spliced genes 
belonging to this GeneGo process network were CD44 molecule (Indian blood group) 
(CD44), collagen, type II, alpha 1 (COL2A1) and COL12A1. CD44 mapped to four nodes 
within the network.  
 
5.7. Discussion 
The aim of the experiments described in this Chapter was to over-express myc-ZNF804A in 
mammalian cells and profile the ensuing genome-wide changes for differential gene 
expression and pre-mRNA splicing changes using Affymetrix GeneChip human exon 1.0 ST 
arrays. The hypothesis was that over-expression of myc-ZNF804A would lead to changes in 
the expression and pre-mRNA splicing of transcripts regulated, directly or indirectly, by 
ZNF804A. The data presented herein suggest that over-expression of myc-ZNF804A altered 
the expression of numerous genes but had relatively few effects on pre-mRNA processing.  
 
The impetus to generate tetracycline-inducible cell lines expressing myc-ZNF804A came 
from unsuccessful attempts to transiently over-express myc-ZNF804A in mammalian cells 
(C. L. Tinsley, personal communication). It was hypothesised that the inability to detect 
exogenous ZNF804A may indicate that over-expression of ZNF804A was cytotoxic or that 
ZNF804A may be produced at extremely low levels. An alternative hypothesis is that the 
cDNA was only taken-up by a few cells. Previous studies have used conditional, stable 
expression to produce proteins that could not be produced by transient expression methods 
(Reeves et al., 2002). Conditional, stable expression lines are successful in such instances 
because they do not require high transfection efficiency, and potential negative effects of 
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gene expression on cell survival may be combated by growing the cells to confluency before 
inducing gene expression. Therefore, it was hypothesised that tetracycline-inducible, stable 
expression may generate detectable levels of myc-ZNF804A. Data presented here show the 
myc-ZNF804A Flp-In TREx cell line produced very low but detectable levels of myc-
ZNF804A protein. In control experiments, GFP-TCF4 was produced to relatively high levels. 
This suggests that the low levels of myc-ZNF804A were specific to this protein and were not 
a consequence of using the Flp-In TREx system. Data presented in Chapter Three show myc-
ZNF804A was only reliably detected after proteasome inhibition (section 3.3.2). Further 
studies using proteasome inhibitors will help determine if myc-ZNF804A produced by the 
Flp-In TREx cell line is degraded by the proteasome.  
 
Immunoprecipitation experiments to isolate myc-ZNF804A from the protein lysates using 
9E10-conjugated protein A beads were unsuccessful. Although control experiments show the 
9E10-conjugated protein A beads could immunoprecipitate transiently expressed myc-tagged 
proteins, it remains to be determined whether myc-tagged protein could be 
immunoprecipitated from induced Flp-In TREx cells. One hypothesis to explain the inability 
to enrich myc-ZNF804A using immunoprecipitation is that the myc-ZNF804A protein 
adopted a conformation which rendered the myc-tag invisible to the 9E10-conjugated protein 
A beads. Further experiments using protein A beads conjugated with the anti-ZNF804A 
antibodies described in Chapter Three (D-14 and 3077) will help to evaluate this hypothesis.   
 
Numerous genes were nominally differentially expressed in cells over-expressing myc-
ZNF804A. However, only the differential expression of ZNF804A survived a multiple test 
correction of 5% FDR. The FDR method is often used in microarray studies to control for 
false-positives however, it is important to strike a balance between sensitivity and controlling 
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for type I errors (Pawitan et al., 2005). Rather than using a larger FDR cut-off and accepting a 
higher number of type I errors, fold change was used to highlight biologically meaningful 
changes in gene expression (McCarthy, 2009). This analysis showed that most of the 
differentially expressed genes had relatively small changes in expression. The gene showing 
the largest change in expression (aside from ZNF804A) was SPARC, which was up-regulated 
five-fold in cells over-expressing myc-ZNF804A. Importantly, this finding was confirmed by 
Q-PCR analysis. The Q-PCR data suggest the exon array method under-estimated the fold 
change in SPARC mRNA abundance by as much as two-fold. The standard deviation of the 
raw Ct values obtained from the Q-PCR analysis highlighted that there was considerable 
variability in SPARC mRNA abundance between the samples over-expressing myc-ZNF804A. 
This variability between samples may explain why differential expression of SPARC 
corresponded to a relatively less significant P value in the ANOVA on the exon array data, 
despite the large fold change in expression. The empirical validation of the up-regulation of 
SPARC confirms that the FDR method was too conservative, negating the identification of 
differentially expressed genes that could be empirically validated. This result is significant as 
it justifies using a nominal P value to identify the differentially expressed genes.  
 
SPARC encodes a 32 kDa matricellular protein which is secreted by glial cells in the 
developing nervous system and is widely distributed with notably high abundance in 
synaptogenic areas (Mendis and Brown, 1994; Mendis et al., 1995; Vincent et al., 2008). 
SPARC has been implicated many cellular processes, including processes implicated in 
schizophrenia pathology, such as neuronal differentiation and synapse formation (Albrecht et 
al., 2012; Bhoopathi et al., 2011; Kucukdereli et al., 2011). Therefore, it is tempting to 
speculate that changes in SPARC expression, as a consequence of genetic variation in 
ZNF804A, may increase susceptibility for schizophrenia. Moreover, data presented in 
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Chapter Four show SPARC was also up-regulated in ZNF804A-depleted cells. It is tempting 
to interpret these data as further evidence that ZNF804A has a role in regulating the 
expression of SPARC.  
 
Enrichment analysis by GO process showed genes belonging to general GO processes such as 
‘regulation of cellular metabolic process’ and ‘regulation of biosynthetic process’ were 
enriched among the differentially expressed genes. There was notable redundancy among the 
most significantly enriched GO processes, for example ‘regulation of cellular metabolic 
process’, ‘cellular metabolic process’ and ‘metabolic process’ were all in the top 10 
significantly enriched pathways. Consistent with ZNF804A’s putative role in the regulation 
of gene expression (Chapters Three and Four), there was enrichment for genes belonging to 
the GO process ‘regulation of transcription (DNA dependent)’.  
 
Enrichment by GeneGo pathway map highlighted more specific biological processes which 
were enriched for ZNF804A-related target genes. The most significant GeneGo pathway map 
among the nominally differentially expressed genes was ‘development_regulation of 
epithelial-to-mesenchymal transition (EMT)’. EMT describes the reversible process whereby 
epithelial cells lose cell-cell adhesions and apical-basolateral polarity, and gain mesenchymal 
cell characteristics such as motility and invasiveness. EMT is essential for neural tube 
formation in development. EMT is initiated by extracellular signals from the extracellular 
matrix and a number of secreted ligands (reviewed by Thiery and Sleeman, 2006). The 
primary and best-characterised of these inducers are members of the transforming growth 
factor beta (TGFβ) family (Polyak and Weinberg, 2009). TGFβ can induce EMT through 
multiple signalling mechanisms or via influencing the activities of other EMT-inducing 
signal transduction pathways, such as those involving Notch or Wnt (Bakin et al., 2000; 
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Massague, 2008; Miettinen et al., 1994; Timmerman et al., 2004). Data presented here show 
genes belonging to the GeneGo pathway map ‘development_TGF-beta-dependent induction 
of EMT via RhoA, PI3K and ILK’ were enriched among the differentially expressed genes. 
Importantly, these data are consistent with recent findings presented by Umeda-Yano and 
colleagues (2013) which showed that genes regulated by ZNF804A were associated with 
TGFβ signalling. The literature suggests TGFβ is the dominant extracellular signalling 
molecule required for axon specification in the developing brain (Yi et al., 2010). Other 
regulators of EMT which were differentially expressed also have additional roles in 
neurodevelopment. For example HEY1, a basic-helix-loop-helix-Orange (bHLH-O) 
transcriptional repressor was down-regulated in cells over-expressing myc-ZNF804A. HEY1 
has been implicated in both the induction of EMT (Zavadil et al., 2004) and the maintenance 
of neural precursor cells (Sakamoto et al., 2003). These data imply over-expression of myc-
ZNF804A alters the expression of critical EMT regulators, some of which have additional 
roles in nervous system development.  
 
The enrichment analysis also identified genes belonging to the GeneGo pathway map 
‘neurophysiological process_receptor mediated axon growth repulsion’ as enriched among 
the differentially expressed genes. In the developing nervous system, axons navigate to their 
targets by sensing attractive and repulsive molecules via receptors expressed on their growth 
cones. The importance of axon connectivity in nervous system development is highlighted by 
disorders that result from aberrant axon guidance (Engle, 2010). Genetic studies have 
identified association between genes implicated in aberrant axon guidance and schizophrenia, 
for example Abelson helper integration site 1 (AHI1) (Amann-Zalcenstein et al., 2006; 
Ingason et al., 2007). Therefore, potential influences on axon guidance may be considered a 
candidate mechanism for ZNF804A’s involvement in schizophrenia pathology.  
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Interestingly, genes belonging to the GeneGo pathway map ‘proteolysis_putative ubiquitin 
pathway’ were significantly enriched among the differentially expressed genes. This is 
consistent with data presented in Chapter Three that show ZNF804A was only reliably 
detected after the proteasome was inhibited. As discussed above, further experiments using 
proteasome inhibitors are required to determine if myc-ZNF804A produced by the myc-
ZNF804A Flp-In TREx cell line was degraded by the proteasome.  
 
Only 27 genes were identified as alternatively spliced in cells over-expressing myc-ZNF804A. 
This was a relatively low number of alternative splicing events; for instance in Chapter Four, 
448 genes were identified as alternatively spliced (one-way ANOVA; Bonferroni corrected P 
< 0.05). Enrichment by GeneGo process network identified genes belonging 
‘cell_adhesion_cell-matrix interactions’ as significantly enriched among the alternatively 
spliced genes. This could suggest a role for ZNF804A in regulating cytoskeletal structure 
which might be important in neuronal migration. Importantly, data presented in Chapter Four 
and in the literature (Hill et al., 2012a) also implicate a role for ZNF804A in cell adhesion.   
 
In the context of the ZNF804A-knockdown data presented in Chapter Four, there were 
relatively fewer statistically significant changes in gene expression and pre-mRNA splicing 
in cells over-expressing myc-ZNF804A. A possible explanation for this finding is that 
unknown downstream mediators of ZNF804A’s effects may not be expressed in the host cell 
line (HEK293) used to generate the myc-ZNF804A Flp-In TREx cell line. An alternative 
hypothesis is that the cells regulated the over-expression of myc-ZNF804A via the ubiquitin-
proteasome pathway. While fewer statistically significant changes in the transcriptome were 
identified, the enrichment analyses presented herein are consistent with data presented in 
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Chapter Four. For example, both the over-expression and knockdown experiments implicate 
a role for ZNF804A in regulating the expression and splicing of genes involved in cell 
adhesion and axonal guidance.  
 
Recent studies have reported that transient over-expression of myc-ZNF804A in rat neural 
progenitor cells altered the expression of four genes (DRD2, PDE4B, COMT and PRSS16) 
between three- and five-fold (Girgenti et al., 2012). Girgenti and colleagues evaluated the 
expression of these specific genes because they had been previously implicated in 
schizophrenia pathology. Based on the prediction that ZNF804A was a DNA transcription 
factor (O’Donovan et al., 2008), Girgenti and colleagues used ChIP to investigate the ability 
of myc-ZNF804A to bind to the promoter regions of these genes. These data showed that 
myc-ZNF804A bound directly to the promoter regions of PRSS16 and COMT and up-
regulated their expression (Girgenti et al., 2012). Using our global, hypothesis-free approach, 
these genes were not identified as differentially expressed in cells over-expressing myc-
ZNF804A. This inconsistency may reflect experimental differences. Specifically, Girgenti 
and colleagues readily produced myc-ZNF804A in rat neural progenitor cells whereas myc-
ZNF804A was only detected to very low levels in induced myc-ZNF804A Flp-In TREx cells 
derived from a HEK293 cell line.   
 
In summary, the data presented in this Chapter show that over-expression of myc-ZNF804A 
using a tetracycline-inducible Flp-In TREx cell line resulted in nominal differential 
expression of numerous genes but had relatively few effects on pre-mRNA splicing. 
Enrichment analysis indicated a significant effect of myc-ZNF804A over-expression on genes 
involved in cell adhesion, axon guidance and regulating EMT during development; in 
particular TGFβ-induced EMT. Previous studies have indicated ZNF804A may regulate the 
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expression of genes involved in TGFβ signalling (Umeda-Yano et al., 2013). Therefore, 
further study to understand the link between ZNF804A, TGFβ signalling and the regulation 
of EMT may provide important insights into the function of ZNF804A and its contribution to 
schizophrenia pathology.  
 
 
 
 
 
 
Chapter Six: General discussion   
 
 194 
Chapter 6: General discussion  
 
The aim of this thesis was to characterise the function of ZNF804A. This protein is encoded 
by the ZNF804A gene, which has been robustly and reproducibly implicated as a 
susceptibility gene for schizophrenia (O'Donovan et al., 2008; Purcell et al., 2009; Riley et 
al., 2009; Steinberg et al., 2011; Strange, 2012). At the outset of this study, the function of 
ZNF804A was unknown. The findings presented in this thesis provide convincing evidence 
that ZNF804A is involved in transcriptional regulation and pre-mRNA processing. 
Remarkably, ZNF804A-associated ‘target’ genes are implicated in biological processes 
relevant to schizophrenia pathophysiology, such as nervous system development.  
 
Often, the first step to understanding the function of an uncharacterised protein is to establish 
which proteins it interacts with. Such data allows the uncharacterised protein to be placed in a 
functional context derived from known information about its interaction partners. In Chapter 
Three, Y2H screening was used to identify the putative protein binding partners of ZNF804A 
using human foetal brain and mouse brain cDNA libraries. The results presented show 
ZNF804A putatively interacted with proteins implicated in processes such as transcriptional 
regulation and pre-mRNA processing. For example, ZNF804A interacted with ZNF40, a 
known transcription factor, and RNA-binding proteins that have important roles in 
constitutive and alternative splicing such as RNPS1, NOVA2, Celf4, Rbfox1 and RBFOX2. 
The identification of these binding partners implicates a functional role for ZNF804A in 
transcriptional regulation and pre-mRNA processing. These data are consistent with recent, 
unpublished Y2H data presented by Rasko and colleagues at the 20
th
 World Congress of 
Psychiatric Genetics that showed putative ZNF804A-interactors were enriched for the GO 
term ‘RNA splicing’ (Rasko et al., 2012). Furthermore, the observation that GPATCH8, a 
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paralog of ZNF804A, localised to nuclear speckles also implicates a role for ZNF804A in 
pre-mRNA processing (Chapter Three). 
 
A key limitation of using genetic techniques such as the Y2H system to identify protein-
protein interactions is that the results must be confirmed in a mammalian in vitro system to 
exclude the possibility that they are false-positive interactions. Previous attempts within our 
laboratory to transiently express ZNF804A had been unsuccessful (C.L. Tinsley, personal 
communication). Data presented in Chapter Three support these findings and show myc-
ZNF804A was only reliably detected after proteasome inhibition (section 3.3.2). Data 
presented in Chapter Five show that the tetracycline-induced myc-ZNF804A Flp-In TREx 
cells produced very low but detectable levels of myc-ZNF804A (section 5.2). These data are 
inconsistent with data reported in the literature which show myc-ZNF804A expression vectors 
produced readily detectable levels of myc-ZNF804A in rat neural progenitor cells (Girgenti et 
al., 2012) and HEK293 cells (Umeda-Yano et al., 2013). To further understand ZNF804A’s 
biological function, it will be useful to establish the nature of the post-translational 
modifications that target ZNF804A to the proteasome for degradation and under what cellular 
conditions these post-translational modifications occur.  
 
Having established that ZNF804A putatively interacts with transcription factors and proteins 
involved in RNA splicing, it was hypothesised that ZNF804A, via interaction with its protein 
binding partners, may have a role in transcriptional regulation and pre-mRNA processing. 
The putative role of ZNF804A in gene expression was investigated using knockdown 
(Chapter Four) and over-expression (Chapter Five) experiments combined with Affymetrix 
GeneChip human exon 1.0 ST arrays. The hypothesis was that manipulation of ZNF804A 
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expression would lead to changes in the expression and pre-mRNA splicing of transcripts 
regulated, directly or indirectly, by ZNF804A.  
 
Data presented in Chapter Four show that there were numerous changes in gene expression 
after ZNF804A knockdown. Among the most differentially expressed genes were genes 
which have been implicated in schizophrenia pathology, including RELN, NPY and NLGN2 
(Table 4.3). Interestingly, genes belonging to the GO term ‘nervous system development’ and 
the GeneGo process network ‘cell adhesion_synaptic contact’ were enriched among those 
showing differential expression (section 4.5.1). These processes have been implicated in 
schizophrenia pathophysiology (Bourgeron, 2009; Fatemi and Folsom, 2009; Melom and 
Littleton, 2011; Zoghbi, 2003). These data are consistent with genetic data that implicates a 
role for ZNF804A in other neurodevelopmental disorders (see section 1.7.1) (Griswold et al., 
2012; Steinberg et al., 2011; Talkowski et al., 2012). Furthermore, the implication that 
ZNF804A has a role in regulating the expression of genes involved in neurodevelopment, and 
particularly synaptic contact, is consistent with recent genetic data suggests risk genes for 
schizophrenia converge at the synapse (see section 1.6.3.4) (O’Dushlaine et al., 2011; Kirov 
et al., 2012; Glessner et al., 2010). Importantly, using the schizophrenia and bipolar disorder 
PGC GWAS datasets, it was shown that the genes with altered expression in ZNF804A-
depleted cells (FDR 0.05) were enriched for genes that are genetically associated with disease 
(P < 0.05) (section 4.5.2). This finding provides independent support for the causal 
involvement of ZNF804A-associated ‘target’ genes in disease.  
 
Data presented in Chapter Five show that over-expression of myc-ZNF804A led to numerous 
nominally significant changes in gene expression. Enrichment analysis indicated a significant 
effect of myc-ZNF804A over-expression on the expression of genes involved in regulating 
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EMT during development; in particular TGFβ-dependent EMT (section 5.5.1). This is 
consistent with recent data presented by Umeda-Yano and colleagues (2013) which indicated 
that genes regulated by ZNF804A were associated with TGFβ signalling. Notably, the 
expression of SPARC was up-regulated in both the ZNF804A knockdown and over-
expression experiments. SPARC encodes the protein SPARC which is associated with 
biological processes implicated in schizophrenia, such as neuronal differentiation and 
synapse development (Albrecht et al., 2012; Bhoopathi et al., 2011; Kucukdereli et al., 2011). 
Therefore, SPARC may be an interesting discovery target for future studies of ZNF804A.  
 
The data presented in Chapter Four show that knockdown of wildtype ZNF804A altered the 
pre-mRNA splicing of a number of transcripts. Enrichment analysis of alternatively spliced 
genes indicated a significant effect of ZNF804A knockdown on genes involved in nervous 
system development, particularly synaptic contact and axonal guidance. As discussed above, 
these biological processes have been implicated in schizophrenia and therefore, aberrant 
splicing of these genes may represent candidate mechanisms for ZNF804A’s role in disease. 
While most of the empirical validations presented in this thesis represent cassette exons, there 
were many complex changes in splicing pattern after ZNF804A knockdown, including 
alternative promoter usage in PTPRR which was empirically confirmed (section 4.6.3). 
Interestingly, knockdown of ZNF804A led to alternative splicing of exon 11a of ENAH, an 
exon whose splicing is known to be regulated by RBFOX2 (section 4.6.2) (Yeo et al., 2009). 
These data are consistent with data presented in Chapter Three which suggest that ZNF804A 
may have a role in pre-mRNA processing via interaction with its binding partners. Recent 
genome-wide transcriptome profiling of post-mortem brains showed a statistically significant 
increase in the exclusion of exon 11a of ENAH in the Brodmann Area 10 and caudate 
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associated with schizophrenia (Cohen, 2012); this finding provides independent evidence for 
the causal involvement of alternative splicing of ENAH in schizophrenia.  
 
Data presented in Chapter Five suggest over-expression of myc-ZNF804A led to fewer 
changes in pre-mRNA splicing than in ZNF804A-knockdown cells. One potential explanation 
for this is that unknown downstream mediators of ZNF804A’s effects were not expressed in 
the host cell line (HEK293) used to generate the myc-ZNF804A Flp-In TREx cell line. 
Consistent with the literature (Hill et al., 2012a) and data presented in Chapter Four, 
enrichment analysis of the alternatively spliced genes indicated a significant effect of myc-
ZNF804A over-expression on genes involved in cell-matrix interactions.  
 
The primary limitation of exon array-based methods is a heavy reliance on prior knowledge 
of the genome. To further evaluate the effects of ZNF804A on pre-mRNA processing, it may 
be informative to use sequence-based methods such as RNA-sequencing. Although RNA-
sequencing technology is still under active development, it does have several advantages to 
the array-based methods; in particular, RNA-sequencing can differentiate more readily 
between different transcript variants and has lower background noise (Ozsolak and Milos, 
2011).  
 
It is important to highlight that the methods used here cannot indicate whether the changes in 
gene expression and pre-mRNA processing after ZNF804A knockdown or over-expression 
are due to direct actions of ZNF804A or due to secondary consequences. ZNF804A contains 
a C2H2 type ZnF domain at its N-terminus (O’Donovan, 2008). The C2H2 type ZnF domain 
can bind to DNA, RNA and proteins and is prevalent in known transcription factors 
(Matthews and Sunde, 2002). Interestingly, although ZnF domain-containing proteins may 
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contain between one and 40 C2H2 type ZnFs, very few proteins which use a single C2H2 
type ZnF domain to bind to DNA have been identified, suggesting that at least two ZnF 
domains in tandem are required for DNA recognition (Iuchi, 2001). By contrast, evidence 
shows that a single C2H2 type ZnF domain is sufficient for RNA binding (Friesen and Darby, 
2001). Therefore, it is plausible that ZNF804A may interact directly with RNA via its C2H2 
type ZnF domain. Alternatively, ZNF804A may interact indirectly with RNA via interactions 
with its putative binding partners that can bind RNA (Chapter Three). Further experiments 
based on chromatin immunoprecipitation or RNA immunoprecipitation will be critical in 
determining the direct targets of ZNF804A. While the degradation of ZNF804A by the 
proteasome poses a challenge for techniques based on immunoprecipitation, it is notable that 
Girgenti and colleagues (2012) successfully used chromatin immunoprecipitation to show 
ZNF804A bound the promoter/enhancer regions of two known schizophrenia susceptibility 
genes in rat neural progenitor cells. If RNA immunoprecipitation experiments show 
ZNF804A interacts directly with pre-mRNA, it will be interesting to establish the potential 
mechanisms of ZNF804A-mediated splicing using minigene constructs. Minigene constructs 
contain a genomic segment from the gene of interest that includes the alternatively spliced 
region and flanking genomic regions (Cooper, 2005). Minigene reporter assays can be used to 
assess the cis-regulatory elements and trans-acting factors that are required for alternative 
splicing events.  
 
In the context of the literature, the implication that ZNF804A may be involved in both 
transcriptional regulation and pre-mRNA processing seems unusual for a C2H2 type ZnF 
domain-containing protein. While C2H2 type ZnF domain-containing proteins are often 
implicated as regulators of DNA transcription, and can function at more than one level of 
gene expression, there are very few examples of C2H2 type ZnF domain-containing proteins 
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that influence pre-mRNA processing (Burdach et al., 2012). A notable example with potential 
similarities to ZNF804A is the C2H2 zinc-finger domain-containing protein synapse 
defective-9 (syd-9) which is specifically required for synaptic function in Caenorhabditis 
elegans (C.elegans) (Vijayaratnam et al., 2003; Wang et al., 2006). Like GPATCH8, syd-9 
localises to nuclear speckles (Wang et al., 2006). Data presented by Wang and colleagues 
implicate a role for syd-9 in post-transcriptional modifications. Specifically, C. elegans null 
mutants for unc-75 (the C. elegans homolog of the CELF/Bruno family of proteins) had less 
severe deficits that combined unc-75 and syd-9 null mutants; suggesting that syd-9 may 
function with unc-75 to regulate transcription and splicing (Wang et al., 2006).  
 
In light of the data presented in this thesis, it is tempting to speculate that genetic variation in 
ZNF804A may increase risk for schizophrenia by altering ZNF804A’s interactions with its 
binding partners and/or target genes in a manner which may have downstream consequences 
on gene expression and/or splicing of transcripts. Recent data presented by Hill and 
colleagues showed that the disease-associated SNP rs1344706 significantly reduced 
expression of RNA transcribed from the risk allele in human foetal brain (Hill et al., 2012b). 
The data presented in Chapter Four show genes belonging to the GO term ‘nervous system 
development’ were enriched among differentially expressed genes in ZNF804A-depleted 
cells. This suggests that it is feasible that a reduction in ZNF804A expression during foetal 
development could have downstream consequences on gene expression and pre-mRNA 
processing which could increase risk for disease.  
 
The notion that dysregulated gene expression and splicing could contribute to schizophrenia 
has been documented in the literature; post-mortem brain studies of schizophrenia patients 
show alternative splicing of several schizophrenia candidate genes including regulator of G-
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protein signalling 4 (RGS4), neuregulin 1 (NRG1) and glutamate receptor, metabotropic 3 
(GRM3) (Ding and Hegde, 2009; Sartorius et al., 2008; Tan et al., 2007). However, very few 
published studies have assessed both gene-level and exon-level changes in schizophrenia 
(Wu et al., 2012; Cohen, 2012). Interestingly, aberrant splicing is also implicated in other 
neuropsychiatric diseases, such as autism. For example, using post-mortem genome-wide 
transcriptome profiling, Voineagu and colleagues showed a number of RBFOX1-dependent 
splicing events were dysregulated in autism (Voineagu et al., 2011).  
 
In summary, the data presented in this thesis suggest that ZNF804A contributes to the 
transcriptional regulation and pre-mRNA splicing of genes implicated in processes which 
underlie schizophrenia, such as nervous system development. This work provides the basis 
for further investigation into how the disease-related SNP in ZNF804A may contribute to 
disease susceptibility via dysregulation of ZNF804A-associated transcriptional regulation and 
pre-mRNA splicing.  
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Appendix 1: The sequences of the PCR primers   
Appendix 1.1: ZNF804A PCR primers 
Primer name Sequence Purpose 
ZNF804A primers  
HZNF804A-Cterm Y2HFWD 
(EcoRI) 
CTGGAATTCTGGGGAAATATCTATTGGAACCAAT 
Cloning C-term 
into pHybLex/Zeo 
HZNF804A-Y2H R2 (Sal) CTGGTCGACCTAGAAGAGAGGTTGCAAAGG 
Cloning C-term 
into pHybLex/Zeo 
ZNF804A-Y2H F1  CTGGAATTCATGGAGTGTTACTACATTGTCAT 
Cloning N-term 
into pHybLex/Zeo 
ZNF804A-Y2H R1  CTGGTCGACCTAGCATTTTCAGTGTAACTATTCTC 
Cloning N-term 
into pHybLex/Zeo 
ZNF EcoRI F1  CTGGAATTCGGATGGAGTGTTACTACATTGTCAT 
Cloning full-length 
ZNF804A into 
YFPN1 
ZNF-YFPN1_REV CTGCGTCGACTGGAAGAGAGGTTGCAAAAGGA 
Cloning full-length 
ZNF804A into 
YFPN2 
ZNF_NT-YFPN1_REV CTGCGTCGACTGAGCATTTTCAGTGTAACTATTCTC 
Cloning N-terminal 
of ZNF804A into 
YFPN1 
ZNF CT_EcoYFP FWD  CTGGAATTCTGGGGAAATATCTATTGGAACCAAT 
Cloning C-terminal 
of ZNF804A into 
YFPN1 
ZNF-Neo_EcoFWD  CTGGAATTCATGGAGTGTTACTACATTGTCAT 
Cloning of full-
length ZNF804A 
into pCIneo 
ZNF-myc(neo)_MLU FWD  CTGACGCGTATGGCATCAATGCAGAAGCTG 
Cloning of full-
length ZNF804A 
into pCIneo 
ZNF_myc_kozak fwd  CTGACGGGTATGGCATCAATGCAGAAGCTG 
Cloning into 
pcDNA5/FRT/TO 
ZNF_500_REV TTGAAATCTTGCTGGTTATTAACT RT-PCR 
hZNF804A749fwd GCATCTAAATCCAGGAAAGATC sequencing 
hZNF804A1497fwd GTGGTAACAGTTTTGAGTTGTTACG sequencing 
hZNF804A2254fwd GTTATGTCAGCATCATCATATGG sequencing 
hZNF804A2970fwd CTTCCTTAAATCCTCTGGATAGG sequencing 
hZNF804A1202fwd AGATTTGTCCCCAGTGC sequencing 
 
Appendix 1.2: TCF4 PCR primers 
Primer name               Sequence                   Purpose 
hTCF4_GFPC1_Sal_Rev CTGGTCGACTTACATCTGTCCCATGTGATTC 
Cloning into 
pcDNA5/FRT/TO 
hTCF4 kozak EGFP C1 CCGGTCGCCACCATGGTGA 
Cloning into 
pcDNA5/FRT/TO 
hTCF4_1467_Fwd TCTGCGACTTCCCCTGACC sequencing 
TCF4_523_REV ATGGCACTACTGTGAAGAGG RT-PCR 
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Appendix 1.3: GPATCH8 PCR primers 
Primer name             Sequence                  Purpose 
GPATCH8 primers  
hGPATCH8_YFP_age_rev CTGCACCGGTCCCGTGCCATGGCTGGGGG 
Cloning into 
pEYFP 
hGPATCH8_start35xho_YFPN1 
fwd CTGCTCGAGATGGCGGACCGCTTCTCC 
Cloning into 
pEYFP 
hGPATCH8_sfi_myc_fwd CTGATGGCCATGGAGGCCATGGCGGACCGCTTCTCC 
Cloning into 
pCMV-myc 
hGPATCH8_stop rev CTGCGCGGCCGCTCACGTGCCATGGCTGGG 
Cloning into 
pCMV-myc 
 
Appendix 1.4: Solaris Q-PCR primers 
Primer name Sequence Purpose 
ACTB fwd TGGAGAAAATCTGGCACCAC Q-PCR 
ACTB rev GGTCTCAAACATGATCTGG Q-PCR 
ACTB probe ACCGCGAGAAGATGACC Q-PCR 
GAPDH fwd GCCTCAAGATCATCAGCAATG Q-PCR 
GAPDH rev CTTCCACGATACCAAAGTTGTC Q-PCR 
GAPDH probe GCCAAGGTCATCCATGA Q-PCR 
hZNF804A fwd TCTCAGCAACGGACACTTTC Q-PCR 
hZNF804A rev CTCAGCATAGTCCAGAGTT Q-PCR 
hZNF804A probe CAAGAACGGGAACAAAAC Q-PCR 
 
Appendix 1.5: Vector and miscellaneous PCR primers 
Primer name Sequence Purpose 
Vector primers 
MYC FWD ATGGCATCAATGCAGAAGCTG RT-PCR 
EGFP FWD ACGGCATCAAGGTGAACTTCA RT-PCR 
M13rev CAGGAAACAGCTATGAC sequencing 
pEYFP-N1 fwd GCTGGTTTAGTGAACCGTCA sequencing 
pEYFP-N1 rev TCGAAGTCCAGCTCGACCAG sequencing 
pCMV-myc fwd ATGGCATCAATGCAGAAGCTG sequencing 
pCMV-myc rev CACTGCATTCTAGTTGTGGTTTGTCCA sequencing 
pPC86 fwd TATAACGCGTTTGGAATCACT sequencing 
pDEST22 fwd TATAACGCGTTTGGAATCACT RT-PCR 
pDEST22 rev GTCTCCAATCAAGGTTGTCGGCT RT-PCR 
Misc. 
Hygromycin fwd GCTCATCGAGAGCCTGCG RT-PCR 
Hygromycin rev GCTCATCGAGAGCCTGCG RT-PCR 
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Appendix 1.6: PCR primers used to validate genes which showed differential expression after ZNF804A knockdown
Primer name Forward primer sequence Reverse primer sequence Purpose 
amplification 
efficiency 
R
2
 
Validation 
for ∆Ct 
ACTB ACGGCCAGGTCATCACCATTG GGAGTTGAAGGTAGTTTCGTGGATG Q-PCR 96 0.9975 – 
NPY GCGCTGCGACACTACATCAA GGGCTGGATCGTTTTCCATA Q-PCR 94 0.9926 0.0273 
CCL2 GAAGAATCACCAGCAGCAAGTGT   GCTTGTCCAGGTGGTCCATG Q-PCR 91 0.9991 0.0973 
SPARC TACATCGGGCCTTGCAAATAC GGGTGACCAGGACGTTCTTG Q-PCR 92 0.9995 0.0113 
TMEFF2 CACAAGGAAATGCCCCAGAA GATTAACCTCGTGGACGCTCTT Q-PCR 99 0.9794 0.1074 
EGR1 CTTCGCCTGCGACATCTGT TTTGTCTGCTTTCTTGTCCTTCTG Q-PCR 100 0.9985 0.0933 
PDK1 AGCCATCATTGCACGTGTCTT CCTTGACCATGCCACTGTACTC Q-PCR 95 1.0000 0.1246 
FSTL4 GTATGCGCTGCTACCAAGATTG GCAGCTTGGCACAGAAATGAT Q-PCR 90 0.9954 0.0764 
EFNB2 CTGCTGCTGCCTCTGAAACA CCTACTGGCCTCTTCGATCTCA Q-PCR 96 0.999 0.0231 
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Appendix 1.7 PCR primers used to validate putative alternative splicing events after ZNF804A knockdown
Exon array validation – alternative splicing 
Primer 
name 
Forward primer sequence Reverse primer sequence Purpose 
amplification 
efficiency 
R
2
 
Validation 
for ∆Ct 
NFYA  CTGGAATTCTTCGACAGAGCAGATTGTTGT CTGGCGGCCGCAGCTATGATGGGTTGGCCAGTTGA RT-PCR       
  CTGGAATTCTTCGACAGAGCAGATTGTTGT CTGGCGGCCGCAGCTCCACCTGGGCCTGGGCCTCAGTCT Q-PCR exon 108 0.9969 0.0575 
  TGGAGGCCTCGACGGTTAC GCCGCAGCACGAAGTTAAAC Q-PCR standard 105 0.9999 – 
SIPA1L1 CTGGAATTCCAGATATTGGTGGCAGCGG  CTGGCGGCCGCAGCTATCCTGCCGCATTAATCTC RT-PCR       
  CCTAGCTGGCAAAGAAGTGA TTCATGCTGCTCGAGGACAA Q-PCR exon 107 0.9979 0.7672  
  CCGTCCCAGGTGCAGAGT GGCATCTTCCCATCTCCTTTT Q-PCR standard 93 0.9999 – 
ENAH GCAGCAAGTCACCTGTTATCT CTGGACTCCATTGGCACTG RT-PCR       
  TGTTATCTCCAGACGGGATTC TCAGCCTGTCATAGTCAAGTCCTT Q-PCR exon 93 0.9963 0.0154 
  CAGAGTGGTGGGCAGGAAGA CCCTTTAGGAATGGCACAGTTT Q-PCR standard 92 0.9998 – 
G3BP2  CCTCCTCCGGCAGAACCT ACGAGGTGGCTGAGATTGAA RT-PCR       
  CAAAGGCTTTCTCCTGGGCT CGACTCTTGGCTGTGAGAC Q-PCR exon 96 0.9937 0.0022 
  GCTCCGGAATATTTACACAGGTTT GCATCTACTCCACCATGAACATAGG Q-PCR standard 95 0.9991 – 
PKM2 CTGGAATTCGCACAGCACAGGGAAGATG CTGGCGGCCGCAGCTGGATGGAGCCGACTGCATC RT-PCR       
  AGTGAT GTGGCCAATG CAGT TGGAACATGGCTGCCTCA Q-PCR exon 104 0.9628 0.0059 
  CCATGAATGTTGGCAAGGCC TCACGGCACAGGAACAA Q-PCR standard 100 0.9989 – 
PTPRR 
130846.2 TTCTCAAGCTCTCATTTAACGT CTGTAAAGAATCATCAAACAC Q-PCR 
95 0.9974 0.1239 
PTPRR 
002849 TGGAATTACAGAAGTCTCTCC GTCTTGTCTTAAGGAAAGCT Q-PCR 
93 0.9939 0.2325 
ATP11C  CTGAGATTCTTCTGATAGTATTA TGTCAGTATGCTTGTAGGAC RT-PCR       
STXBP1 ACGAGGTGACCCAGGCCA TCTTCAGTGTGTCCAGCAGT RT-PCR   
  
BAZ1A AAGCTAAGATGTGCAGTCTGAG ATCTTCCAGGCAATAGCTGAA RT-PCR   
  
RCOR2 TGGACCACAGATGAGCAGC GGCTGTCGGAGCAGAGTG RT-PCR   
  
SEC14L1 ACCGGCGGTCGAGCTACG CTGAATATCCTCAAGGAGCC RT-PCR   
  
MAP2K5 GGAGCAGTATGGAATTCATTC CAACAATGCACTGCAGAAGC RT-PCR       
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Appendix 2: Summary of the ZNF804A expression constructs  
Construct name Description 
Primers used to clone the insert (see 
Appendix 1.1) 
FL-ZNF804A-YFPN1 
Full-length ZNF804A 
cloned into pEYFP-N1 
ZNF EcoRI F1 + ZNF-YFPN1_REV 
C-term-ZNF804A-
YFPN1 
C-terminal ZNF804A 
cloned into pEYFP-N1 
ZNF CT_EcoRIYFP FWD + ZNF_ YFPN1_REV 
N-term-ZNF804A-
YFPN1 
N-terminal ZNF804A 
cloned into pEYFP-N2 
ZNF EcoRI FWD + ZNF_NT-YFPN1_REV 
FL-ZNF804A-myc 
Full-length ZNF804A 
cloned into pCMV-myc 
ZNF EcoRI F1 + ZNF-YFPN1_REV 
FL-ZNF804A-myc-neo 
Full-length ZNF804A-
myc cloned into pCIneo 
ZNF-myc(neo)_MLU FWD + ZNF-Sal 
REV(Y2HR2) 
 
Appendix 2.1: The ZNF804A expression constructs  
Prior to the start of my studies, a number of different ZNF804A expression constructs were 
used to try to transiently over-express ZNF804A. Each of these ZNF804A expression 
constructs was tested in COS-7, HEK293T, SH-SY5Y and HeLa cells. In each instance, no 
tagged-ZNF804A expression was detected by western blot analysis or immunocytochemistry 
using an antibody designed to target the tag. 
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Appendix 3: Description of the custom anti-ZNF804A antibodies   
The custom antibodies used in this study were designed and generated by C.L.Tinsley.  
To generate the human ZNF804A antibodies, an N-terminus immunogen (highlighted 
in yellow in Appendix 3.1) with a thioredoxin-tag was used. The resulting antibodies 
were designated 3077 and 3078.  To generate the mouse Zfp804a antibodies, an N-
terminus immunogen (highlighted in yellow in Appendix 3.2) with a thioredoxin-tag 
was used. The resulting antibodies were designated 001 and 002. 
Appendix 3.1 The human ZNF804A amino acid sequence 
MECYYIVISSTHLSNGHFRNIKGVFRGPLSKNGNKTLDYAEKENTIAKALEDLKANFYCELCDKQYYKHQ 
EFDNHINSYDHAHKQRLKELKQREFARNVASKSRKDERKQEKALQRLHKLAELRKETVCAPGSGPMFKST 
TVTVRENCNEISQRVVVDSVNNQQDFKYTLIHSEENTKDATTVAEDPESANNYTAKNNQVGDQAQGIHRH 
KIGFSFAFPKKASVKLESSAAAFSEYSDDASVGKGFSRKSRFVPSACHLQQSSPTDVLLSSEEKTNSFHP 
PEAMCRDKETVQTQEIKEVSSEKDALLLPSFCKFQLQLSSDADNCQNSVPLADQIPLESVVINEDIPVSG 
NSFELLGNKSTVLDMSNDCISVQATTEENVKHNEASTTEVENKNGPETLAPSNTEEVNITIHKKTNFCKR 
QCEPFVPVLNKHRSTVLQWPSEMLVYTTTKPSISYSCNPLCFDFKSTKVNNNLDKNKPDLKDLCSQQKQE 
DICMGPLSDYKDVSTEGLTDYEIGSSKNKCSQVTPLLADDILSSSCDSGKNENTGQRYKNISCKIRETEK 
YNFTKSQIKQDTLDEKYNKIRLKETHEYWFHKSRRKKKRKKLCQHHHMEKTKESETRCKMEAENSYTENA 
GKYLLEPISEKQYLAAEQLLDSHQLLDKRPKSESISLSDNEEMCKTWNTEYNTYDTISSKNHCKKNTILL 
NGQSNATMIHSGKHNLTYSRTYCCWKTKMSSCSQDHRSLVLQNDMKHMSQNQAVKRGYNSVMNESERFYR 
KRRQHSHSYSSDESLNRQNHLPEEFLRPPSTSVAPCKPKKKRRRKRGRFHPGFETLELKENTDYPVKDNS 
SLNPLDRLISEDKKEKMKPQEVAKIERNSEQTNQLRNKLSFHPNNLLPSETNGETEHLEMETTSGELSDV 
SNDPTTSVCVASAPTKEAIDNTLLEHKERSENINLNEKQIPFQVPNIERNFRQSQPKSYLCHYELAEALP 
QGKMNETPTEWLRYNSGILNTQPPLPFKEAHVSGHTFVTAEQILAPLALPEQALLIPLENHDKFKNVPCE 
VYQHILQPNMLANKVKFTFPPAALPPPSTPLQPLPLQQSLCSTSVTTIHHTVLQQHAAAAAAAAAAAAAG 
TFKVLQPHQQFLSQIPALTRTSLPQLSVGPVGPRLCPGNQPTFVAPPQMPIIPASVLHPSHLAFPSLPHA 
LFPSLLSPHPTVIPLQPLF 
 
 
Appendix 3.2 The mouse Zfp804a amino acid sequence 
MECYYIVISSTHLSNGHFRNIKGVFRGPLSKNGNKTLDYAEKENTIAKALEDLKANFYCELCDKQYYKHQ 
EFDNHINSYDHAHKQRLKELKQREFARNVASKSRKDERKQEKALQRLHKLAELRKETVCAPGSGPMFKST 
TVTVRENLNDVSQRESVDPINNQQDLIPSEEKERDGTTALAETETASNCTANNCQIGDQSQAVHRHRIGF 
SFAFPKKATVKLESCSAAAFSEYSDESSMEKEFSRKTRFVPSTSHLQLPPPTCELLSSEEKGNSPPPEAM 
CTDKATAQTEERKITSNENNTLLTSSFCQLQHYIPTCSEADTCQNLAPFEDQLPMEAVIVNEDGPVSKSN 
PNIIEKNPTVPNDRTSAQMTTEENITINDVTKMETRNKIDHEPLTPSSTIEESIRLQKRPDLCKRQCDPF 
VPVLNKLGSTVLQWPSEMLAYTTTEPSISYSCNPLCFDFKSTKLNNNQDKNKLTLNDLFSEQKEDCCKGA 
HADCKDVPIARVTNDETGHSKNDYPQVTTLSPVHVLSNGCDLGQNENVGQRYKHISCTNRQTNKYKFTRC 
QIKRDMLNEKYDKMRLKETREHWFHKSRRKKKRRKLCRYHPGKSSKEPEGSGKTERSRQRTDEARKNPRE 
PVLEKHPRSPERASDLHQLPDERPKAASTHLGEKETMNTTVNTESNDAAPGSQNCGGKNATVVNEQAKPL 
VIHSVKQNLTYVRTYCCWKARTSRYQEDDGSLASQSNVKGPTQNQPVKRGYSSLTNDSERIHRKRRQHSC 
SYSSDESLNQQHHLGEYLKPLSTSLISCQPKKKRRRKRSRLHIGDGTTKMKGNSNYPMKCSSLSQPDELA 
KDCIKEDINPQENVSIEKNSEQTEQTEIKGMLHPYNPLLSEPSGEGEHSVTETTPCDSSQTSNDLATPVN 
VTRDPSNSTTDNTLLEHNQRSQTTNSNEKQTPFKVTNPERNFRHSQAKSYICRYELAETIPQGKTNEAST 
EWLCYNSGILNTQPPLQFKEAHVSGHAFVTTEQILAPLPLPEQALLIPLENHDKLKHLPCEVYQHIIQPN 
MLTNKVKFTFPPPPLPPPSTPVQPLPLQRPFCSTSVTTIHHTVLQHHAAAAAAAAAAAAAGTFKVLQPHQ 
QFLPQVPALARTSIPQISVGTVGPRLCPGGQPALVASPQMPIIPASVLHPSPLAFPPLPHSFFPSLLSPH 
PTVIPLQPLF 
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Appendix 4: Quality assessment of the RMA processing step    
 
 
Appendix 4.1: Quality assessment of the RMA processing step in the exon array 
analyses. On import to the PGS the data was processed using the robust multiarray averaging 
(RMA) algorithm. The charts show the median distributions of the log2 expression signals 
across the (A - C) knockdown and (D) over-expression exon array data pre- and post RMA 
processing.  
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 Appendix 5: Supplementary data for Chapter Four 
 
 
 
 
 
 
 
 
 
 
Appendix 5.1: Location of siRNA target sites and Q-PCR primer sequences in relation 
to gene structure 
Two siRNA duplexes were designed to target exons two and three of ZNF804A. These 
siRNAs were designated siZNFA and siZNFB respectively. The location of the sites of 
siRNA directed cleavage are illustrated by the red arrows (not to scale). To confirm ZNF804A 
knockdown, Solaris Q-PCR primer/probe sets were designed complementary to ZNF804A. 
The location of the Q-PCR primers is shown by the black arrows (not to scale). In this 
schematic, exons are represented by grey boxes, introns are represented by black lines and 
untranslated regions are represented by black rectangles. (Fwd = forward; rev = reverse.) 
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Gene name Gene symbol P value FC 
ATP-binding cassette, sub-family C (CFTR/MRP), member 4 ABCC4 5.70E-08 -1.82 
colony stimulating factor 1 (macrophage) CSF1 2.81E-07 1.40 
kinesin light chain 2 KLC2 3.73E-07 1.25 
KIAA1539 KIAA1539 3.95E-07 1.59 
tumor necrosis factor receptor superfamily, member 12A TNFRSF12A 4.91E-07 2.37 
RAB15, member RAS onocogene family RAB15 1.43E-06 1.13 
methyl CpG binding protein 2 (Rett syndrome) MECP2 1.53E-06 -1.78 
limb region 1 homolog (mouse)-like LMBR1L 1.60E-06 1.90 
inositol polyphosphate-5-phosphatase INPP5A 1.77E-06 -1.94 
ciliary neurotrophic factor receptor  CNTFR 2.29E-06 1.56 
family with sequence similarity 198, member B FAM198B 2.43E-06 1.79 
TIMP metallopeptidase inhibitor 3 TIMP3 2.70E-06 -1.29 
NEL-like 2 (chicken) NELL2 2.85E-06 1.42 
carnitine palmitoyltransferase 1C CPT1C 3.33E-06 1.17 
mediator complex subunit 25 MED25 3.77E-06 1.27 
FYVE, RhoGEF and PH domain containing 1 FGD1 4.43E-06 -1.38 
discs, large homolog 4 (Drosophila) DLG4 4.64E-06 1.51 
synaptotagmin IX  SYT9 4.85E-06 1.39 
calcium channel, voltage-dependent, T type, alpha 1G subunit CACNA1G 7.10E-06 1.55 
motile sperm domain containing 2 MOSPD2 7.38E-06 -1.82 
transmembrane protein 135 TMEM135 8.23E-06 -1.49 
phosphate cytidylyltransferase 1, choline, beta PCYT1B 8.40E-06 -1.76 
placental growth factor  PGF 1.04E-05 1.78 
5'-nucleotidase, ecto (CD73)  NT5E 1.05E-05 2.27 
damage-specific DNA binding protein 2, 48kDa  DDB2 1.22E-05 1.50 
CD68 molecule CD68 1.24E-05 2.27 
LIM homeobox 8  LHX8 1.28E-05 1.39 
tissue factor pathway inhibitor (lipoprotein-associated coagulation 
inhibitor) 
TFPI 1.31E-05 1.84 
phosphatidic acid phosphatase type 2B PPAP2B 1.41E-05 -1.18 
clusterin  CLU 1.42E-05 1.50 
insulin-like growth factor binding protein 4 IGFBP4 1.43E-05 1.27 
annexin A1 ANXA1 1.48E-05 4.82 
solute carrier family 7 (amino acid transporter light chain, L 
system), member 5 
SLC7A5 1.68E-05 -1.51 
transmembrane protein 132A  TMEM132A 1.79E-05 -1.47 
WD repeat domain 18  WDR18 1.83E-05 1.10 
roundabout, axon guidance receptor, homolog 1 (Drosophila) ROBO1 1.84E-05 -2.10 
glucuronic acid epimerase GLCE 1.87E-05 1.68 
enolase 3 (beta, muscle) ENO3 1.88E-05 1.84 
GrpE-like 2, mitochondrial (E. coli)  GRPEL2 1.90E-05 -1.38 
toll-like receptor 4  TLR4 1.92E-05 1.97 
pre-B-cell leukemia homeobox interacting protein 1 PBXIP1 1.96E-05 1.89 
extracellular matrix protein 1 ECM1 1.98E-05 1.84 
cathepsin A CTSA 2.05E-05 1.87 
secretogranin II SCG2 2.05E-05 1.84 
vesicle amine transport protein 1 homolog (T. californica)-like VAT1L 2.06E-05 2.05 
sestrin 3 SESN3 2.11E-05 1.97 
v-raf murine sarcoma 3611 viral oncogene homolog  ARAF 2.12E-05 1.11 
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Appendix 5.2: The list of genes which showed differential expression after GAPDH 
knockdown relative to mock samples  
The .CEL files were imported into the PGS using the core metaprobe set and RMA 
normalisation. The .CEL files were assigned as either siGAP-treatment or mock. A one-way 
ANOVA was performed on the gene-summarised expression values, using treatment as the 
candidate variable in the ANOVA model. The expression of 47 genes differed significantly 
(FDR 0.01). The ten genes in bold were also identified in the siZNF-treated versus siGAP-
treated analysis with the same direction of fold change with respect to GAPDH.  
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Appendix 5.3: Manual annotation of the alternative splicing events in ZNF804A-
depleted cells. The geneviews of the 116 genes that showed alternative splicing after 
ZNF804A knockdown were examined manually alongside the UCSC genome browser. (A) 
The statistically significant calls were attributed to the categories described. (B) The 63 events 
which corresponded with changes in exon usage (with and without changes in transcript 
abundance) were further categorised to establish the nature of the change.  
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Appendix 5.4: The list of genes which showed alternative splicing after GAPDH 
knockdown, relative to mock samples  
To identify alternatively spliced transcripts, an alternative splicing one-way ANOVA was 
performed on the probe set log2 signal intensities greater than three. Treatment was chosen as 
the candidate variable in the ANOVA model. The gene list was filtered to exclude genes 
containing fewer than five markers or a fold change greater than five. Alternative splicing 
ANOVA P values were corrected using the Bonferroni method. To enable a comparison of 
the number of statistically significant alternative splicing events in GAPDH-depleted and 
ZNF804A-depleted cells, a significance threshold of P < 1 x 10-6 was used. The splicing of 13 
genes was altered after GAPDH knockdown, relative to mock samples. (FC = fold change.) 
Gene name 
Gene 
Symbol 
Gene expression P 
value 
Bonferroni corrected 
alternative splicing 
P value 
FC 
fms-related tyrosine kinase 1 FLT1 2.99E-05 2.27E-24 2.42 
annexin A1 ANXA1 1.48E-05 3.68E-14 4.82 
G-protein coupled receptor 162 GPR162 4.32E-03 1.69E-13 1.23 
La ribonucleoprotein domain family, 
member 6 
LARP6 1.50E-01 6.33E-13 -1.08 
integrin, alpha 5 (fibronectin receptor, 
alpha polypeptide) 
ITGA5 9.18E-05 1.03E-11 1.46 
glycoprotein (transmembrane) nmb GPNMB 4.47E-05 2.22E-11 2.82 
microtubule-associated protein 4 MAP4 2.15E-01 2.86E-11 1.08 
toll-like receptor 4 TLR4 1.92E-05 1.51E-10 1.97 
UDP-GlcNac:betaGal beta-1,3-N-
acetylglucosaminyltransferase 4 
B3GNT4 5.12E-06 4.40E-09 1.34 
CD68 molecule CD68 1.24E-05 1.06E-08 2.27 
utrophin UTRN 2.41E-01 6.42E-08 1.12 
glutamate receptor, ionotrophic, AMPA 3  GRIA3 3.11E-04 2.04E-07 2.05 
protocadherin 10 PCDH10 1.37E-04 2.78E-07 1.86 
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Appendix 5.5 The list of genes identified as nominally differentially expressed both in 
this study and by Hill and colleagues (2012) 
Data presented in Chapter Four show there were numerous changes in gene expression in 
ZNF804A-depleted cells. To determine if these data were consistent with data published by 
Hill and colleagues (2012), the overlap between the two datasets was considered. The table 
below outlines the 20 genes which were nominally differentially expressed in the same 
direction in both of the datasets. HSS150612 and HSS150613 are siRNA duplexes used by 
Hill and colleagues to deplete ZNF804A.  
Gene name 
 Gene 
symbol   RefSeq 
pooled 
siZNFA+B HSS150612 HSS150613 
   P value Ratio P value Ratio  P value Ratio  
anthrax toxin receptor 1 ANTXR1 NM_032208 2.92E-02 0.82 4.23E-02 0.9 3.82E-02 0.9 
ankyrin repeat and SOCS 
box containing 8 
ASB8 NM_024095 4.22E-02 1.13 8.00E-04 1.22 2.37E-02 1.11 
CD151 molecule (Raph 
blood group) 
CD151 NM_004357 2.11E-04 1.40 3.15E-02 1.11 2.03E-02 1.06 
CD83 molecule CD83 NM_004233 6.38E-04 0.77 1.90E-03 0.75 3.14E-02 0.73 
carboxylesterase 2 CES2 NR_036684 5.82E-02 1.26 2.44E-02 1.09 4.08E-02 1.11 
coiled-coil-helix-coiled-coil-
helix domain containing 7 
CHCHD7 NM_001011667 6.83E-03 0.77 1.70E-02 0.87 1.45E-02 0.86 
eukaryotic translation 
initiation factor 4A2 
EIF4A2 NM_001967 3.51E-02 1.17 1.70E-03 1.15 5.00E-04 1.26 
ELAV-like 1  ELAVL1 NM_001419 4.88E-02 0.83 3.94E-02 0.85 3.08E-02 0.88 
eva-1 homolog A (C. 
elegans) 
FAM176A NM_001135032 1.86E-02 1.45 2.99E-02 1.28 2.36E-02 1.23 
family with sequence 
similarity 46, member A 
FAM46A NM_017633 4.22E-02 0.77 1.03E-02 0.82 8.40E-03 0.82 
FH2 domain containing 1 FHDC1 NM_033393 3.38E-03 0.58 7.20E-03 0.77 2.90E-03 0.77 
monooxygenase, DBH-like 1 MOXD1 NM_015529 3.68E-04 0.56 4.45E-02 0.87 3.11E-02 0.86 
mannose receptor, C type 2 MRC2 NM_006039 1.39E-03 0.64 1.91E-02 0.81 3.95E-02 0.84 
organic solute carrier partner 
1 
OSCP1 NM_145047 2.07E-03 0.76 4.92E-02 0.93 4.77E-02 0.84 
poly (ADP-ribose) 
polymerase 2 
PARP2 NM_005484 4.27E-02 1.11 3.72E-02 1.15 3.14E-02 1.1 
protease, serine, 35 PRSS35 NM_001170423 9.60E-05 0.84 1.77E-02 0.77 2.73E-02 0.86 
quiescin Q6 sulfhydryl 
oxidase 2 
QSOX2 NM_181701 3.55E-04 0.59 1.48E-02 0.78 2.46E-02 0.83 
RAS, dexamethasone-
induced 1 
RASD1 NM_016084 1.35E-02 0.60 4.35E-02 0.81 1.90E-03 0.75 
sperm associated antigen 16 SPAG16 NM_024532 2.27E-02 0.65 6.30E-03 0.82 1.80E-03 0.73 
ubiquitin protein ligase E3C UBE3C NM_014671 1.13E-02 0.70 4.82E-02 0.91 2.30E-02 0.9 
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Appendix 6.1 GeneGo MetaCore™ pathway map legend 
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Appendix 6.2: Manual annotation of the alternative splicing events in cells over-
expressing myc-ZNF804A. The geneviews of the 27 genes that showed alternative splicing 
after myc-ZNF804A over-expression were examined alongside the UCSC genome browser. 
(A) The statistically significant calls were attributed to the categories described. (B) The 20 
events which corresponded with changes in exon usage (with and without changes in 
transcript abundance) were further categorised to establish the nature of the change.  
 
 
 
 
 
 
 
